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ABSTRACT 
 
 
Mechanisms of Growth Inhibition Induced by Methylene-Substituted and Ring-
Substituted DIMs in Breast Cancer Cells. (May 2007) 
Kathryn Elisabeth Vanderlaag, B.Sc., University of Guelph 
 
Chair of Advisory Committee:  Dr. Stephen H. Safe 
 
 
 One in 8 women will be diagnosed with breast cancer in the United States and 
estrogen receptor (ER) status largely influences the type and subsequent success of 
treatment employed.  Although ER-positive breast cancer can be treated with endocrine 
therapy, the more invasive ER-negative breast cancer is non-responsive to this therapy 
and cytotoxic agents are often utilized which are associated with many adverse side 
effects.  Consequently, there is a genuine need to develop more effective, less toxic 
treatments for invasive breast cancer. 
 Indole-3-carbinol is a phytochemical found in cruciferous vegetables and one of 
its major metabolites, 3,3’-diindolylmethane (DIM), exhibits a broad range of anticancer 
and antitumorigenic activities.  ER-negative MDA-MB-231 and MDA-MB-453 breast 
cancer cell growth was inhibited after treatment with a novel series of methylene-
substituted DIMs (C-DIMs), namely 1,1-bis(3’-indolyl)-1-(p-substitutedphenyl) 
methanes containing trifluoromethyl (DIM-C-pPhCF3), t-butyl (DIM-C-pPhtBu) and 
phenyl (DIM-C-pPhC6H5) groups.  In addition, DIM-C-pPhC6H5 (40 mg/kg/d) inhibited 
tumor growth in nude mice bearing MDA-MB-231 cells as xenografts.  Treatment of 
  
 
iv 
breast cancer cells with C-DIMs lead to downregulation of cyclin D1 and induction of 
non-steroidal anti-inflammatory drug-activated gene 1.  Detection of necrosis, caspase-
dependent or caspase-independent apoptosis were not observed in breast cancer cells 
treated with C-DIMs, however autophagic cell death was induced by C-DIMs. 
 DIM and ring-substituted DIMs have exhibited antitumorigenic activity in tumor 
murine mammary models.  An investigation into the mechanism of cell death induced by 
DIM and 5,5’-dibromoDIM (5,5’-diBrDIM) in both ER-positive (MCF-7) and ER-
negative (MDA-MB-231) breast cancer cells revealed modulation of several key 
signaling pathways involved in growth control.  Both DIM and 5,5’-diBrDIM 
downregulated cyclin D1, although only 5,5’-diBrDIM induced a depolarization of the 
mitochondrial membrane.  In addition, apoptosis was observed in MCF-7 cells treated 
with 5,5’-diBrDIM but not MDA-MB-231 cells. 
 In summary, C-DIMs may represent new mechanism-based agents for treatment 
of breast cancer through induction of autophagic cell death.  The ring-substituted DIMs 
correspond to a novel class of uncharged mitochondrial poisons that are also highly 
effective in inhibiting breast cancer cell growth.  Results of this research provide 
evidence for the potential role of two new series of DIM analogs for the treatment of 
highly aggressive breast cancer. 
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CHAPTER I    
INTRODUCTION 
1.1. Cancer 
Cancer cells are abnormal cells that can grow uncontrollably and have the ability 
to invade normal tissues.  Cancer encompasses a diverse range of diseases that are 
named based on their biological origin (prefix) and cell type (suffix).  The 4 distinct 
types of cancer based on the cell origin of the cancer:  carcinomas, sarcomas, 
lymphomas and leukemias (see Figure 1.1). Carcinomas are the most frequent type of 
cancer and arise from epithelial cells covering internal or external surfaces such as lung, 
This dissertation follows the style of Cancer Letters. 
Figure 1.1:  Classification of common cancers.  There are 4 types of cancer based on type of cell 
the cancer originated from:  carcinomas (epithelial), leukemias (immature blood cells in bone 
marrow), lymphomas (lymph nodes and immune system) and sarcomas (supportive tissue).   
Examples of tissues pertaining to each type of cancer are illustrated. [1] 
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breast or colon.  Sarcomas are initiated in the supportive tissue including bone, cartilage, 
muscle and connective tissue.  Tumors originating in lymph nodes or the immune system 
are classified as lymphomas whereas leukemias are cancers originating from immature 
blood cells in the bone marrow.  Prefixes used to identify the location of the cancer are 
summarized in Table 1.1. [1] 
Table 1.1:  Cancer nomenclature.  Prefixes based on the location of cancer are summarized in the chart 
below (adapted from [1]). 
Location Prefix 
Gland Adeno- 
Cartilage Chondro- 
Red blood cell Erythro- 
Blood vessels Hemangio- 
Liver Hepato- 
Fat Lipo- 
Lymphocyte Lympho- 
Pigment cell Melano- 
Bone marrow Myelo- 
Muscle Myo- 
Bone Osteo- 
  
1.1.1. Cancer statistics 
Cancer accounted for 22.7% of all deaths in 2003 in the United States, second 
only to heart disease (see Table 1.2).  It is estimated that more than 1.4 million new 
cases of cancer will be diagnosed in 2006.  Cancer incidence varies among sexes with 1 
in 2 men and 1 in 3 women expected to develop cancer in their lifetime.  It is estimated 
that more than 1500 Americans die from cancer every day.  A comparison of death rates 
in 1950 compared to 2003 show no change in the cancer mortality rate.  The 5-year 
  
 
3 
survival rate for a variety of cancers has increased significantly in the past few decades 
due to earlier diagnosis and advances in treatment.   However, cancer continues to be a 
major cause of death in all industrialized countries. [2] 
Table 1.2:  2003 US mortality statistics.  Causes of death ranked based on number of deaths occurring in 
2003.  Adapted from [2]. 
Rank Cause of Death No. of Deaths % of All Deaths 
1 Heart diseases 685,089 28.0 
2 Cancer 556,902 22.7 
3 Cerebrovascular diseases 157,689 6.4 
4 Chronic lower respiratory diseases 126,382 5.2 
5 Accidents (Unintentional injuries) 109,277 4.5 
6 Diabetes mellitus 74,219 3.0 
7 Influenza and pneumonia 65,163 2.7 
8 Alzheimer disease 63,457 2.6 
9 Nephritis 42,453 1.7 
10 Septicemia 34,069 1.4 
 
1.1.2. Stages of cancer 
Cancer is the result of an accumulation of mutations in genes controlling cellular 
homeostasis [3].  These include genes that are involved in DNA repair, apoptosis, 
oncogenes and tumor suppressor genes [3].  An oncogene refers to a gene that when 
altered, leads to the progression of cancer due to its direct or indirect role in controlling 
cell growth. In contrast, tumor suppressor genes are normally involved in restricting cell 
proliferation and mutation or inactivation of tumor suppressor genes can lead to 
uncontrolled cell growth and cancer progression.  In a study of retinoblastoma cases, 
Knudson determined that the function of a tumor suppressor gene is only lost once both 
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copies are mutated, which is also true of DNA repair genes [4].  These mutations can be 
a result of inheritance or environmental exposures. 
Genetic damage to homeostatic genes and the resulting development of cancer is 
a multistage process that can be divided into 3 steps:  Initiation, promotion and 
progression (see Figure 1.2).  Initiation is characterized by a genetic mutation occurring 
as a result of a DNA damaging agent that covalently binds to DNA and is not repaired 
by cellular DNA repair machinery.  At this stage, the cell is not morphologically 
different from a normal cell.  In the next stage of promotion, mutated cells proliferate 
through epigenetic mechanisms and the expression of genes controlling important cell 
processes including proliferation, inflammation and differentiation is altered.  Mutational 
activation of oncogenes as well as inactivation of tumor suppressor genes are probable 
targets of altered gene expression in these early stages of cancer development [5].   
Benign tumors can form during the promotion stage but the cells do not yet have 
invasive or metastatic properties.  The final stage of cancer is progression in which cells 
acquire the ability to invade and metastasize due to the acquisition of additional genetic 
alterations and progressive genetic instability.  Alterations in cell size, shape and 
organization (dysplasia) occurs at this stage, and ultimately leads to an advanced form of 
cancer. [3] 
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Figure 1.2:  Model for skin multistage carcinogenesis.  The first stage of carcinogenesis is initiation, 
where a genetic mutation occurs that is not repaired.  In the promotion stage, the mutated cells proliferate 
and can form benign papillomas.  The final stage involves invasion and metastases of the mutated cells.  
[3] 
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1.2. Breast Cancer 
1.2.1. Rates and statistics  
 Up to one third of all new cancer cases in women are breast cancer (see Table 
1.3) [2].  Breast cancer is the second most common type of cancer diagnosed, next to 
skin cancer.  With the exception of melanoma, all types of cancer listed in Table 1.3 
have a lower 5-year survival rate than breast cancer [2], but the high incidence of this 
disease is cause for concern.  Female deaths from breast cancer are second only to lung 
cancer in cancer deaths, with over 41,000 women dying from breast cancer each year in 
the US [1]. 
 
Table 1.3:  2002 Cancer lifetime probability rates for US women.  Adapted from [2]. 
Site Rate 
All sites 1 in 3 
Breast 1 in 8 
Lung and bronchus 1 in 17 
Colon and rectum 1 in 18 
Uterine corpus 1 in 38 
Non-Hodgkin lymphoma 1 in 55 
Ovary 1 in 68 
Melanoma 1 in 77 
Pancreas  1 in 79 
Urinary bladder 1 in 88 
Uterine cervix 1 in 135 
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1.2.2. Mammary gland development 
1.2.2.1. Stages of development 
The mammary gland has distinct stages of development and is a unique organ 
due to its ability to continually change over a lifetime.  These stages of mammary 
development have been summarized in Figure 1.3.  The mammary gland develops early 
in embryogenesis as a derivative of the epidermis [6].  During puberty, ductal branching 
and elongation occurs and at the distal epithelial-stromal boundary, a club-shaped 
terminal end bud forms.  There are two distinct ductal branching processes:  (1) terminal 
end bud bifurcation, leading to the formation of two smaller ductules or alveolar buds; 
Figure 1.3:  Distinct stages of mammary gland development.  The mammary gland initially 
develops during embryogenesis.  During puberty, there are events of ductal branching and 
elongation.  Alveolar proliferation occurs during pregnancy.  Critical gene products including 
hormones and hormone receptors are shown.  Abbreviations used:  ΕRα (estrogen receptor),  
PRL (prolactin), PRLR (prolactin receptor), PR (Progesterone receptor), CSF-1 (macrophage 
specific colonary stimulating factor 1). [9] 
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(2) sprouting of side branches from mature ducts [7,8].  A group of branches is referred 
to as a lobule and lobule (Lob) types 1, 2, 3 are defined by the cluster size, with 11, 47 
and 80 being the average number of ductules, respectively [7]. During pregnancy, 
alveolar proliferation occurs to prepare for lactation.  The expansion of the mammary 
epithelium into milk-producing alveoli occurs as a result of hormonal stimulation.    
Functional differentiation is another morphogenetic change that can occur during 
parturition and lactation [9].  At this stage, the secretory epithelium dies via apoptosis, 
the fat cell redifferentiates and the mammary gland is remodeled to its pre-pregnancy 
state [8]. 
1.2.2.2. Stromal-epithelial interactions 
The mammary gland consists of both stromal and epithelial cells that 
communicate with each other via the extracellular matrix [8].  This communication is 
critical for proper patterning and normal mammary gland function and its disruption can 
lead to the development of breast cancer [6].  There are parallels between the different 
stages of mammary development and tumor progression including invasion, reinitiation 
of cell proliferation, resistance to apoptosis and angiogenesis [8].  Epithelial cells 
possess invasive properties in that they proliferate and invade the stroma.  
Tumorigenicity is greatest in the mammary epithelium due to its proliferative and 
invasive abilities but epithelial cells are controlled by stromal cells.  The stroma is a 
heterogenic combination of adipocytes, pre-adipocytes, fibroblasts, blood vessels, 
inflammatory cells and extracellular matrix that are all subject to regulation in various 
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stages of mammary development.  The lactating mammary gland possesses anti-
apoptotic mechanisms to prevent premature involution.  Angiogenic remodeling is also a 
part of the morphogenetic changes that occur in the mammary gland [10]. 
1.2.2.3. Hormones and mammary gland development 
 The exact roles of the hormones estrogen and progesterone on mammary 
proliferation are still somewhat controversial.  The potential effects of estrogen on 
various types of mammary epithelial cells are summarized in Figure 1.4.  Normal ductal 
growth is controlled by estrogen and progesterone that are secreted from the ovaries and 
their excretion is positively regulated by growth hormone (GH) [7].    Estrogen is 
thought to play a major role in stimulating growth of both normal and neoplastic 
mammary epithelium [11,12], however, when estrogen and progesterone are at their 
peak levels during normal cycling, maximal proliferation is not achieved.  Peak growth 
is achieved during the luteal phase where levels of progesterone and estrogen are 
significantly lower [8].  There is added complexity regarding the effects of estrogen and 
progesterone in animal models and cell culture, estrogen stimulates growth of cells in 
culture and in athymic nude mouse models whereas progesterone has no effect on 
growth and can be growth inhibitory [13,14]. 
The estrogen receptor (ER) and progesterone receptor (PR) status is correlated 
with proliferative capacity.  Lob 1 contains the highest level of these ovarian hormone 
receptors and has the greatest proliferative capacity [7].  Interestingly, nulliparous 
women have the highest percentage of Lob 1 and also have an enhanced risk of breast 
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cancer [15].   Another intriguing observation is the lack of correlation between 
proliferating cells and ER-positive cells, yet there is a positive association between 
proliferation and nuclear receptor expression [16]. 
 
 
Figure 1.4:  Potential pathways of estrogen action on mammary epithelial cells.    Estrogen can 
stimulate ΕRα  positive proliferating cells.  The effects of estrogen on ΕRα  positive nonproliferating cells 
may involve the production of a growth factor that in turn, stimulates growth in ΕRα negative cells.  
During neoplastic transformation, ΕRα negative cells may convert to ΕRα positive cells.  [7] 
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Several other hormones principally are also involved in mammary gland 
development.  Both activins and inhibins, which are members of the transforming 
growth factor beta (TGF-β) family are involved in ductal elongation and alveolar 
development, as shown in Figure 1.3 [6].  The exact role of activins/inhibins in these 
processes has yet to be elucidated but may involve a role as local mediators of hormone 
signals [9].  Prolactin signaling is also essential for lobulo-alveolar differentiation during 
pregnancy [17] and prolactin acts through the JAK-STAT pathway to induce this stage 
of differentiation [18].  There is also evidence that prolactin may play a role earlier in 
development during puberty [19].  Oxytocin is another hormone that is necessary for 
milk ejection and alveolar cell proliferation [9].   Oxytocin is transported through the 
bloodstream, interacts with receptors on the surface of myoepithelial cells to initiate their 
contraction and the subsequent release of milk from the alveoli into the ducts [20]. 
Colony-stimulating factor-1 (CSF-1) is also important for lactation.  Deletion mutants of 
CSF-1 have reduced ductal growth during pregnancy and lack of milk secretion [20]. 
1.2.3. Characterization of breast cancer 
1.2.3.1. Histologic types of breast cancer 
Breast tumors can be classified based on histological examination of their tumor 
location.  In situ refers to a non-invasive form of breast cancer that can be confined to 
the ducts (ductal carcinoma in situ, DCIS) or lobules (lobular carcinoma in situ, LCIS).  
DCIS is the most common type of non-invasive breast cancer.  If women have DCIS or 
LCIS, they run a higher risk of developing an invasive form of breast cancer.  Once 
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cancer cells break through the duct wall and spreads into the fatty tissue of the breast, it 
is classified as invasive ductal carcinoma (IDC) which comprises about 10-15% of 
invasive breast cancer.  Conversely, invasive lobular carcinoma constitutes 85-95% of 
breast cancer cases and involves cancer cells extending past the lobule wall [5].  
Medullary carcinoma is a special type of IDC where there is a distinct boundary between 
the tumor and normal tissues and accounts for 5% of breast cancer cases.  There are also 
a large number of tumor cells and immune cells at the edges of the tumor.  Colloid 
cancer is a specific type of ductal breast cancer formed by mucus-producing cancer cells.  
Tubular carcinoma is a special type of infiltrating ductal breast carcinoma.  
Inflammatory breast cancer is found in 1-3% of breast cancer cases. [3] 
1.2.3.2. Breast cancer stages 
Breast cancers are initially categorized by tumor size (T), lymph node 
development (N), and the presence or absence of distant metastases (M).  Based on these 
parameters, they are graded into 4 stages, with a higher stage pertaining to increased 
invasiveness.  A summary of the stages and combination of T, N, and M values is shown 
in Table 1.4.  Stage I is early-stage cancer and refers to the presence of a breast tumor 
less than 2 cm and no signs of lymph node development or distant metastasis. In the next 
stage, the tumor is between 2 and 5 cm or there are signs of lymph node development 
but no signs of metastasis.  Inflammatory breast cancer is characterized as IIB as long as 
it has not spread to other organs. Stage IIIA characterizes tumors more advanced than 
Stage II tumors in terms of a higher degree of lymph node development where they may 
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Table 1.4:  Summary of characteristics for each stage of breast cancer. Tumor size classes (T):  T0=no 
tumor; T1=≤ 2.0 cm, T2=≥ 2.0 cm ≤ 5.0 cm; T3=≥ 5.0 cm; T4= Any size with direct extension to chest 
wall or skin.  Lymph node development classes (N):  N0=No regional lymph node metastasis; N1= 
metastasis to movable ipsilateral axillary lymph node; N2=Metastasis to ipsilateral axillary lymph node(s) 
fixed or matted.  Distant metastasis classes (M):  M0= No distant metastasis; M1=Distant metastasis.  
Adapted from [2,21] 
Stage 
5-Year 
Survival 
Rate 
Stage 
Subtype 
Tumor 
size (T) 
Lymph node 
development 
(N) 
Distant 
Metastasis 
(M) 
I 
 
95-98 % - T1 N0 M0 
A T0-T2 N0-N2 M0 
II 
 
76-88 % 
B T2-T3 N0-N1 M0 
A T0-T3 N1-N2 M0 
B T0-T3 N0-N2 M0 III 
 
49-56 % 
C T4 N0-N2 M0 
IV 
 
15-20 % - T4 Any N M1 
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be clumped or a tumor larger than 5 cm.  In Stage IIIB, the tumor includes the breast 
skin or extends to the chest wall or involves internal mammary lymph nodes.  The fourth 
and most advanced stage of breast cancer can be generally applied to tumors that have 
metastasized most commonly to the liver, lung or brain.  Each increase in stage is 
correlated with a worse prognosis which requires more aggressive treatment modalities. 
[21] 
1.2.3.3. ER status of breast cancer 
 The ERα status of a tumor is a critical prognostic factor and important for 
determining appropriate treatments.  ΕRα−positive breast cancers are defined as those 
that positively respond to hormone therapy.  Hormone therapy specifically targets 
estrogen signaling and the subsequent mitogenic effects of estrogen on tumor cells.  
ΕRα−negative breast cancers do not respond to hormone therapy and are considered 
more aggressive with a worse prognosis than their ΕRα−positive counterparts.  Because 
they do not respond to hormone therapy, the use of cytotoxic drugs is often employed 
and these compounds have an extensive list of adverse side effects. 
ERα-negative nondividing cells constitute the largest group of cells in the 
mammary gland [22].  Only 30% of cells are ERα-positive at any one time and these 
cells are rarely dividing [16].  Invasive breast cancer typically arises from an 
increasingly abnormal series of hyperplasias, atypical hyperplasias and noninvasive 
carcinomas [23].  There are two models used to describe the origins of ERα-negative 
tumors: (1) the loss of the ability to synthesize ERα or (2) ERα-positive and ERα-
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negative cancers originate from entirely different subpopulations of cells [24,25]. 
 ΕRα methylation is more prominent in ERα-negative breast cancer and may account for 
repressing ΕRα expression [26].  ΕRα is degraded via hypoxia-induced factor 1 alpha 
under hypoxic conditions, which is common feature of the tumor microenvironment [27].  
The precise etiology of ΕRα−negative breast cancer is still under investigation. 
1.2.4. Influences on breast cancer development 
1.2.4.1. Genetic factors 
 Inherited genetic susceptibility accounts for approximately 5-10% of breast 
cancer cases [28] and the genes associated with hereditary breast cancer include breast 
cancer 1 gene (BRCA1), breast cancer 2 gene (BRCA2), tumor protein p53 (TP53), 
checkpoint kinase 2 (CHK2) and Ataxia-telangiectasia gene (ATM) [29].  All of these 
genes are involved with DNA repair and maintenance of genomic integrity.  BRCA1 
was initially named in 1992 after early-onset familial breast cancer cases were linked to 
chromosome 17q21 [30].  Families with high incidences of male breast cancer did not 
have BRCA1 mutations, which spurred the discovery of BRCA2 on chromosome 13q12-
13 [31].  BRCA mutations are frequently protein truncations and occur at a frequency of 
1 in 250 women [29].  Penetrance is defined as the risk of developing breast or ovarian 
cancer by the age of 70 and is 80% for women with BRCA1 and BRCA2 mutations [29].  
Tumor characteristics of BRCA1 and BRCA2 mutations are summarized in Table 1.5.  
Both BRCA1 and BRCA2 function in DNA repair by interacting with RAD51, a key 
DNA repair enzyme which catalyzes homologous recombination.  Therefore BRCA 
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mutations lead to hypersensitivity to agents that crosslink DNA strands [29].  BRCA1 
also plays a role in ubiquitylation, a process by which proteins are tagged for 
degradation.   The BRCA1-BARD1 (BRCA1-associated ring domain protein) 
heterodimer has significant ubiquitin ligase activity [32].  In addition, BRCA1 plays a 
role in checkpoint control and chromatin remodeling [29].  In summary, BRCA proteins 
play roles in a number of critical cell processes. 
 
Table 1.5:  Key characteristics of BRCA1 and BRCA2-associated breast cancers. [29] 
Phenotype BRCA1-associated BRCA2-associated 
Morphology Ductal (75%), atypical 
medullary  (~10%) 
Ductal (75%), atypical 
medullary (<5%) 
Grade High (grade 3) Medium (grade 2) or high (grade 3) 
Estrogen receptor expression Negative (75%) Positive (75%) 
ErbB2 expression Negative (95%) Negative (95%) 
p53  Positive (50%) Positive (40%) 
Cyclin D1 expression Negative (90%) Positive (60%) 
Carcinoma in situ Rare Common 
 
 
Another frequently mutated gene in breast cancer is p53, with 30% of breast 
tumors having a mutation [33].  p53 is a transcription factor that is involved in cell cycle 
regulation, DNA maintenance and genomic integrity, repair after DNA damage and 
apoptosis [33]. p53 mutations commonly precede loss of heterozygosity (LOH) of the 
wild-type allele [33].  Due to the critical role of p53 in the cell, its mutation can lead to 
cancer since cell growth continues in spite of damaged DNA and therefore increases the 
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frequency of other gene mutations.  Germline mutations in the p53 gene have been 
responsible for Li-Fraumeni syndrome [34].  The penetrance for breast cancer in families 
with Li-Fraumeni syndrome is a minimum of 50% by the age of 50, suggesting that p53 
is important in the early stages of breast cancer [33].  The type and frequency of p53 
mutations is modulated by BRCA1/BRCA2 status, with a higher tumor incidence of p53 
mutations in BRCA1/2 patients [35]. Recently, CHK2 germline mutations have been 
associated with classical and variant Li-Fraumeni syndrome [28].  CHK2 and p53 
closely interact and CHK2 directly phosphorylates the site where p53 binds to Mdm2, 
thus preventing the Mdm2 inhibition of p53 [36]. 
The third principal syndrome associated with autosomal dominant inheritance of 
breast cancer risk is Cowden syndrome [28].  Cowden syndrome is due to PTEN 
germline mutations [37] and is a rare autosomal dominant condition.  Women with 
Cowden’s syndrome have a 30-50% chance of developing breast cancer by the age of 50 
[38].  PTEN is a phosphatase that negatively regulates the phosphoinositide 3-kinase 
signaling pathway [39]. 
Ataxia-telangiectasia is a rare autosomal recessive disorder, with homozygotes 
occurring only 3 in 1 million and increases risks for a variety of diseases including an 
increased incidence of breast cancer [39].  Both in vivo and in vitro studies have shown 
AT carriers have an extreme sensitivity to radiation and an increased risk of radiation 
leading to cancer [40].  ATM is the only gene causally linked to ataxia-telangiectasia.  
Like many other genes implicated in inherited breast cancer, ATM is involved with 
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DNA repair and is required for DNA double-strand break repair, apoptosis and cell cycle 
arrest [39].  Although homozygosity is rare, AT heterozygosity is present in 1.5% of the 
population and may account for 7.5% of breast cancer cases [41]. 
1.2.4.2. Environmental factors   
 In addition to genetic factors, there are a variety of factors that can influence the 
development and severity of breast cancer.  Environment plays a much larger role than 
genetics in terms of cancer susceptibility.  In an epidemiology study of twins in Finland, 
18% and 77% of the liability in inter-individual variation in the risk of breast cancer 
were attributable to shared environmental factors and unique environmental factors, 
respectively [40].   Female gender, country of birth and age are major risk factors for 
breast cancer [42].  Only 0.6% cases of breast cancer are males.  A summary of 
established risk factors is shown in Table 1.6.  There are other more inconclusive risk 
factors that may contribute to breast cancer risk.  Rodents fed a high-fat diet had 
enhanced mammary tumor development [43].  More specifically, diets rich in linoleic 
acid have increased breast cancer development [44].  Other fats including oleic acid and 
fish oil have a protective effect against cancer [44].  
 Many of the known risk factors of breast cancer are associated with reproductive 
characteristics including pregnancy-related and menstrual factors.  The risk of breast 
cancer increases the older a woman is for her first pregnancy.  The relative risk is 0.5 for 
mothers aged 20 or younger and increases to 1.4 over the age of 35 [45].  This may be 
due to changes in breast tissue that result in decreased susceptibility to carcinogenic 
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agents or hormonal changes that reduce breast cancer risk [46].  Nulliparity is also a risk 
factor for breast cancer.  Women with at least 5 pregnancies have a breast cancer relative 
risk of 0.5 compared to women who have had no children [47,48].   
Females that have begun menstrual cycles at an earlier age and women that reach 
menopause at a later age have an enhanced breast cancer risk [47,49].  These effects are 
due to a positive association between the total number of years of menstrual active and 
breast cancer incidence [49].  Oophorectomies at a young age (before 40) are also 
associated with a decreased risk of breast cancer [50].  Both human  reproductive and 
menstrual factors and animal studies indicate that hormones play a significant role in 
breast cancer incidence and epidemiology studies suggest that lifetime estrogen exposure 
is associated with an increase risk of breast cancer [50,51].  However, the mechanisms of 
estrogen-induced breast cancer are not that well understood.   
A Women’s Health Initiative (WHI) study recently showed that combined 
estrogen and progestin used in postmenopausal women was associated with an increased 
incidence in invasive breast cancer taking these hormones for a 5-year period [52,53].  In 
addition, breast cancers diagnosed in women taking estrogen and progestin therapies 
were a more advanced form of cancer [53].  Other studies suggest estrogen and progestin 
exposure increase mammographic breast density when compared to control groups or 
women treated with estrogen alone [54,55].  The biological relevancy of breast density 
on breast cancer risk is still under investigation.  Although the WHI study did not 
support a relationship between postmenopausal hormone replacement therapy and the 
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incidence of invasive lobular breast cancers [53], other studies reported an increased 
incidence in this type of cancer with hormonal replacement therapy [56,57]. 
Prior to the WHI study, breast cancer mortality was reported to be lower in 
women using hormone replacement therapy [58-60], and it was suggested that this was 
due to earlier diagnosis and treatment [61,62].  Differences between studies may be a 
result of older women and the different treatment regimen in the WHI study compared to 
the younger women studied in previous reports [63]. 
Exogenous hormones from oral contraceptives, depot-medroxyprogesterone 
acetate and estrogen replacement therapy have been studied and a number of 
epidemiology studies have shown no correlation between oral contraceptive use and 
breast cancer risk [64-66], however, this conclusion remains controversial [67].  No 
relationship has been found between the injectable contraceptive, depot-
medroxyprogesterone (DMPA) and breast cancer risk [68,69].  Several studies have 
reported no association between breast cancer risk and hormone replacement therapy 
[70-72], however an increased risk was observed with the use of hormone replacement 
therapy for more than 20 years [73,74] or estrogen/progestin therapy [75]. 
In postmenopausal women, body weight and height have been correlated to 
breast cancer risk [76].    Heavy menopausal women have higher rates of conversion of 
androstenedione to estrogen in adipose tissue and lower levels of sex-hormone-binding 
globulin compared to thinner women [46].  For younger, premenopausal women, there is 
a higher risk of breast cancer in thinner women but this may be due to easier detection of 
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tumors in these individuals [76].  Adult weight gain increases the premenopausal risk of 
breast cancer whereas weight loss may be protective.   
There have also been some reports linking diethylstilbestrol (DES) use during 
pregnancy to a modest but significant increase in breast cancer risk and this does not 
increase over time [77,78].  The proportion of ERα-positive tumors increases with age, 
is higher in whites than in blacks and may be higher in postmenopausal than in 
premenopausal women.  It is not known whether the estrogen-receptor status of normal 
cells affects the likelihood of cancer following exposure to a carcinogenic agent. 
 The effects of several environmental exposures on breast cancer incidence have 
also been investigated.  Organochlorine compounds are present in the environment due 
to their use in industry and as pesticides and environemental persistence.  High serum 
levels of organochlorines in breast cancer patients in some studies have been associated 
with up to 4-fold increased breast cancer risk [79-81].  However, epidemiology studies 
have not shown a statistically significant link between organochlorine exposure and 
increased breast cancer incidence [82-84].  Organic solvents are commonly employed in 
the production of glues, paints and other industrial chemicals.  The influence of organic 
solvent exposure on breast cancer risk have been inconclusive with some occupational 
studies showing an increased risk [85,86] whereas other studies showed no increased 
breast cancer risk in women occupationally exposed to high levels of organic solvents 
[87,88].  Epidemiological studies have also shown a modest increase in breast cancer 
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risk after metal exposure [89] and some divalent metals including cadmium, copper and 
cobalt exhibit estrogenic activity in MCF-7 breast cancer cells [90]. 
 Cigarette smoke contains an array of carcinogens and for this reason has been of 
interest as a risk factor for a variety of cancers.  In vitro and in vivo studies have 
suggested the breast as a target tissue for tobacco smoke carcinogens since they can pass 
through the alveolar membrane and are transported by lipoproteins to the breast [91-93].  
The link between breast cancer and smoking has been extensively studied but has 
generated inconclusive results, with positive, inverse and null relationships between 
smoking and breast cancer risk [91].  Critical timing of smoking has also been 
investigated and this is based on the hypothesis that when the breast is developing, it is 
most susceptible to carcinogens present in cigarette smoke.  The temporal effects of 
smoking on breast cancer have been investigated and exposures during breast 
development has also failed to yield any positive associations with increased breast 
cancer risk [94,95]. 
 A recent meta-analysis of 89 studies comparing alcohol consumption to breast 
cancer incidence showed 29 studies with odds ratios less than 1 and 60 studies greater 
than 1, overall supporting a modest, but enhanced risk of breast cancer associated with 
increased alcohol consumption [96].  There was no significant difference in breast 
cancer risk seen between consumption of beer, wine or spirits.  An increase of one drink 
per day resulted in a 10-13% increase in breast cancer risk. 
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Table 1.6:  Established risk factors for breast cancer in females.  Adapted from [46,97] 
 
Risk Factor High-Risk Group Low-Risk Group 
HIGHEST RISK (RELATIVE RISK GREATER THAN 4.0) 
Age Old Young 
Country of birth North America 
Northern Europe 
Asia, Africa 
Mother and sister with history of 
breast cancer 
Yes No 
MODERATE RISK (RELATIVE RISK FROM 2.0 TO 4.0) 
Socioeconomic status High Low 
Age at first full-term pregnancy >30 years <20 years 
Oophorectomy premenopausally No Yes 
History of cancer in one breast Yes No 
History of benign proliferative lesion Yes No 
Any first-degree relative with history 
of breast cancer 
Yes No 
Mammographic parenchymal patterns Dysplastic parenchyma Normal parenchyma 
Radiation to chest Large doses Minimal exposure 
LOWER RISK (RELATIVE RISK FROM 1.1 TO 1.9) 
Marital status Never married Ever married 
Place of residence Urban Rural 
Race >45 years 
       <40 years 
White 
Black 
Black 
White 
Nulliparity Yes No 
Age at menopause Late Early 
Age at menarche Early Late 
Weight, postmenopausal women Heavy Thin 
Alcohol consumption >4 alcoholic 
beverages/day 
No alcohol 
History of primary cancer in 
endometrium or ovary 
Yes No 
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1.2.5. Current treatments 
There are 3 primary surgical options for treatment of breast cancer:  (1) 
lumpectomy surgery and radiation (2) mastectomy plus reconstruction (3) mastectomy 
alone.   Lymph node surgery also may be employed in cases where cancer has spread to 
the lymph nodes (>T0).  There are adjuvant therapies, which increase the efficacy of the 
primary treatment and therefore reduce the likelihood of cancer reoccurrence and these 
include radiation, systemic therapy, chemotherapy and monoclonal antibody therapy.  
Radiation therapy is used to destroy any remaining cancer cells left in the breast, chest 
wall or lymph nodes after surgery and is most commonly used after lumpectomies.  
Adjuvant systemic therapy targets cells that may have spread beyond the breast and 
adjacent tissues.   This includes hormone therapy if the tumor is ER-positive and drugs 
such as tamoxifen, or aromatase inhibitors (e.g. anastrozole) are used.  There is also 
neoadjuvant therapy, which is carried out prior to surgery as a potential method to shrink 
the tumor so it can be removed surgically without the need for mastectomy. [1,98] 
Adjuvant chemotherapy usually involves the use of a genotoxic agent and 
common genotoxic agents employed in breast cancer are summarized in Table 1.7.  
Doxorubicin and epirubicin work by two mechanisms:  (1)  DNA intercalation and 
subsequent blockage of DNA synthesis and transcription and (2) inhibition of 
topoisomerase II enzyme.  These effects lead to breaks in the genomic DNA.  
Cyclophosphamide acts as a DNA alkylating agent and other chemotherapeutic agents 
also interact with DNA by acting as a DNA alkylating agent (cyclophosphamide) or a 
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pyrimidine analog (gemcitabine).  Other drugs interfere with chromosomes and hence 
halt cell division and induce cell death.  In the presence of paclitaxel or docetaxel the 
chromosomes are unable to move to opposite sides of the dividing cell because 
microtubules are not broken down. The vinca alkaloids first bind to tubulin monomers 
inhibiting the formation of microtubules. Without adequate numbers of microtubules, the 
newly replicated chromosomes can not be separated and cell division is blocked. The 
aborted cell division process triggers cell death.  Capecitabine is metabolized into 5-FU 
in the cells which interferes with cell division, RNA and protein processing and 
ultimately results in cell death. [99] 
 
Table 1.7:  Summary of commonly used cytotoxic chemotherapeutic breast cancer drugs [1,99] 
Brand Name (Generic Name) Mechanism of Action 
Adriamycin (Doxorubicin) DNA intercalation Topoisomerase II inhibition 
Cytoxan (Cyclophosphamide) DNA alkylating agent 
Ellence (Epirubicin) DNA intercalation 
Topoisomerase II inhibition 
Gemzar (Gemcitabine) Pyrimidine analog 
 
Navelbine (Vinolrelbin) Inhibits microtubule formation 
 
Taxol (Paclitaxel) Prevents microtubule breakdown 
 
Taxotere (Docetaxel) Prevents microtubule breakdown 
Xeloda (Capecitabine) Interferes with RNA and protein 
processing 
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Adjuvant monoclonal antibody therapy is also commonly employed in women 
who have HER2/Neu overexpressing tumors.  HER2/Neu activates the PI3K/Akt 
pathways which inhibits apoptosis, therefore enhancing cell proliferation. In addition, 
HER family members have also been associated with secretion of pro-invasive proteins 
that degrade the basement membrane.  Monoclonal antibody therapy inhibits the 
function of HER2/Neu receptor to favor cell death and therefore reduces the invasive 
capacity of the cells. [1] 
1.2.6. Chemoprevention 
Cancer chemoprevention refers to the use of a chemical, either natural or 
synthetic, that can block cancer in the early stages or hinder cancer progression before 
the cancer progresses to a malignant stage.  To block the early stages of cancer 
development, chemicals can reduce the likelihood of DNA damage by modulating 
metabolizing enzymes or by increasing the quantity of antioxidants that detoxify 
potentially mutagenic compounds.  Since cancer also requires cell proliferation to 
progress, inhibition of cell proliferation is a necessity and this can be accomplished by 
either reducing inflammation, which can lead to increased cell proliferation or by 
modulating regulatory components involved in cell growth. 
1.2.6.1. Antimutagens 
Antimutagens encompass agents that inhibit the initiation stage of cancer.  
Sulforaphane is a glucosinolate phytochemical found in cruciferous vegetables and is 
considered an antimutagen.  Early studies showed that sulforaphane inhibits Phase I drug 
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metabolizing enzymes involved in carcinogen activation as well as induce Phase II drug 
metabolizing enzymes such as glutathione-S-transferase (GST) involved in the 
detoxification of carcinogens [100].  However, more recently other effects of 
sulforaphane have been reported.  For example, sulforaphane induces cell cycle arrest 
including a G2/M arrest also disrupts microtubule polymerization in MCF-7 breast 
cancer cells [101,102].  Other studies have also shown that sulforaphane is an HDAC 
inhibitor, inhibitor of H. pylori inflammation and induces apoptosis in other cancer cell 
lines [103-105] . 
1.2.6.2. Antiinflammatory compounds 
Antiinflammatory drugs such as cyclooxygenase-2 (COX-2) inhibitors inhibit 
both the promotion and progression of neoplasia.  NSAIDs, which inhibit both 
cyclooxygenase (COX-1) and COX-2 also reduce breast cancer incidence [106].  
Cyclooxygenase enzymes are involved in prostaglandin synthesis, which play important 
roles in blood clotting, wound healing, immune response, bone metabolism, nerve 
growth and development [107].  Inhibition of COX-2 has been associated with decreased 
cell proliferation, induction of apoptosis and a reduction in inflammation [108] and 
therefore is a putative chemotherapeutic target.   In addition, COX-2 expression is 
elevated in some tumors such as colorectal tumors [109]. 
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1.2.6.3. Antioxidants 
Tea is the second most popular beverage in the world and recent epidemiological 
studies have linked an increased consumption of green tea with a decreased incidence of 
breast cancer [110].  In addition to the epidemiological data, green tea has been 
extensively investigated by cancer researchers due to its antioxidant properties [111].  
Antioxidants have the ability to inhibit both initiation and promotion of cancer due to 
their ability to act as reactive oxygen species (ROS) scavengers [112].  In vitro and in 
vivo studies have also shown that green tea extracts, specifically catechins, inhibit breast 
cancer cell growth and reduce the size and multiplicity of carcinogen-induced rodent 
tumors [113,114].  Green tea extracts are promising new cancer agents, although more 
work on the mechanism of growth inhibition still needs to be carried out. 
Omega-3 fatty acids also have a protective effect against breast cancer 
development.  Fish oil, which is rich in omega-3 fatty acids, inhibited growth in breast 
cancer cells and reduced lung metastases in a xenograft model [115] and there is 
increasing evidence that omega-3 fatty acids also have effects on cell transformation 
based on data showing that omega-3 fatty acids decreased levels of ras p21, a proto-
oncogene. However, case control studies have been unable to show a link between fish 
consumption and breast cancer incidence in the United States and Norway [116,117].  
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1.2.6.4. Hormone modulators 
Endocrine therapy for breast cancer targets estrogen by either inhibiting the 
binding of estradiol to ER through the use of selective estrogen receptor modulators 
(SERMs) such as tamoxifen or by reducing the amount of estrogen produced through the 
use of aromatase inhibitors.  Aromatase inhibitors interfere with the conversion of 
testosterone to estradiol by blocking the aromatase enzyme necessary for this reaction.  
Both endocrine therapies are focused on decreasing the mitogenic effects of estrogen on 
mammary epithelial cells.  There have been large prospective clinical trials showing a 
reduction in breast cancer incidence in women with adjuvant treatment of tamoxifen [47-
49,118] and aromatase inhibitors such as anastrozole look even more promising.   
Premenopausal women with early breast cancer had significantly reduced onset to an 
invasive form of breast cancer with anastrozole treatment compared to tamoxifen 
treatment [52]. 
1.2.6.5. Signal transduction modulators 
Signal transduction modulators inhibit the promotion and progression of 
neoplasia.  Vitamin D is known to play a significant role in controlling Ca2+ homeostasis 
and is involved in cell proliferation and hence has been investigated for its 
chemotherapeutic potential.  1,25-dihydroxyvitamin D3 (1,25(OH)2D3) inhibited tumor 
growth in the 7,12-dimethylbenz[a]anthracene (DMBA)-induced rat mammary cancer 
model as well as inhibiting cell proliferation in breast cancer cells [119].  However, there 
were many side effects after treatment with 1,25(OH)2D3 and these are associated with 
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its prominent role in calcium homeostasis [119].  Treatment with analogues of vitamin 
D3 also inhibited mammary tumor growth without the potent hypercalcemic side effects 
of Vitamin D [120,121].  These compounds may be inhibiting growth by modulating 
genes involved in proliferation, differentiation and cytokine production via the vitamin 
D receptor [122].  Synthetic analogs of Vitamin D are promising new agents for breast 
cancer treatment.  
The consumption of cruciferous vegetables has been correlated with a decreased 
risk of several types of cancer [123-127]. 3,3’-Diindolylmethane (DIM) is formed in the 
gut as a condensation product of the phytochemical indole-3-carbinol (I3C) [128,129]. 
Several studies show that cruciferous vegetables (or their extracts), indole-3-carbinol 
(I3C) and 3,3’-diindolylmethane (DIM) exhibit antitumorigenic activity in in vivo rodent 
models and inhibit growth of cancer cell lines in vitro [130-135].  For example, I3C 
inhibited growth and/or formation of DMBA-induced and spontaneous age-dependent 
mammary tumors and decreased the incidence of spontaneous endometrial tumors in 
rodent models [131,133].   
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1.3. Mechanism-Based Treatment Targets 
 The ideal anticancer drug specifically targets cancer cells with minimal side 
effects on other tissues.  Two properties that can significantly influence the adverse 
effects associated with a drug include the mode of cell death and the specificity of the 
biological target.  Early chemotherapeutic agents such as mustard gas primarily affected 
rapidly dividing cells due to its DNA alkylation properties.  Although tumor cells are 
rapidly dividing, there are a number of other cell types that undergo rapid proliferation 
and these include epithelial cells lining the intestine and cells of the immune system and 
cytotoxic drugs can induce many adverse side effects in these rapidly dividing 
tissues/cells.  The form of cell death induced by a drug can also have a critical influence 
on its side effects since only necrotic cell death elicits an unfavorable immune response. 
1.3.1. Types of cell death 
Cell death has been an area of scientific interest for decades.  Initially, two 
distinct forms of cell death were described; namely apoptosis and necrosis.  Apoptosis is 
related to a programmed form of cell death and another form of cell death was 
characterized as necrosis.  Currently 11 different forms of cell death have been 
characterized and these are summarized in Table 1.8 [136].  The differences between 
these forms of cell death are now less clear since they have overlapping characteristics 
[137].  Anoikis refers to apoptotic cell death triggered by cell detachment.  In addition, 
forms of cell death referred to as apoptotic necrosis has also been described 
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Table 1.8:  Different types of cell death.  The features of 11 different forms of cell death are summarized below.  Abbreviations used:  WD, Wallerian 
degeneration; PLT, platelets; TG, transglutaminases; NO, nitric oxide; NCX, sodium calcium exchange channel; IAP, inhibitor of apoptosis proteins 
[136] 
 Necrosis Apoptosis Anoikis Caspase-
independent 
apoptosis 
Autophagy WD Excito 
toxicity 
Erythro-
poiesis 
PLT Corni-
fication 
LENS 
Genetic 
Program 
None Yes Yes Yes Yes Yes Yes Yes Yes Yes Yes 
Membrane Lysed Intact 
PS 
exposure 
Intact 
PS 
Exposure 
Intact 
PS exposure 
Intact 
PS 
exposure 
Intact Intact Intact Intact Intact  
Organelles Lysed Intact Intact Intact Intact lipid-
reassembly 
Intact Intact Intact Intact Crosslinked 
lipid-
reassembly 
 
Mitos Blown Intact Intact     Lost  Lost Lost 
Nucleus  Chr. 
condens. 
DNA 
fragm. 
Chr. 
condens. 
DNA 
fragm. 
Chr. 
condens. 
DNA fragm. 
Chr. 
condens. 
DNA 
fragm. 
  Lost Lost Lost Lost 
Enzymes None Caspases Caspases Calpains Lysosomal 
Beclin1 
VPR Calpains 
NCX 
Calpains  TG 1,3,5 TG 
Receptors  Death Rec          
Regulators  Bcl 
family 
IAP 
    NO 
calcium 
GATA2  AP1 
calcium 
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where apoptotic cells are not recognized by phagocytes and consequently display 
necrotic features [138].  The form of cell death induced is dependent on the specific 
agent as is also cell-context dependent.  These factors critically influence which 
signaling pathways are activated or inhibited, ultimately determining the pathway of cell 
demise.  Apoptosis, autophagy and necrosis are the three most relevant forms of cell 
death in terms of cancer treatments and will be described in detail below. 
1.3.1.1. Apoptotic cell death 
 Apoptosis refers to programmed cell death that is a genetically encoded form of 
cell suicide and critical during development and tissue homeostasis [139,140].  During 
development, cells produced in excess undergo apoptosis for organ and tissue sculpting 
[141].  The morphologic hallmarks of apoptosis include membrane blebbing, cell 
shrinkage, chromatin condensation, DNA fragmentation and eventual engulfment by 
macrophages or neighboring cells [142].  Packing of cell contents into apoptotic bodies 
and subsequent phagocytosis occurs in the later stages of apoptosis.  One of the “eat me” 
signals on apoptotic cells is phosphatidylserine flipping from the inner surface to the 
external surface of the cell membrane as an indicator for phagocytic engulfment [142]. 
1.3.1.1.1. Intrinsic and extrinsic pathways of apoptosis 
 There are 2 major pathways of apoptosis:  the extrinsic pathway, which is 
mediated by death receptors and the intrinsic pathway, which is mitochondrial-mediated 
(see Figure 1.5).  Death receptors are cell surface receptors belonging to the tumor 
necrosis factor receptor (TNFR) family that bind ligands which sense abnormal 
intracellular or extracellular conditions.  Ligands of this family include tumor necrosis
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Figure 1.5:  Apoptotic death pathways in mammalian cells.   There are 2 apoptotic pathways in cells:  
(1) The extrinsic pathway involving death receptors (e.g. CD95L) that upon ligand binding induce 
formation of a DISC complex which activates the apical caspase-8 and downstream effector caspase-3 and 
subsequent cleavage of death substrates.  FLIP can inhibit caspase-8 activation.  Activated caspase-8 can 
also cleave Bid, which can induce the mitochondrial-mediated apoptotic pathway.  (2)  The intrinsic 
pathway involves the mitochondria and can be activated by various apoptotic stimuli including DNA 
damage, which can lead to the release of small molecules from the mitochondria including cytochrome c, 
AIF, Smac/DIABLO.  Cytochrome c release triggers the formation of the apoptosome and activation of 
apical caspase-9, leading to caspase-3 activation, cleavage of death substrates and ultimately apoptosis.    
Smac/DIABLO induces apoptosis by inhibiting IAP proteins. [143]   
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factor-alpha (TNF-α), CD-95L/Fas and tumor necrosis factor-related apoptosis-inducing 
ligand (TRAIL).  TNFRs are ligand-specific in that TNF-α binds to TNFR1, TRAIL 
binds to DR4 and DR5 and CD-95L bind to the CD-95 receptor.  There have also been 
decoy receptors identified including a soluble CD-95 decoy receptor (TNFR) and three 
decoy receptors for TRAIL:  osteoprotegerin (OPG), decoy receptor 1 (DcR1) and decoy 
receptor 2 (DcR2).  These decoy receptors have mutations to account for their 
nonfunctional activity.  DcR1 lacks a cytosolic region and DcR2 has a truncated 
nonfunctional form of the death domain.  Upon homotrimeric ligand binding, the 
receptors trimerize and changes occur to the death receptor domain such that the adaptor 
protein Fas-associated death domain (FADD) and procaspase-8 are recruited, forming 
the death-inducing signaling complex (DISC).  Caspase-8 is autoactivated, which then 
activates downstream effectors caspases including caspases-3, -6 and -7.  In addition, 
Bid can also be cleaved by caspase-8 to form truncated Bid (tBid), which activates the 
mitochondrial-mediated pathway of apoptosis. [144] 
The intrinsic apoptotic pathway can be activated by various stimuli including 
DNA damage, growth factor deprivation or oxidative stress [145].  Mitochondria are 
critical regulators of apoptosis with mitochondrial membrane potential perturbations 
leading to the production of ROS or mitochondrial membrane permeabilization (MMP) 
[146].   ROS production can trigger lysosomal membrane permeabilization (LMP) which 
releases lysosomal enzymes that can cause MMP or lysosomal-mediated autophagic cell 
death [77,147].  Mitochondria sequester many anti- and pro-apoptotic proteins 
principally involved in the regulation of apoptosis and these pro-apoptotic proteins can 
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be released from the mitochondria after MMP.  These proteins cause the induction of 
apoptosis through a multitude of mechanisms. 
MMP is regulated by the family of Bcl-2 proteins, however their role in the 
release of pro-apoptotic proteins from the mitochondria is a subject of debate and several 
models have been suggested [143].  One model involves Bcl-2 family members 
undergoing a conformational change such that they insert into the outer mitochondria to 
form a channel, but the disagreement lies in whether these channels are large enough to 
allow for protein transport.  Bcl-2 members may also form channels with other proteins 
such as the voltage-dependent anion-exchange channel (VDAC) located in the outer 
mitochondrial membrane, however this model must include a significant conformational 
change of VDAC in order to accommodate the proteins.  Another postulation is that Bcl-
2 causes the outer mitochondrial membrane to rupture by altering mitochondria 
physiology such as perturbations in ion exchange or oxidative phosphorylation that 
would induce membrane fission. 
Regardless of the pathway, depolarization of the mitochondrial membrane leads 
to the release of a number of small molecules including cytochrome c, second 
mitochondria-derived activator of caspase/direct IAP binding protein (SMAC/Diablo), 
apoptosis-inducing factor (AIF), endonuclease G (EndoG) and Omi/HtrA2 and these 
proteins can lead to both caspase-dependent and -independent activation of various 
cellular pathways (see Table 1.9) [148,149].  Cytochrome c release causes formation of 
the apoptosome, which include the apical caspase-9 and Apaf-1 and requires ATP for 
activation [143].  Downstream of caspase-9 is the effector caspase-3, which activates a 
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pathway leading to the cleavage of a diverse range of substrates.  The intrinsic and 
extrinsic apoptotic pathways converge at activation of caspase-3. 
 
Table 1.9:  Summary of mechanism of action for small molecules released from mitochondria 
[143,147,148] 
 
 
 
 
 
 
 
 
 
1.3.1.1.2. Pro- and anti-apoptotic proteins 
Apoptosis is carried out by two major families:  Bcl-2 proteins and caspases.  
Bcl-2 was originally discovered as a protein that promoted oncogenesis due to its ability 
to prevent cell death [150].  There are 3 groups in the Bcl-2 family of proteins that are 
classified based on the number of Bcl-2 homology (BH) domains.  Anti-apoptotic 
proteins Bcl-2, Bcl-xL and Mcl-1 contain 4 BH domains.  The pro-apoptotic proteins can 
be divided into 2 groups:  BH3-only proteins (Bid, Bax, Bim, Noxa, PUMA) or BH1-3 
proteins (Bax, Bak, Bok) [151].  The majority of BH1-4 and BH3-only Bcl-2 proteins 
reside in the mitochondrial outer membrane.  The Bcl-2 family of proteins can form 
homodimers and perhaps more importantly, heterodimers; heterodimer combinations 
Mitochondrial protein Mechanism of action 
Smac/DIABLO Inhibits IAPs, survivin 
 
Omi/HtrA2 Inhibits IAPs 
AIF Nuclear translocation, induce caspase-
independent DNA fragmentation and 
chromatin condensation 
 
Endo G Induces internucleosomal DNA fragmentation 
Cytochrome c Forms apoptosome and activates apical 
caspase-9 
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vary by cell type [143].  Since anti-apoptotic factors can negate the actions of pro-
apoptotic factors, the ratio of pro-apoptotic factors to anti-apoptotic factors is a critical 
indicator of determining sensitivity to cell death.  By contrast, BH3-only family 
members and pro-apoptotic protein Bax relay death stimuli to the mitochondria.  Bid, as 
mentioned previously, is part of the extrinsic pathway and relays trophic factor 
deprivation signals [152].  PUMA or Noxa respond to DNA damage by translocating to 
the mitochondria and interact with Bcl-2/Bcl-xL or Bax/Bak families to cause the release 
of pro-apoptotic proteins from the mitochondria [152].   
Bcl-2 proteins play a critical role in intrinsic apoptotic initiation; however, 
caspases are fundamental for both the initiation and execution stages of apoptosis.  There 
are 14 mammalian caspases that are synthesized as inactive zymogens.  Upon apoptosis 
induction, caspases can be cleaved to their active form that cleaves Asp-Xxx bonds.  
There are 3 functional groups of caspases:  (1)  inflammation caspases (caspase-1, -4, -5, 
-11, -12, -13, -14); (2) apoptotic initiator caspases that have either a death effector 
domain (DED) (caspase-8, -10) or caspase activation and recruitment domain (CARD) 
(caspase-2, -9); (3) apoptotic executioner caspases (caspase-3, -6, -7) that have a short 
prodomain and are activated by upstream caspases to cleave a variety of cellular 
substrates. [153]  Caspases have a wide variety of targets, ranging from apoptotic and 
structural proteins to cellular DNA repair and cell cycle proteins. [154] 
 In addition to the Bcl-2 family of proteins, inhibitors of apoptosis (IAPs) are anti-
apoptotic proteins involved in apoptosis regulation.  As their name suggests, they can 
confer protection from death-inducing stimuli [155].  There are currently 8 human IAPs:  
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NAIP, cIAP1, cIAP2, X-linked inhibitor of apoptosis (XIAP), Ts-XIAP, ML-IAP, 
apollon, and survivin.  c-IAP1 and c-IAP2 are part of a signaling complex recruited to 
the cytoplasmic domain of Type 2 tumor necrosis factor receptor [156].  Survivin is a 
unique IAP since its expression is cell-cycle regulated [157].  There are several 
postulated functions of survivin in apoptosis.  It may bind to caspase-3 or caspase-9, but 
it does not possess the functional domains of other IAPs that directly bind to these 
caspases.  Survivin may also bind to procaspase-9 and thus inhibiting the intrinsic 
pathway of apoptosis [157].  Survivin may also bind to Smac/DIABLO, therefore 
hampering the inhibitory function of Smac/DIABLO on IAPs. XIAP is the most 
characterized IAP and is considered the most potent suppressor of apoptosis.  XIAP 
functions by directly inhibiting several caspases including caspase-3, -7, -9 [158].  Both 
c-IAP2 and XIAP are regulated by the stress-response transcription factor NF-kB, when 
it exerts a pro-survival effect [159].  Smac/DIABLO is the regulator of IAPs by 
displacing caspases from XIAP and most likely other IAPs [156]. 
1.3.1.2. Autophagic cell death 
 Autophagy is an evolutionarily conserved mechanism of survival triggered by 
stress-associated damage or nutrient deprivation and encompasses 3 distinct types of 
autophagy.  Chaperone-mediated autophagy refers to the degradation of cytosolic 
proteins with a specific pentapeptide consensus motif [160].  Microautophagy is the 
direct engulfment of cytoplasm at the surface of the degradative organelle.  In contrast, 
macroautophagy is characterized by cytoplasmic materials including organelles that are 
bound in double membrane vesicles and degraded after fusion with lysosomes.   
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Autophagic cell death, which is morphologically characterized by the 
accumulation of autophagic vacuoles in cells lacking hallmarks of apoptosis such as 
nuclear condensation and cell fragmentation, is a controversial death pathway [161].  In 
the case of nutrient-deprived cells, autophagy can provide short-term relief by degrading 
the cytoplasmic contents for both proteins and energy production and therefore has 
traditionally been considered a mechanism of cell survival [162].  However, excess 
autophagy may lead to type II autophagic cell death; however, it is not known whether 
formation of autophagic vacuoles in dying cells are generated for cell survival or cell 
death [147]. 
Understanding autophagy was enhanced after identification of autophagy-related 
genes (Atg) that were shown to be involved in the vacuole targeting (Cvt) pathway and 
pexophagy (peroxisome degradation) [163,164].  Beclin 1 is essential for 
autophagosome formation and its overexpression induced autophagy and inhibited 
tumorigenicity in breast cancer cells [165].  LC3/Atg8 is also critical for autophagosome 
formation and becomes lipidated during activation of autophagy and serves as a marker 
protein for autophagic vacuoles [166]. 
Upon nutrient starvation or growth factor deprivation, nutrient-sensing signaling 
pathways are activated and initiate autophagy.  Autophagy is characterized by the 
sequestration of cytoplasmic material to form a double-membrane vacuole referred to as 
an autophagosome (Figure 1.6). Several Atg genes are critical in this initial stage of 
vacuole formation.  The next stage involves a late endosome or lysosome which fuses 
with the autophagosome to form the autolysosome.  The final stage in autophagic cell 
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death is degradation of the autolysosomal contents via lysosomal degradative enzymes. 
[167] 
 
Figure 1.6:  Formation and maturation of autophagosomes in mammals.  Induction of autophagy  
involves formation of a double membrane around cytoplasmic materials and/or cytoplasmic organelles and 
requires Atg genes for this initial stage of autophagosome formation.  This induction can be inhibited by 
Class III PI3K inhibition (3-MA or wortmannin treatment).    The autophagosome fuses with a lysosome 
and the lysosomal enzymes degrade the contents of the autolysosome.  Abbreviations used:  AVi – Initial 
autophagic vacuole; AVd – Degradative autophagic vacuoles. [147] 
 
 Under growth factor deprivation, autophagy is a critical mechanism for cell 
survival [147].  Yeast mutants that have defective autophagy genes cannot survive 
starvation-induced conditions whereas yeast with functional autophagy genes can 
survive starvation in the short term [168].  The essential role of autophagy genes in cell 
survival can also be demonstrated in amino acid-deprived mammalian cells [169].  These 
observations were consistent with autophagy being an unavoidable requirement to 
prevent apoptosis [169].  Further evidence to support the pro-survival effects of 
autophagy involved a study utilizing immortalized bone marrow cells from Bax- and 
Bak-deficient mice that were resistant to apoptotic stimuli [170].  Bone marrow cells 
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were deprived of the growth factor interleukin 3 (IL3) and were able to maintain ATP 
production via autophagy; when autophagy genes were inhibited, the cells died.  
Autophagy, however, can only be considered a short-term mechanism of survival since 
degradation of all organelles will eventually lead to cell death [147]. 
 Autophagic cell death has been extensively studied in the literature and much 
remains to be elucidated in terms of the molecular mechanism of autophagic cell death 
compared to the well-studied process of apoptosis.  Cell death could be induced in 
several cell lines treated with caspase inhibitors and this provided some of the initial 
evidence for autophagic cell death [171].  Cell death was inhibited via knockdown of 
caspase-8 or the autophagy proteins Beclin 1 or Atg7.  This data suggested that 
autophagosome formation was important in the mode of cell death induced.  The authors 
also proposed that upstream effectors of autophagy included both RIP and JNK; no 
evidence has supported the importance of these pathways in autophagy, which could 
suggest different signaling pathways are involved for autophagy and autophagic cell 
death [147]. 
 Embryonic fibroblasts from Bax- Bak- mice treated with etoposide or 
staurosporine also showed signs of autophagic cell death [172].  Etoposide or 
staurosporine induced formation of autophagic vacuoles and the cell death could be 
reversed through knockdown of autophagy genes Atg5 and Beclin 1.  This data supports 
autophagic cell death as a viable mechanism of cell demise. 
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1.3.1.3. Necrotic cell death  
 Necrosis has traditionally been considered an accidental and uncontrolled form 
of cell death but more recent findings suggest necrosis is as programmed as apoptosis.  
Necrosis is morphologically characterized by cytoplasmic swelling, plasma membrane 
damage and organelle breakdown, eventually leading to cell explosion [173].  Release of 
the cellular contents elicits an immune response, which does not occur in apoptosis.  
Recent experiments have suggested that necrosis may be a backup form of cell death 
when caspases are blocked or caspase-dependent pathways cannot be properly activated 
[140]. 
 There are a variety of intercellular mediators and their receptors and other 
responses can induce either apoptosis or necrosis, depending on the cell type and 
intensity of stimulus (Figure 1.7) [174].  One of the major crossroads for deciding 
between apoptosis and necrosis is the adaptor protein FADD.  As already mentioned, 
FADD is recruited upon ligand binding to Fas and TRAIL-R death receptors and 
initiates activation of apoptotic pathways, NF-κB and MAPKs.  When caspase activation 
is inhibited, necrosis ensues.  The deciding factor between apoptosis versus necrosis via 
Fas/TNFR/TRAIL-R is receptor-interacting protein 1 (RIP1) [175].  RIP1 has been 
involved in NF-kB activation and induction of cell death [176,177].  Toll-like receptor 
(TLR)4 and TLR3 activation can also cause necrosis [140].  In addition, stimulation of 
glutamate receptors with excitotoxins in certain cell types lead to necrosis [174]. 
 There are several important mediators of necrosis including both calcium and 
ROS.  Physiologic levels of ROS can regulate transcription, serve as signaling molecules, 
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and defend against pathogen infection [178].  ROS are primarily produced in the 
mitochondria due to electron production in the electron transport chain and there are 
buffers and a number of antioxidants in specific subcellular locations to minimize ROS-
induced cellular damage; however, when ROS are in relative excess of their antioxidant 
mechanisms, cellular damage can occur due to oxidative stress, damage of intracellular 
molecules and organelles, and ultimately necrosis [140,179]. 
 Calcium can also have a profound effect on cellular function due to its central 
role as a stimulator of oxidative phosphorylation and nitric oxide synthase (NOS) 
production.  Both increase production of ROS through enhanced electron flow and 
nitric oxide production, respectively.  Elevated levels of calcium can produce both 
apoptosis and necrosis and the outcome is based on calcium concentration with low to 
moderate calcium (200–400 nM) leading to apoptosis, whereas higher concentrations of 
calcium (>1 µM) are associated with necrosis [26].  In addition to ROS production, 
calcium also regulates a wide variety of enzymes that can also enhance necrosis 
including phospholipases and proteases.   
Phospholipases are responsible for fatty acid liberation from phospholipids.  
Cytosolic phospholipase A2 (cPLA2) hydrolyzes arachidonic acid-containing 
phospholipids and its translocation is mediated by calcium [180].  The liberation of 
arachidonic leads to the production of cyclooxygenase (COX), lipoxygenase (LOX) and 
cytochrome P450 monooxygeneases.  LOXs are involved not only with inflammation 
but also with lipid mobilization and peroxidation, which can lead to the disruption of 
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organelles and plasma membranes and ultimately trigger cellular necrosis via damage to 
protein structure and lipid bilayers [174]. 
Calpains are calcium-dependent proteases that have a diverse range of targets 
including cytoskeletal proteins, membrane proteins, adhesion molecules, ion transporters, 
kinases, phosphatases, and phospholipases [179].  Elevated levels of calcium can lead to 
overactivation of calpain.  One of the functions of calpains is the cleavage of the 
Na+/Ca2+ exchanger which is essential for maintaining normal intracellular calcium 
levels and its cleavage leads to sustained elevated calcium.  Calpains can also disrupt 
lysosomal membranes and release of cathepsins, which are involved in the cell death 
pathway.  Ceramide is also critically involved in necrosis due to its role in transmitting 
the death signals of RIP1 [140].  
In contrast to apoptotic cells, necrotic cells are phagocytosed after loss of 
membrane integrity, which is a delayed and less effective “clean-up” process compared 
to apoptosis [181].  These conditions lend itself to an inflammatory response since it 
allows dying cells to activate pro-inflammatory and immunostimulatory responses, 
which involves a diverse range of cells involved in the immune response including 
neutrophils, macrophages and dendritic cells.  By comparison, apoptotic cells stimulate 
antigen-presenting cells (APC) to release cytokines that inhibit the immune response. 
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Figure 1.7:  Molecular model of necrosis. Necrosis can be triggered by DNA damage directly (e.g. 
radiation, chemotherapeutic drugs) or indirectly through oxidative stress (e.g. ischemia) or by several 
receptors such as FAS, TNF receptors, excitoreceptors.  Calcium is among the second messengers 
participating in receptor-mediated necrosis.  The last stage of necrotic destruction is the activation of 
proteases, which leads to plasma membrane permeabilization and necrosis.  [174] 
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1.3.2. Functional capabilities of cancer 
To discover drug targets more specific to tumors, it is essential to first understand what 
distinguishes tumor cells from normal cells and then exploit these differences for 
developing more effective treatments.  Understanding cancer is highly complex and 
recent advances have provided more information but have also added to the complexity.   
Cancer is a result of acquired genetic mutations that lead to the transformation of a 
normal cell to a highly malignant cell; Hanahan and Weinberg have described six 
categories of genetic changes that occur in cancer cells [182].  These categories relate  
 
 
Figure 1.8:  Acquired capabilities of cancer.    Six hallmarks of cancer progression. [182] 
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to various cellular mechanisms that are in place to prevent cancer development (Figure 
1.8).  The categories include:  self-sufficiency in growth signals, insensitivity to 
antigrowth signals, evasion of programmed cell death, limitless replicative potential, 
sustained angiogenesis and tissue invasion and metastases.  These events do not 
necessarily occur in any particular order, as the order varies between cancer types and 
subtypes [182]. 
1.3.2.1. Self-sufficiency in growth signals 
 Cells are dependent on growth signals to proliferate and these signals may be in 
the form of diffusible growth factors, extracellular matrix components or cell-to-cell 
adhesion/interaction molecules [182].  These molecules are often secreted from one cell 
to induce growth of another cell.  If cells can become self-sufficient in their growth 
signals and independent of neighboring cells, they have a greater ability to grow 
uncontrollably.  There are 3 growth signal targets that can be altered and lead to self 
sufficiency:  (1) extracellular growth signals; (2) transcellular transducers (3) and 
intracellular signaling pathways that translate signals [182].   
1.3.2.1.1. Overview of receptor tyrosine kinase receptors 
 One of the most common mechanisms of self-sufficiency is deregulation of 
receptor tyrosine kinases that are often involved in transmitting growth signals.  
Receptor tyrosine kinases constitute a family of 20 receptors that have an extracellular 
growth factor binding domain, a transmembrane region and an intracellular tyrosine 
kinase catalytic domain (see Figure 1.9).  The intracellular portion of these receptors also 
contains a juxtamembrane region and carboxy-terminal tail which have regulatory sub-
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domains that can influence substrate binding and phosphorylation [183].  The function of 
receptor tyrosine kinases is to catalyze the transfer of the γ-phosphate of ATP to tyrosine 
residues on its own chain and other substrates.  This results in to second messenger 
binding and intracellular signal transduction that leads to growth-promoting effects. 
 
 
Figure 1.9:  Schematic representation of receptor tyrosine kinases and their activation.  (a) 
extracellular ligand-binding domain; (b) unique transmembrane domain; (c) juxtamembrane region; (d) 
kinase domain; (e) C-terminus.  Receptor tyrosine kinases are initially activated upon ligand binding (1), 
which leads to the catalytic domains becoming closer in proximity and transphosphorylation (2), leading 
to the fully activated state of the receptor.  [183] 
 
Adaptor and scaffolding proteins play a critical role in transmitting signals from 
receptor tyrosine kinases.  They recruit proteins to a specific location and also put 
together networks of protein to influence signaling pathways [183].  The traditional 
pathways activated through receptor tyrosine kinases are the phosphoinositide-3 kinase 
(PI3K) and mitogen-activated protein kinase (MAPK) pathways.  Recently, there has 
also been a link to the signal transducers and activators of transcription (STAT) proteins, 
where receptor tyrosine kinases directly phosphorylate and induce nuclear translocation 
of these proteins.  Constitutive activation of kinases in cancer cells can occur due to 
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overexpression of receptor tyrosine kinases and hence an increased concentration of 
active dimers [184]. 
 
Figure 1.10:  Signaling pathways associated with receptor tyrosine kinases.  The main pathways are 
shown and the kinases names are italicized.  Abbreviations used:  PI3K, phosphatidylinositol 3-kinase; 
Pdk1, phosphoinositide-dependent protein kinase-1; Akt, oncogenic kinase; p70S6K, ribosomal S6 kinase; 
Shc, src homology collagen; Sos, son of sevenless; Grb2 growth factor receptor-bound protein 2; 
Erk/MAPK, extracellular signal-regulated kinase/mitogen-activated protein kinase; Jak, janus kinase; Stat, 
signal transducer and activator of transcription; PLC, phospholipase C; PKC, protein kinase C; Src, 
oncogenc of chicken Rous sarcom virus. [183] 
 
1.3.2.1.2. Receptor deregulation in breast cancer 
Three common receptor tyrosine kinase families associated with breast cancer 
include epidermal growth factors (EGF), fibroblast growth factors (FGF) and insulin-like 
growth factors (IGF). The EGF family consists of 3 families of ligands, the first being 
EGF, transforming growth factor α (TGF-α) and amphiregulin and these ligands bind 
specifically to EGF receptor (EGFR/ErbB1).  Betacellulin, heparin-binding EGF (HB-
EGF) and epiregulin form another group of EGF ligands that bind both ErbB1 and 
EGFR4/ErbB4 receptors.  The final group of EGF ligands is the neuregulins (NRGs), 
  
 
51 
where NRG1 and NRG2 bind EGFR3/ErbB3 and ErbB4 and NRG3 and NRG4 bind 
only ErbB4.  There are no ligands that bind ErbB2 (HER-2/Neu), but it is the preferred 
heterodimerization partner for other family members [185].  Activated ErbBs 
preferentially stimulate certain signaling pathways. [186]   
Both in vitro and in vivo studies have demonstrated the effects of EGF ligands on 
mammary epithelial cells.  EGF induces DNA synthesis and promotes growth in vitro.  
EGF, TGF-α and amphiregulin are essential for ductal outgrowth and genetic loss of 
these ligands in murine models severely affects ductal outgrowth.  With the exception of 
ErbB4, overexpression of EGF receptors has been reported in breast cancer cases 
[187,188]. Overexpression of ErbB2 both in vitro and in vivo using transgenic mouse 
mammary glands lead to transformation, tumorigenicity and metastasis [189,190].  A 
strong relationship has been established between the EGF family and breast cancer in 
animal models and in humans.  ErbB2 is overexpressed in 20-30% of breast cancers and 
is also associated with a poor prognosis.  Poor breast cancer prognosis is also associated 
with EGFR expression [191]. 
The IGF family of ligands is another family of growth factors associated with 
breast cancer progression due to their role as endocrine, paracrine and autocrine 
regulators of biological processes.  There are two IGF ligands, IGF-I and IGF-II which 
induce proliferation in vitro.  In vitro studies show that IGF1R is critical in breast cancer 
as reduction in IGF1R by siRNA or dominant negative mutants reduces cell growth and 
transformation in MCF-7 cells [192].  The C-terminal region of IGF1R is critical for 
tumorigenesis in vitro and in vivo [192].  Other in vivo experiments have demonstrated 
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the role of IGF-I in terminal end bud formation and ductal growth and like EGF, IGF-I 
induces DNA synthesis.  IGF-II is important during pregnancy since this growth factor is 
downstream of prolactin, which is essential for alveolar differentiation.  IGF1R gene 
transcription can be stimulated by hormones including growth hormone (GH), follicle 
stimulating hormone (FSH), leutinizing hormone (LH), thyroid hormone, 
glucocorticoids and estrogens [193] as well as other growth factors including FGF and 
PDGF and oncoproteins such as c-myb.  PI3K is a major kinase pathway implicated in 
survival and is activated by IGF1R.  Downstream effectors of this pathway lead to such 
pro-survival events as sequestration of the pro-apoptotic protein BAD as well as 
induction of cyclin D1.  Other survival pathways induced by IGFRs include the 
Ras/Raf/MAPK pathway.    In addition, circulating levels of IGF-I and IGFBP3 (IGF 
binding protein 3) have been correlated with breast cancer in premenopausal women 
under the age of 50 [194].  IGF1R expression is seen in many cancer cell lines [195,196] 
and its overexpression is associated with differentiation, transformation and apoptosis 
[197]. 
IGF/ER crosstalk has also been shown by a number of studies where E2 and 
IGF-I synergistically stimulates proliferation and the extent of IGF1R stimulation is 
positively correlated with ER expression [198].  Further evidence of the interaction 
between ER and the IGF family proteins in breast cancer is that antiestrogens inhibit IGF 
signaling in ER positive breast cancer cell lines. 
The FGF family encompasses 22 ligands that bind and activate cell surface 
receptors (FgfRs) and can act as mitogens, motogens and angiogenic agents [199].  Four 
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functional FGF receptors (FgfR1-FgfR4) are involved in tyrosine kinase activity in 
mammals [200].  The role of these growth factors and their receptors in breast cancer is 
still under investigation, although there are strong links shown in murine models.   
Mouse mammary tumor virus (MMTV) predisposes mice to breast cancer by retroviral 
replications, which leads to insertional mutations in the host DNA.  Since the provirus 
remains at the mutation sites, genes can be identified that induced tumor formation [201].  
Protooncogenes activated by the MMTV include Fgf3, Fgf4 and Fgf8 [202-204].  
Activation of the FgfR1 or Fgf3 expression led to mammary hyperplasia and the 
formation of invasive lesions in mouse models [205,206].  The data in humans is less 
convincing and this may be due to issues commonly related to human studies including 
small sample size and high variability among samples [201].  However, some evidence 
that supports the role of the Fgf pathway in breast cancer is that both FGFR1 and FGFR4 
are amplified in a significant percentage of breast cancer cases [207-209]. 
1.3.2.2. Insensitivity to anti-growth signals 
 Cell growth is controlled by a balance of growth stimulatory and growth 
inhibitory pathways, both involving signal transmission via transmembrane receptors.  
Growth inhibitory pathways respond to soluble factors, those immobilized in the 
extracellular matrix and on the surface of neighboring cells.  There are 2 major 
mechanisms that inhibit cell proliferation and these include:  (1) forcing cells into a 
quiescent stage (G0) of the cell cycle and (2) inducing cells into terminal differentiation 
[197].  
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1.3.2.2.1. Overview of cell cycle 
The division of cells is tightly regulated by the cell cycle and there are several 
phases of the cell cycle (see Figure 1.11) including G0, G1, S, G2 and M, each with its 
own distinct function.  Cells in G0 are in a non-cycling, quiescent state.  During G1 phase 
of the cell cycle, RNA and protein are synthesized; and DNA is replicated in the S-phase.  
G2 is another resting phase as the cell prepares for ‘M’, which is the phase of mitosis or 
cell division. [210] 
 
 
Figure 1.11:  Negative and positive regulation of the cell cycle. CDK/cycline complexes driving each 
phase of the cell cycle are depicted.  Inhibitors and promoters of the different phasesa and checkpoints 
monitoring the proper completion of every phase of the cell cycle are indicated.  [211] 
 
  
 
55 
 Throughout the cell cycle, there are several checkpoints for “quality control”.  If 
the checkpoint is failed, cells can be arrested and blocked from proceeding through the 
cell cycle until the cell meets the standards of the checkpoint.  The most critical of these 
checkpoints is in G1 which is the major point of decision and therefore is appropriately 
termed the restriction/start point of the cell cycle.  This checkpoint is necessary for DNA 
integrity and to ensure that any damaged DNA is repaired prior to DNA replication.  In 
addition to the G1 checkpoint, there is also another one after DNA replication (S phase) 
to confirm that all DNA has been replicated.  A checkpoint also occurs during mitosis to 
ensure that kinetochores are paired and that other stages of mitosis are carried out 
without errors prior to cell division. [212,213] 
The cell cycle is regulated by the presence of specific protein dimers that 
facilitate progression through the cell cycle.  Cyclins provide the regulatory subunit and 
cyclin-dependent kinases (cdks) provide the catalytic activity of the dimers [214].  D 
cyclins are synthesized and activated in response to growth factors and form dimers with 
cdk4, cdk6, which are required for the latter part of the G1 phase [215].  Cyclin E forms 
a dimer with cdk2, which is required for S phase entry [216].  Cyclin A/cdk2 and Cyclin 
A/cdc2 regulate progression through S phase and entry into mitosis, respectively [217].  
Cyclin B/cdc2 is also involved in mitosis [218]. 
The critical nature of the cell cycle in maintaining cellular integrity demands 
tight regulation of all aspects of the cycle including cyclin/cdk complexes.  There are 
three families of proteins that inhibit the action of these complexes:  Retinoblastoma 
protein (Rb), inhibitors of cdk4 (INK4) family and the KIP family. 
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 Rb activity is controlled by phosphorylation.  Typically, Rb is phosphorylated by 
cyclin D/cdk4,6.  In its nonphosphorylated state in G1, Rb binds E2F family transcription 
factors, which represses transcription of genes including those critical for S phase.  
Therefore, S phase cannot be initiated until Rb is phosphorylated and released from E2F.  
Rb consequently represents one mechanism of regulating progression through G1. 
[219,220] 
 The INK4 family includes p15INK4a, p16 INK4b, p18 INK4c and p19 INK4d.  All 
members of the INK4 family specifically bind to cdk4, cdk6 and consequently inhibit 
the activity of cyclin D/cdk complexes [221].  p15 has the additional function of being 
involved in transforming growth factor β (TGF-β) mediated cell cycle arrest [222].  
 The KIP family of proteins include p21 WAF1/Cip1, p27 KIP1 and p57 KIP2.  These 
proteins have a less restricted range of cdk substrates compared to their INK4 
counterparts, and these include all G1 and S phase cdk enzyme complexes.  These 
proteins bind to cdks and prevent their phosphorylation by CAKs, a process required for 
activation of the cyclin/cdk complexes.  In addition, the catalytic activities of the 
cyclin/cdk complexes are inhibited by KIP proteins.  p21 is activated by p53, a gene that 
is dramatically increased in response to stress stimuli including DNA damage, oncogene 
activation or hypoxia [223].  In addition, p15, p27 responds to TGF-β and other extrinsic 
growth signals [224].    
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1.3.2.2.2. Terminal differentiation 
 The decision to divide or withdraw from the cell cycle and undergo 
differentiation occurs during G1 phase of the cell cycle [225].  Differentiation refers to a 
complex, multi-step process of cell specialization where a genetic program leads to the 
expression of lineage-specific genes that dictate biological function [226].  The final step 
of differentiation is terminal differentiation, which leads to an irreversible loss of 
proliferative capacity.  A multi-step model of differentiation is summarized in Table 
1.10 and includes both reversible and irreversible steps of differentiation.  The initial 
stage of predifferentiation quiescence occurs in the G1 phase of the cell cycle, which 
leads to the induction of factors that induce the expression of lineage-specific 
differentiation genes and their consequent biological functions.  These genes cause a 
progressive repression of growth factor responsiveness.  Under some conditions, cells 
may enter an irreversible state of growth arrest, designated terminal differentiation.  The 
decision to undergo terminal differentiation has been linked to an array of genes and is 
cell-context specific.  Repression of P2P gene expression is associated with loss of 
replicative potential in adipocytes due to its role in encoding proteins that influence 
RNA expression [226,227].  Other cells such as melanoma cells undergo terminal 
differentiation after induction of the p21 gene [228]. 
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Table 1.10:  Multi-step model of cell differentiation.  R=reversible; IR=irreversible [226] 
Step 1 Growth and proliferation of determined cells 
Step 2 Induction of predifferentiation quiescence (R) 
Step 3 Expression of lineage-specific transacting factors (R) 
Step 4 Induction of lineage-specific differentiation genes (R) 
Step 5 Expression of lineage-specific biological functions (R) 
Step 6 Progressive repression of growth factor responsiveness (R) 
Step 7 Decision whether or not to undergo terminal differentiation (R/IR) 
Step 8 Activation of molecular mechanisms for terminal differentiation (R/IR) 
Step 9 Terminal differentiation (IR) 
 
Terminal differentiation is a process for achieving replicative senescence but in 
many cancer cells, there is a myriad of defects that prevent this final stage of 
differentiation from occurring.  Under physiological conditions, many cancer cells lack 
the ability to be growth arrested.  Cancer cells can be induced to quiescence but have 
defects with respect to expression of the appropriate combination of lineage-specific 
genes and lineage-specific biological functions.  In addition, cancer cells are typified by 
their aberrant growth characteristics including both dysplasia and metaplasia since they 
cannot correctly differentiate.  Many cancer cells also lack the ability to be terminally 
differentiated and hence retain their immortality. [226,229] 
1.3.2.2.3. Cell cycle deregulation in breast cancer 
 The TGF-β family includes activin, inhibin and bone morphogenic protein 
(BMP) and these factors exert a diverse a range of cellular effects including growth 
suppression, differentiation, stromal production and immune modulation [230].  TGF-β 
is of particular interest to cancer researchers due to its tumor suppressive capabilities.  
TGF-β inhibits growth of mammary epithelial cells and overexpression in mice lead to 
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mammary hypoplasia and inhibition of tumorigenesis [231,232].  The growth inhibitory 
effects of TGF-β can be attributed to its influence on cell cycle progression (see Figure 
1.12).  TGF-β can reversibly arrest cells in G1 or irreversibly cause terminal 
differentiation [233] [234]. 
Cyclins are commonly activated in breast cancer cells.  For example, cyclin D1 is 
overexpressed in a variety of cancers including 60% of breast carcinomas [235] and 
cyclin E is also overexpressed in breast cancer patients and is a powerful prognostic 
indicator of breast cancer stage [236].  Cyclin E is associated with chromosome 
instability and therefore promotes tumorigenesis [237]. 
p53 is a key player in cell cycle control and may mediate arrest of cells at G1 near 
the border of S-phase or in G2 before mitosis due to its interaction with p21 or GADD45 
and 14-3-3σ, respectively [238].  p53 mutations are detected in close to 75% of breast 
carcinomas [239].  p53 breast carcinomas are typically ER-negative and progesterone-
receptor negative and are associated with a high proliferation rate, high histologic grade, 
aneuploidy and a poor prognosis [238].  p53 expression is also commonly found in 
ErbB2 overexpressing breast tumors [219]. 
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Figure 1.12:  Mechanisms of cell cycle arrest induced by TGF-β. TGF-β receptor activation leads to 
Smad2 phosphorylation, which binds to Smad4.  The Smad2-Smad4 complex translocates to the nucleus 
and modulates transcription.  The effects of p15 and p21 may be indirect effect of Smad2-Smad4 action 
(dotted lines).  TGF-β inhibits G1 cyclin-cyclin-dependent kinases (cdks) by increasing p15 and p27 
binding to their respective cyclins, thereby inhibiting retinoblastoma protein (pRb) phosphorylation.  [240] 
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1.3.2.3. Evading apoptosis 
The breast is a unique tissue since it continues to develop after birth during both 
puberty and pregnancy [70].  The Bcl-2 family of proteins regulates apoptosis and 
changes in these protein levels are partially influenced by circulating hormone levels of 
estrogen and progesterone [70].  Normal breast epithelium goes through fluctuations in 
apoptosis and Bcl-2 expression during the menstrual cycle [241].  Tissue homeostasis 
and development in the breast is achieved by a balance between proliferation, 
differentiation and apoptosis [70].  Apoptosis is a critical programmed cell death 
pathway essential for inhibiting carcinogenesis since it potentiates the accumulation of 
genetic mutations and as a result increases the likelihood of breast cancer [242].  In 
normal breast tissue around invasive breast cancer, there is a comparatively higher rate 
of proliferation compared to apoptosis [242] (Figure 1.13).  Ductal carcinoma in situ and 
invasive breast cancer both have increased rates of apoptosis compared to normal cells 
[243,244].  A comparison of human ductal carcinoma in situ and adjacent invasional 
cancer showed that spontaneous apoptosis is lost concurrently with invasive 
transformation [245].   
Regulators of apoptosis can be divided into sensors and effectors.  Sensors of 
apoptosis are transmembrane receptors that monitor and detect abnormal conditions both 
intracellularly and extracellularly.  Intracellular sensors detect cellular abnormalities 
such as DNA damage and hypoxia and respond by activating death pathways [246].  
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Figure 1.13:  Phenotypic changes in stages of breast cancer development. The rate of apoptosis and 
proliferation is increased in both atypical ductal hyperplasia and ductal carcinoma in situ.  As the breast 
tumor cells become more invasive and are classified as invasive ductal carcinoma, the cells acquire the 
ability to evade apoptosis.  [70] 
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p53 is an example of an intracellular sensor that activates apoptosis arising from DNA 
damage due to its role in enhancing expression of the proapoptotic protein Bax.  Sensors 
regulate caspases, which function as effectors of apoptotic death in response to either 
extracellular or intracellular sensor activation.  Bcl-2 family members also are critical 
effectors in inducing the apoptosis cascade.  [182] 
1.3.2.3.1. Deregulation of apoptotic proteins in breast cancer 
Sensors of apoptosis are frequently mutated in breast cancer patients.  p53 is a 
intracellular DNA damage sensor and as mentioned previously is frequently mutated in 
breast cancer patients [247].  FasL and its receptor, Fas, are extracellular sensors 
involved in the initiation of apoptotic death pathways.  Non-transformed breast cell lines 
have a high expression of Fas whereas a number of breast cancer cell lines exhibit low 
Fas mRNA and protein expression [248].  Fas-positive breast tumors have a higher 
survival rate than Fas-negative tumors [249].  In addition, when the ratio of FasL to Fas 
mRNA is greater than 1, there is a significant association with shorter survival and 
higher mortality rates in breast cancer patients [250]. 
Bcl-2 expression has a paradoxical role in breast cancer.  Bcl-2 is overexpressed 
in approximately 80% of human breast cancer cases [251].  Hormone receptor positivity 
and low histologic grade tumors have also been correlated with the expression of the 
anti-apoptotic protein Bcl-2 [252] and a positive association between Bcl-2 expression 
and prognosis and survival rate has been reported [253].  Conversely, other studies 
showed loss of Bcl-2 expression was strongly correlated with increased apoptotic and 
necrotic cell death, high proliferation rates and high tumor grade [21].  The role of Bcl-2 
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in mediating anti-apoptotic effects is widespread.  Moreover, other Bcl-2 family 
members have also been linked to increased breast cancer incidence.  Bax is a pro-
apoptotic member of the Bcl-2 protein family.  In breast cancer cells and malignant 
breast tissue, low expression of Bax has been reported [254] and its low expression has 
been associated with a poor response to chemotherapy in metastatic breast cancer [251]. 
Caspases play a critical role in acting as effectors of apoptosis and in invasive 
forms of breast cancer, increased expression of caspase-3, -6 and -8 and their inhibitors 
have been reported [255].  This group of caspases has also been linked to high levels of 
apoptosis and histological grade of breast cancer [256].  Enhanced levels of caspases in 
tumors suggest that either caspases have a different role in cancer cells or caspases may 
be inactive due to overexpression of caspase-inhibitor IAPs [257].  IAPs are significantly 
involved in apoptosis regulation and the IAP, survivin, functions as a caspase inhibitor.  
Survivin is also overexpressed in a variety of human neoplasms, suggesting that 
reactivation of the survivin gene frequently occurs in cancers.  High survivin expression 
in neoplasms correlates with more aggressive behavior, decreased response to endocrine 
agents but enhanced response to chemotherapeutic agents, and shortened survival times 
compared to cancers that are survivin-negative [255,258]. 
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1.3.2.4. Limitless replicative potential 
Although having the ability to evade apoptosis, self-sufficiency in growth signals 
and insensitivity to antigrowth signals would seem to be sufficient for cancer cells, there 
is evidence that additional steps are required for cancer progression [197].  One of these 
steps involves elements that control the stability of the genetic material of the cell that 
are critical in the pathogenesis of cancer.   Cells have a limited replicative potential in 
place for this purpose [259,260]. 
1.3.2.4.1. Overview of senescence 
The progression of cancer requires an accumulation of genetic mutations.  The 
probabilistic time lapse between acquisition of a first and second genetic mutation is at 
least 20-30 cell divisions.  Since mutations are often recessive it is likely that even more 
replication events are necessary to achieve loss-of-heterozygosity [210].  Since cells 
have a finite number of cell divisions, this should limit the progression of a pre-
malignant cell into a tumor [261]. 
Senescent cells are metabolically active but do not proliferate and therefore 
senescent stromal cells provide an environment of nutrition and growth support for 
adjacent to premalignant epithelial cells, ultimately instigating epithelial neoplasia by 
allowing epithelial cells to survive, migrate and divide [261].  Senescent cells secrete 
factors that are both mitogenic and antimitogenic in tumors and this can lead to changes 
in the cell function such as secretory pathways, expression of proteases, extracellular 
matrix components and inflammatory cytokines [210,262,263]. 
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The ends of human chromosomes contain TTAGGG repeat DNA sequences 
called telomeres that provide both genetic stability and a resource of potentially 
dispensable DNA [264].  The ends of telomeres have a protective cap called the t-loop 
that prevents telomeres from being recognized as damaged DNA and consequently this 
minimizes degradation, recombination and end-joining reactions [210].  DNA 
polymerase cannot replicate the end sequence during lagging strand synthesis and there 
are also processing events that ultimately lead to the loss of telomeric repeats after each 
cell division and this eventually leads to replicative senescence [210].  Malignant tumors 
therefore must have a method of bypassing this proliferative limitation. 
Telomerase is an enzyme that adds telomeric repeats onto the 3’ end of 
chromosomes.  It has a protein component that is a human telomerase reverse 
transcriptase catalytic subunit (hTERT) as well as an RNA component (hTR or HTERC) 
which acts as a template to synthesize telomeric DNA directly onto the ends of 
chromosomes [210,265,266].  Telomerase is an ideal therapeutic target because with the 
exception of germline and somatic stem cells, it is present at undetectable levels in cells 
but can be highly expressed in proliferating cells.  Telomerase expression in telomerase-
negative cells can lead to infinite growth and provides direct evidence for this enzyme in 
pathways that evade replicative senescence (see Figure 1.14) [267]. 
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Figure 1.14:  Role of telomerase in replicative senescence.  Telomeres play an important role in both 
stages of replicative senescence:  M1 (senescence) and M2 (crisis).  Expression of telomerase either before 
or after senescence (M1) can lead to cell immortality. [210] 
 
The initiation steps of replicative (M1) senescence are still uncertain and 3 
models have been proposed: (1) telomere position effect (TPE); (2) DNA damage 
signaling; (3) loss of 3’ G-rich telomere single-strand overhangs [210].  In the TPE 
model, it assumes that genes near telomeres are often silenced and as telomeres shorten, 
these genes are de-repressed and can potentially reactivate previously silenced genes.  
There also may be a DNA damage signal induced from “too-short” of a telomere.  An 
alternative hypothesis involves loss of 3’ G-rich single-strand overhang since 60-85% of 
these overhangs are eroded in cancer cases.  The sequence of DNA damage response and 
shortening of the overhang has yet to be determined [210]. 
1.3.2.4.2. Telomerase expression in breast cancer 
Telomerase is overexpressed in approximately 95% of breast cancer cases [226].  
Others studies have reported a significant correlation between mean telomerase levels 
and severity of histopathological change with 14% staining positive in benign breast 
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disease compared to 94% in invasive breast cancer cases.  A significant association 
between telomerase-positive breast cancer and lymphovascular invasion has also been 
described and this is a critical step in breast cancer progression.  Altogether this data 
illustrates the critical role of telomerase in breast cancer. 
1.3.2.5. Sustained angiogenesis 
 Tumors have an absolute requirement for a sustained supply of new blood 
vessels that can provide oxygen and nutrients and aid in metastasis [268].  Angiogenesis 
refers to the process of new capillaries growing from existing blood vessels that involves 
basement membrane degradation via enzyme, endothelial cell (EC) migration, 
proliferation and formation of tubes [269].  This process is regulated by both pro-
angiogenic and anti-angiogenic factors.  Identified stimulators of angiogenesis include 
fibroblast growth factor-1 (FGF-1), FGF-2, vascular endothelial growth factor (VEGF), 
TNF-α, angiogenin, transforming growth factor-α (TGF-α), TGF-β, platelet-derived 
endothelial cell growth factor (PD-ECGF), pleiotropin and interleukin-8 [270].  Negative 
regulators of angiogenesis include thrombospondin, cartilage-derived inhibitor, platelet-
factor 4, angiostatin, interferon-α and interferon-β. 
1.3.2.5.1. Overview of VEGF family 
 The best characterized angiogenic factor is VEGF which functions as both an EC 
mitogen and can also increase vascular permeability [268].  VEGF is unique among 
growth factors due to its specificity for vascular ECs [271].  VEGF can bind 3 EC 
receptors:  VEGFR-1/Flt1, VEGFR-2/Flk1 and VEGFR-3/Flt4, with both VEGFR1 and 
VEGFR2 being part of the receptor tyrosine kinase family.  There are several ligands 
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involved in the VEGF/VEGF network including VEGF-A, -B, -C, -D, -E and placental 
growth factor. 
 A multitude of growth factors and cytokines can stimulate VEGF production 
such as platelet-derived growth factor, epithelial growth factor, TNF-α, TGF-β1, 
interleukin 1-β.  Hypoxia is also a key regulator of VEGF expression in both normal and 
malignant cells.  mRNA levels are increased in tumor cells near necrotic areas and in 
cell culture studies there is a substantial increase in VEGF mRNA seen in cells grown 
under hypoxic conditions compared to normoxic conditions elicited in cultured cells 
[272,273]. 
 Hypoxic conditions lead to upregulation of growth  factor receptors which 
induce a cascade of events including vascular permeability and matrix 
metalloproteinases, the latter being of fundamental importance in terms of tissue 
invasion.  These events lead to the formation and movement of ECs resulting in vessel 
extension and formation of a vascular network [268].  VEGF also increases expression 
of a variety of apoptosis inhibitors including Bcl-2 [274]. 
1.3.2.5.2. Angiogenesis in breast cancer 
 Recent reports have shown that breast cancer cells may express cell surface 
VEGFRs and this ligand/receptor combination may function as an autocrine loop in 
addition to the paracrine loop between breast cancer cells and endothelial cells [275].  
VEGF is also an indicator of breast cancer progression.  VEGF-overexpressing breast 
cancer cells have immense growth and metastatic potential based on data from xenograft 
studies [276].  HER2-overexpressing cancers are typically a more invasive form of 
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breast cancer and recently HER2 overexpression has been positively correlated with 
VEGF overexpression and this may be essential for the poor prognosis of patients 
overexpressing high levels of HER2 [277,278].  VEGF is critical for tumor progression 
since tumor growth is angiogenesis-dependent and angiogenesis is VEGF-dependent 
[270].  
1.3.2.6. Tissue invasion and metastasis 
 Metastasis refers to the ability of cancer cells to invade other tissues and systems 
including the vasculature and lymphatic system and is a critical step in cancer 
progression [279].  Metastatic tumors are the primary cause of death in cancer patients 
and tumor invasion and metastasis are critical activities of aggressive tumors. 
Normal cells require adhesion to grow and anchorage-independent growth is a 
fundamental feature of invasive and metastatic tumors [280].  The extracellular matrix is 
normally impermeable to cell migration and therefore major changes occur in the 
relationship between cancer cells and the extracellular matrix during metastasis and 
include:  (1) disruption of cell-cell contacts; (2) loss of epithelial cell polarity and 
acquisition of a motile phenotype; (3) disruption of cell-extracellular matrix interactions.  
1.3.2.6.1. Cell-cell adhesions 
Cell-cell contacts allow for adhesion and intercellular communication.  These 
adhesive contacts are limiting factors for tumor metastasis and must be broken down for 
tumor cells to invade other tissue.  Breast epithelial cells are normally attached via 
specialized cell-cell contacts to the basement membrane, which are thin “sheets” of 
connective tissue containing collagen type IV, laminins, entactins (nidogen) and 
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proteoglycans [281,282] and breaching this membrane is a key event in cancer 
metastasis.   
Laminins are a family of 12 distinct heterotrimeric glycoproteins that are major 
basement membrane components [279].  Several surface proteins act as receptors for 
laminins and these include members of the integrin family, dystroglycan and heparan 
sulfate [282,283].  The predominant receptors on mammary epithelial and breast 
carcinoma cells are integrins [279] and integrins are receptors for extracellular matrix 
components and metastasis alters their expression.   
Integrins form heterodimeric receptors for extracellular matrix molecules 
including laminins.  There are 18 α-subunits and 8 β-subunits and each integrins consists 
of a noncovalently linked α- and β-subunit [154].  There are at least 25 distinct pairings 
that are specific for a unique set of ligands [284].  Integrins are key regulators of cell 
adhesion but also play a role in influencing cell shape, survival, proliferation, gene 
transcription and migration [285]. 
Ligand binding to integrin receptors triggers a cluster formation of integrins and 
cytoskeletal components including actin-associated proteins such as α-actinin, vinculin, 
tensin and paxillin [286].  Kinases that phosphorylate cytoskeletal proteins are also 
activated by integrins that regulate cell shape and migration [154].  The cytoplasmic tail 
of integrins can recruit regulatory proteins for integrin adhesiveness to the extracellular 
matrix [154].  The α6β4 integrin is a key component in many epithelia for adhering 
epithelial cells to the basement membrane via hemidesmosomes [178].  
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Hemidesmosomes link the intermediate filament cytoskeleton with laminins in the 
basement membrane.   
1.3.2.6.2. Epithelial-mesenchymal transition and acquisition of motile phenotype 
The epithelial-mesenchymal transition (EMT) refers to a process where epithelial 
cells lose their polarity and cell-cell contacts, undergo cytoskeletal remodeling and 
acquire mesenchymal and migratory characteristics [144,287].  EMT most likely 
involves disassembly of cell-cell connections including tight junctions, adherens 
junctions and desmosomes.  Growth factors can activate EMT by means of receptor 
tyrosine kinase activation and these factors include scatter factor/hepatocyte growth 
factor, FGF, EGF, IGF-I and IGF-II (Figure 1.15) [144].  The majority of growth factors 
turn on EMT through MAPK activation, but Src, PI3K or Rac may also be involved 
[288].  Normal breast cell lines respond to TGF-β, which cooperatively acts with Ras to 
induce EMT [289]. 
Cadherins are proteins critical for epithelial cell-cell adhesion.    The ectodomain 
of cadherin functions in homophilic adhesion and the cytoplasmic domain is essential for 
interaction with the actin cytoskeleton via the β-catenin-α-catenin complex [290].  E-
cadherin expression is frequently lost during cancer progression and is a hallmark of 
EMT [287]. 
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Slug and Snail are transcriptional repressors that can downregulate E-cadherin 
expression [173,288].  Snail is a zinc finger protein that recognizes E-box motifs in the 
E-cadherin promoter [291].  Slug also binds with lower affinity to the same region of the 
E-cadherin promoter [288].  SIP1 is downstream of TGF-β and is overexpressed in E-
cadherin deficient cell lines and also binds to E-boxes in the E-cadherin promoter and 
like Snail, exhibits similar repressor effects [292].  Overexpression of Snail and SIP1 
inhibit E-cadherin adhesion and promote invasion [292].  Recently, Twist has been 
added to the list of repressors of E-cadherin and subsequent induction of EMT [293].  
Migration is a key step in invasion and metastasis and involves lamellipodia that 
attach to the extracellular matrix and propels the cell forward [294].  In the metastatic 
stages of cancer, tumor cells express vimentin, which is typical of migratory motile 
mesenchymal cells instead of cytokeratin, which is characteristic of epithelial cells [158].  
Cell migration is initiated by polarizing the cell to have distinctive front and rear 
advancing and tracking regions.  Lamellipodia are formed by actin polymerization and 
decreased cell membrane tension.  The leading edge also is flooded with receptors and 
signaling molecules to allow for new adhesive cell-cell contacts to be formed.  At the 
rear end of the cell, cell-cell integrins contacts are released to allow for migration [154]. 
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1.3.2.6.3. Extracellular matrix remodeling 
Penetrating the basement membrane is a key event in cancer metastasis [295].  A 
three-step model of invasion has been proposed suggesting that tumor cells attach 
themselves to the basement membrane secrete proteases to dissolve the basement 
membrane to facilitate access to the basement membrane.  Extracellular matrix 
remodeling also occurs during metastasis and involves extracellular matrix degradation 
via proteases and the synthesis of new extracellular matrix proteins [154].  These 
proteases break down the basement membrane and allow access of epithelial cells to 
stroma and other tissues.  Breaching the basement membrane necessitates secretion of 
specific proteases for the extracellular matrix in close proximity to the cancer cells and 
proteases to stop excess matrix degradation.   
Matrix metalloproteases (MMPs) are critical enzymes involved in tissue 
remodeling and destruction of the microenvironment [158].  In the context of 
extracellular matrix remodeling, MMP-2 and MMP-9 can degrade a major component of 
the basement membrane, type IV collagen [296].  MMPs are secreted as inactivated 
zymogens and can be activated by other proteases that regulate activation and 
localization of MMPs and tissue inhibitors of MMPs (TIMPs) are critical in this process 
[154].  Overexpression of MMPs is a critical step in tumor invasion and metastasis since 
this destroys barriers and allows access of cancer cells to other tissues [297].  MMPs are 
also critical in the loss of epithelial cell identity since MMPs can destroy factors critical 
for epithelial differentiation [158]. 
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Figure 1.15:  Regulators of the Epithelial-Mesenchymal Transition (EMT).   Twist, Snail, SIP1 
repress E-cadherin transcription via E boxes and activate expression of genes that triggers EMT.  Twist, 
Snail and SIP1 are regulated by various pathways in tumor cells and those shown in parentheses are 
involved during development. [287] 
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1.3.2.6.4. Integrins, E-cadherins and breast cancer 
 Integrins are receptors involved in facilitating contact between the extracellular 
matrix and cellular cytoskeleton.  Integrins expressed on epithelial and myoepithelial 
cells of the breast include α2β1, α3β1, α5β1, α6β1, α6β4, αvβ6 [298].  The α6 
integrins (α6β1, α6β4) have been linked to aggressive forms of breast cancer and have 
been the main focus of investigators for this reason.  Reduced survival times in women 
were significantly correlated with high expression of α6 subunits [299].  Coexpression 
of α6β4 and laminin in breast tumors has been associated with a poor prognosis [300].  
Although migration principally involves disassembly of cell-cell contacts such as 
hemidesmosomes, α6β4 integrin has recently been shown to promote migration through 
its function in the formation and stabilization of filopodia and lamellae [181].  In 
addition, decreased expression of α1, α6, β1, β4 integrin subunits is associated with 
neoplastic formation in breast tissue [301]. 
 E-cadherin is another protein linked to breast cancer due to its critical role in 
EMT initiation.  In vitro and in vivo studies have shown that E-cadherin loss increases 
tumor cell invasiveness and adenomas convert to carcinomas, respectively [144].  E-
cadherin expression is inversely correlated with tumor grade and stage and hence is 
considered a tumor suppressor gene [287].  Approximately half of breast lobular 
carcinomas have E-cadherin mutations [144].  An inverse relationship exists between E-
cadherin and Twist expression in invasive lobular carcinomas [293]. 
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1.4. Current Drug Strategies 
 Despite scientific advances, metastatic breast cancer remains an incurable disease 
and treatment is used to delay disease progression, improve the quality of life and 
prolong life [302,303].  Adjuvant therapy is a critical component of treatment regimens 
for women with primary breast cancer and the chosen therapy is based on characteristics 
that can be divided into 3 categories:  patient characteristics, disease characteristics and 
biologic features [304]. 
1.4.1. Endocrine therapy 
 Endocrine therapy is universally employed for hormone receptor positive breast 
tumors and the agents used are based on menopausal status.  In premenopausal women, 
the therapeutic options include tamoxifen or ovarian ablation/suppression.  Ovarian 
ablation significantly increases survival in women less than 50 years of age [305].  
Tamoxifen has exhibited favorable therapeutic effects in both premenopausal and 
postmenopausal women, reducing recurrence and death from breast cancer [306]. 
In postmenopausal women, tamoxifen and aromatase inhibitors are both used, the 
latter of which is only effective in the absence of ovarian function [307].  A comparison 
of the aromatase inhibitor anastrozole and tamoxifen showed anastrozole to be 
comparable to tamoxifen with respect to objective response and clinical benefit and 
significantly better than tamoxifen for delayed disease progression [308].  Letrozole, an 
alternative aromatase inhibitor, showed better objective response, clinical benefit and 
time to progression compared to tamoxifen [309].  In addition, aromatase inhibitors are 
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beneficial since they do not have an enhanced risk of endometrial cancer like tamoxifen 
but are associated with accelerated bone loss [304]. 
1.4.2. Cytotoxic drugs 
  Cytotoxic drugs inhibit cell proliferation by an array of mechanisms and have 
been studied for the past 40 years in treating cancer patients.  An extensive range of 
single agent and combination therapies have been investigated.  Early chemotherapeutic 
drugs functioned as DNA alkylating agents including cyclophosphamide or 
antimetabolite agents including methotrexate and fluorouracil and were frequently 
utilized in the 1970s [310].  In the next decade, cyclophosphamide was used in 
combination with the anthracycline doxorubicin [311].  Currently, the most common 
cytotoxic drugs used in breast cancer treatment are the anthracyclines, doxorubicin and 
epirubicin and the taxanes, paclitaxel and docetaxel [302]. 
1.4.2.1. Anthracyclines 
 Anthracyclines function by interacting with DNA, inhibiting tumor cell 
proliferation and gene expression and production of free radicals that will ultimately 
result in tumor cell death [312].  Cardiotoxicity is one of the major toxic effects 
associated with anthracyclines and has prompted more recent formulations to include 
liposomal anthracyclines, which have a more favorable cardiac safety profile [313].  
Single agent use of doxorubicin produced response rates of 40-50% in untreated 
patients and 32-36% in previously treated patients [307].  Comparative response rates of 
other chemotherapeutic agents are summarized in Table 1.11. Anthracyclines used in 
combination with other chemotherapeutic agents has produced enhanced response rates 
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in the range of 60-85%, however, with no statistically significant change in survival 
[314].   
Table 1.11:  Response rates with single-agent chemotherapy administered to patients with 
metastatic breast cancer. (reviewed in [307]) 
Response Rates (%) 
CHEMOTHERAPEUTIC 
AGENT First-line Second-line 
Doxorubicin (including 
liposomal formulations) 
40-50 32-36 
Epirubicin 52-68 25-35 
Paclitaxel 29-63 19-57 
Docetaxel 47-65 39-58 
Capecitabine 20-30 20-27 
Gemcitabine 23-37 13-41 
Vinorelbine 40-44 17-36 
 
1.4.2.2. Taxanes 
Taxanes are commonly employed as a first line of treatment of metastatic breast 
cancer.  Both paclitaxel and docetaxel interfere with mitosis by binding to the β-subunit 
of tubulin, which leads to the formation of stable nonfunctional microtubule bundles 
[315].  The effects of paclitaxel and docetaxel are active in G2/M and S phase 
respectively of the cell cycle [315].  The pharmacokinetics of the two taxanes are 
slightly different; docetaxel has linear pharmacokinetics and longer plasma half-life and 
intracellular retention time. 
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In early single agent studies with either paclitaxel or docetaxel as the first agent 
to treat metastatic breast cancer, response rates were as high as 60% [316,317].  A 
comparison of docetaxel given 3 weeks at 100 mg/m2 and doxorubicin 75 mg/m2 showed 
docetaxel being more active therapeutically and less toxic than doxorubicin [318].  A 
comparison of the two taxanes showed that although docetaxel had a higher overall 
survival than paclitaxel, there was a higher toxicity in the form of neutropenia and 
treatment-related death [319].  Taxanes has also been effective in patients that have 
developed resistance to anthracyclines [320]. 
Taxanes plus doxorubicin as a treatment regimen elicited response rates from 28-
58% [311].  Docetaxel/doxorubicin versus doxorubicin/cyclophosphamide combination 
treatments showed the taxane-containing combination had a significantly improved 
response rate and time to cancer progression [321]..   However, other taxane treatment 
combinations produced synergistic toxic effects, such as between the HER2 humanized 
antibody, trastuzumab, and taxanes [322]. 
1.4.3. Kinase inhibitors 
 ErbB receptors respond to various growth factor ligands and their overactivation 
can lead to uncontrolled cell growth.  ErbB2/HER2/neu is frequently overexpressed in 
25-30% of breast tumors and is associated with a more invasive form of breast cancer 
and poor prognosis [323].  Overexpression of EGFR/HER1 occurs in 16-48% of human 
breast cancer cases and has also been linked with an invasive metastatic breast cancer 
phenotype [324,325].  ErbB positive tumors are customarily resistant to antiestrogen 
therapy [326] and cytotoxic agents have been traditionally used.  Alternative drug targets 
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for HER positive tumors have been extensively studied that have fewer side effects than 
their cytotoxic counterparts; both HER1- and HER2-targeted treatments have been 
investigated clinically for use in treating metastatic breast cancer with promising 
antitumorigenic effects. 
1.4.3.1. HER2 inhibitors 
 Trastuzumab is a monoclonal antibody that recognizes the extracellular domain 
of HER2 and is effective when used alone or in combination with other 
chemotherapeutic agents when treating HER2 positive tumors [327,328].  The 
mechanisms of trastuzumab action include:  (1) reduced receptor signaling; (2) G1 arrest 
via p27 modulation; (3) induction of apoptosis; (4) inhibition of angiogenesis; (5) 
immune-related mechanisms of cytotoxicity; (6) inhibition of HER2 extracellular 
domain cleavage; (7) inhibition of DNA repair [329].  Another HER2-targeted agent is 
pertuzumab, which inhibits HER2 dimerization and is currently in clinical trials [330].  
In addition, small-interfering RNAs (siRNAs) against HER2 expression slowed cell 
proliferation, increased apoptosis and reduced tumor growth in ovarian and breast cancer 
cells [331]. 
1.4.3.2. HER1 inhibitors 
 Gefitinib is a small molecule receptor tyrosine kinase inhibitor with specificity 
towards EGFR by being a competitive inhibitor of adenosine triphosphate (ATP) 
receptor binding [330].  Gefitinib has proven effective in vitro not only in EGFR 
overexpressing cells but also HER2-expressing cells presumably by reducing 
EGFR/HER2 heterodimer phosphorylation [332].  However, these results did not 
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necessarily translate into successful clinical trials.  Gefitinib had low efficacy in a pre-
treated population are metastatic breast cancer.  The exception is in tamoxifen-resistant 
ER positive tumors, where a therapeutic effect was achieved with gefitinib treatment 
[330].  
1.4.4. Antiangiogenic therapy 
Angiogenesis is an absolute requirement of primary tumors due to the role of 
new blood vessels in tumor growth and invasion [333].  In solid tumors, angiogenesis is 
critical in order for the tumor to grow beyond 2-3 mm [334].  There have been 4 classes 
of antiangiogenic agents studied:  (1) Endothelial toxins; (2) Growth factor/receptor 
antagonists; (3) Protease inhibitors; and (4) Natural inhibitors [335].   
1.4.4.1. Endothelial toxins 
Endothelial chemotaxis and migration are important steps in the angiogenic 
process and perturbations can impede angiogenesis.  Integrins are key targets in this 
process since they link endothelial cells to the extracellular matrix components, 
particularly integrin αVβ3 [336].  Vitaxin™ is a monoclonal antibody against αVβ3 and 
has shown growth inhibitory and antitumorigenic effects in vitro and in vivo [337]. 
1.4.4.2. Growth factor antagonists 
There are a variety of factors that regulate angiogenesis including growth factors 
and external stimuli.  VEGF is considered the predominant factor that initiates 
angiogenesis.  It is expressed in a variety of tumor types and a higher expression of 
VEGF mRNA is seen in invasive ductal carcinoma, metastatic ductal carcinoma 
compared to lobular carcinoma [338].  In invasive HER2 positive tumors, VEGF is 
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upregulated and may be involved in the switch to an aggressive phenotype [339].  VEGF 
stimulates endothelial cell proliferation and increases microvascular permeability, which 
leads to the release of plasma protein that can change extracellular matrix components 
and promote new blood vessel formation [340].  Since VEGF plays such a critical role in 
angiogenesis, it has become a common chemotherapeutic target by pharmaceutical 
companies. 
Bevacizumab is an antibody directed against VEGF-A and has shown promise in 
animal and clinical studies [341,342].  Combination therapy of bevacizumab and 
capcitabine showed improved therapeutic benefit when compared to single treatments of 
either drug [343]. 
1.4.4.3. Protease inhibitors 
 Another key step in the angiogenic process is breakdown of the basement 
membrane and stroma by a specific class of proteases, the MMPs.  MMP inhibitors have 
shown promise in xenograft studies with breast cancer cells but not when tumors are 
large and breast cancer is in an advanced stage [344].  Clinical trials involving MMPs 
inhibitors for treatment at the earlier micrometastatic stage of breast cancer showed 
antitumorigenic effects after treatment but also lead to high musculoskeletal toxicity 
[345]. 
1.4.4.4. Endogenous antiangiogenics 
Certain naturally-occurring chemicals have exhibited antiangiogenic effects.  2-
Methoxyestradiol (2ME2) is metabolic product of estradiol and inhibits both 
proliferation and angiogenesis [346].  Clinical trials of 2ME2 have prompted the 
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development of new formulations since there was a significant conversion to an inactive 
metabolite in patients administered the drugs [347]. 
1.4.5. Proteasome inhibitors 
 Ubiquitination refers to a process of regulating proteins whereby the highly 
conserved 76 amino acid protein ubiquitin can be covalently conjugated to lysine 
residues [348].  This process is carried out by 4 critical enzymes:  ubiquitin-activing 
enzyme (E1), ubiquitin-conjugating enzyme (E2), ubiquitin ligase (E3) and the 26S 
proteasome [349].  E1 binds to and activates ubiquitin, which is an ATP-dependent 
process, then passes ubiquitin to E2 and is then transferred to the lysine residue by way 
of E3 that acts as a scaffolding protein.  The polyubiquitinated form is then targeted for 
degradation via the 26S proteasome.  E3 confers substrate specificity [350]. 
 The ubiquitin-proteasome pathway critically regulates a number of key signaling 
pathways.  Nuclear factor kappa-B (NF-κB) is a transcription factor and integral player 
in immune and inflammatory responses, apoptosis and cell proliferation [351,352].  
Temporal expression of cyclins and CKIs in the cell cycle is essential for successful 
progression and is regulated by ubiquitin-proteasome dependent degradation [350].  The 
ubiquitin-proteasome machinery is critical in terms of generating antigenic peptides 
from cytosolic proteins [352]. 
 Growth factors receptors can be degraded through both ligand-dependent and 
ligand-independent degradation.  The ligand-dependent mechanism involves a rapid 
reduction in cell surface expression of EGFR upon ligand binding.  This downregulation 
involves two steps:  internalization of membrane receptor and receptor degradation [353].  
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Internalization of EGFR is accomplished by recruitment of Cbl proteins upon ligand 
binding that have E3 and adaptor protein capabilities and therefore the ubiquitin-
proteasome pathway is crucial in terms of regulation of growth factor expression. 
1.4.5.1. Indirect effects on ubiquitin-proteasome function 
Several drugs indirectly influence the ubiquitin proteasome pathway by either 
increasing or inhibiting the function of this pathway.  Examples of drugs and their 
effects on the proteasome pathway are summarized in Table 1.12. Camptothecin and 
fulvestrant are chemotherapeutic agents that act by stimulating the proteasome pathway.  
Camptothecin inhibits the religation step of topoisomerase 1 by stimulating the 
ubiquitination and subsequent degradation of topoisomerase 1 [354].  Fulvestrant 
partially functions as a pure estrogen receptor antagonist by activating proteasome-
dependent degradation of ERα [355].  Arsenic is an example of a drug that inhibits 
proteasome function by inhibiting the action of IқB kinase and thus preventing the 
necessary phosphorylation of IқB that leads to proteasome-mediated degradation of IқB 
[356].  Trastuzumab is an antibody that targets ErbB2 and recent work has shown that it 
recruits Cbl proteins and stimulates the subsequent ubiquitination and degradation of 
ErbB2 via the proteasome pathway [357]. 
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Table 1.12:  Drugs that influence ubiquitin-proteasome activity.  [350,358,359] 
Drug class Action and mechanism 
Chemotherapeutic agents 
Aclarubicin Inhibits the chymotrypsin-like proteolytic activity of the proteasome 
All-trans retinoic acid May accelerate PML fusion protein degradation through the proteasome 
Arsenic trioxide Inhibits ubiquitination and degradation of IKB through effects 
on the IKB kinase 
Camptothecin Stimulate ubiquitination and degradation of topoisomerase 1 
Geldenamycin Inhibits HSP90 ATPase, stimulating proteasomal degradation 
of client proteins 
PS-341 Inhibits the chymotrypsin-like activity of the proteasome 
Trastuzumab Stimulates ubiquitination and subsequent degradation of ErbB2 
Vinblastine, Vincristine Inhibits the chymotrypsin-like, trypsin-like- and peptidyl-glutamyl peptide hydrolyzing proteasome activities 
Immunosupressive agents 
Cyclosporin A Uncompetitive inhibitor of the proteasomal chymotrypsin-like 
activity 
Rapamycin Inhibits proteasome function by inhibiting the proteasome 
activator PA28 
Miscellaneous agents 
Fulvestrant Stimulates proteasome-dependent proteolysis of ERα 
Tannic acid Inhibits the chymotrypsin-like activity of the proteasome 
Lovastatin Mechanism unknown, but appears structurally similar to proteasome inhibitor lactacystin 
Anti-retroviral drugs Inhibits the chymotrypsin-like and trypsin-like proteasome 
activities 
Bortezomib Inhibits 26S proteasome activity 
 
1.4.5.2. Direct effects on ubiquitin-proteasome 
Several agents directly target the ubiquitin-proteasome system.  The 
immunosuppressive agent rapamycin inhibits the expression of proteasome activator 
PA28 and therefore inhibits proteasome function [360].  Other chemotherapeutic drugs 
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inhibits the proteasome including aclarubicin, vinblastine and vincristine [361,362].  
Peptide aldehydes such as MG132 and MG115 are inhibitors of the 20S proteasome and 
have been used extensively to study the role of proteasomes in various cellular functions 
[363].  Bortezomib is an inhibitor or the 26S proteasome however, clinical trials of 
bortezomib used as a single agent against metastatic breast cancer did not yield any 
therapeutic benefit [359]. 
1.4.6. Gene replacement therapy 
 Gene therapy is a promising new field of cancer treatments and is a method for 
transferring genetic material that will either promote cell death or inhibit cell growth by 
gene transfer.  Gene therapy can be classified into 4 strategies:  (1) suppression of 
oncogenes or transfer of tumor suppressor genes; (2) enhancement of immunological 
response; (3) transfer of suicide genes; (4) protection of bone marrow using drug 
resistance genes [364].  There are 3 primary methods for gene transfer: (1) transient 
transduction of naked DNA via lipofection; (2) transduction of adenoviral vector or 
vaccinia virus vector; (3) transduction of retroviral vector [365].  Only transduction of a 
retroviral vector leads to stable expression; the two former procedures for gene transfer 
lead to transient expression of the desired genes. 
1.4.6.1. Oncogene suppression or tumor suppressor gene transfer 
 Tumor suppressor genes are critically involved in apoptosis induction or 
suppression of tumor growth and their loss due to functional defects or absence of one or 
more tumor suppressor genes leads to cancer.  Gene replacement therapy is based on the 
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principle that the addition of functional copies of tumor suppressor genes will lead to a 
reduction of tumor cell growth and cancer progression [366]. 
 The most commonly altered tumor suppressor gene in cancer is p53 and p53 
mutations will lead to cell cycle arrest or apoptosis [365].  Viral introduction of p53 into 
human breast cancer cells can restore cellular homeostasis in terms of balanced cell 
growth and death [366].  An added benefit of this technique was that in addition to cell 
death observed in p53-transduced cells, cells surrounding the transduced cells are also 
killed and this is dubbed the bystander effect [367].  The bystander effect is 
advantageous because it reduces the need for high transduction efficiency in order to 
achieve desired efficacy [368]. 
 Other gene abnormalities common in breast cancer patients include 
overexpression of ErbB2, c-myc and cyclin D1 [369].  ErbB2 overexpression is common 
in invasive forms of breast cancer and associated with a poor prognosis and hormone 
therapy resistance [369].  ErbB2 gene therapy in patients overexpressing ErbB2 
decreases the number of tumors cells and reduces ErbB2 expression [370].  Transfer of 
c-myc and c-fos genes under control of the MMTV promoter inhibit tumor formation in 
murine models [371]. 
1.4.6.2. Suicide gene therapy 
 Gene transfer of drug-activating enzymes leads to increased cellular 
concentrations of activated prodrugs and this results in increased death of tumor cells.  
The bystander effect is also relevant for suicide gene therapy such that cells adjacent to 
transduced tumor cells are also affected [365].   Cytosine deaminase gene transfer and 
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subsequent treatment of breast cancer patients with fluorocytosine (prodrug form) 
yielded positive tumor reduction results [372].  CYP2B6 gene therapy and 
cyclophosphamide co-treatment was antitumorigenic in Phase I clinical trials for patients 
with metastatic breast cancer [373]. 
1.4.6.3. Bone marrow protection by drug resistance 
 High dose chemotherapy cannot completely kill residual disease and this stage of 
the disease is also associated with insufficient bone marrow function.  One approach is 
to transplant drug-resistant gene-transduced hematopoietic stem cells, resulting in 
normal bone marrow cells that are resistant to the effects of chemotherapeutic drugs.  
The multi-drug resistant 1 (MDR1) gene excretes various drugs from the cytoplasm and 
MDR1 gene transfer to bone marrow cells is a new therapy for treating cancer patients.  
Clinical trials involving advanced breast cancer patients that received MDR1 gene 
transfer in combination with docetaxel exhibited therapeutic benefits compared to 
conventional therapy. [365] 
1.4.7. Immunotherapies 
The immune system has originally been thought to induce a response based on 
recognizing self versus non-self [374].  However, more recent evidence supports the 
danger theory which suggests that cells experiencing stress release “alarm” signals [375] 
and therefore the microenvironment surrounding the cell in terms of immunostimulatory 
molecules versus immunosuppressive molecules are critical in eliciting a T-cell 
mediated response [376].  The immune cells involved in responding to these signals are 
summarized in Table 1.13. 
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Table 1.13:  Function of cells in the immune response.   Abbreviations used: IL=interleukin; IFN-
γ=interferon gamma [377] 
 
Cell Type Function 
CD8+ cytotoxic T cells (CTL) Kills cells expressing antigens 
CD4+ T helper cells (CTh) 
 
• Th1 
 
• Th2 
Augment antigen-specific immune response via 
cytokine secretion 
Secrete cytokines (e.g. IL-2, IFN-γ) that stimulate 
proliferation and activity of cytotoxic T cells 
Secrete cytokines (e.g. IL-4, 5, 6, 10) that results in 
more effective antibody production 
B cells Signals from CD4+ cells trigger antibody-producing 
cells that secret antibodies 
Natural Killer (NK) cells Constitutively kill small set of hematopoietic cells 
IL-2 or IL-15 stimulation permits recognition of 
broader range of altered “self” 
 
1.4.7.1. Cytokine treatment 
Cytokines are critical molecules involved in the regulation of inflammation, cell 
growth and differentiation [377] and delivery of these molecules via gene therapy can 
enhance the immune response.  IL-2, Il-12, GM-CSF, TNF, IFN-γ are all cytokine genes 
that have been genetically transferred with the intention of boosting the immune system 
[365].   
1.4.7.1.1. Interferon-γ (IFN-γ) 
Interferons (IFNs) are natural glycoproteins that enhance the immune response 
by increasing the expression of cell surface proteins including major histocompatiblity 
complexes (MHC) [378] and IFNs play a role in the activity of other cytokines.   IFNs 
can be divided into 2 classes:  Type I and Type II IFNs [379].  Type I IFNs typically 
respond to viral infection and include IFN-α and IFN-β [380].  In contrast, Type II IFNs 
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such as IFN-γ are induced by immune and inflammatory stimuli and are produced by 
immune cells including T lymphocytes and NK cells [381,382].  IFN-γ acts as a 
homodimer with its receptor that is ubiquitously expressed on the surface of normal cells.  
Upon receptor activation, JAKs are activated, leading to activation of the JAK/STAT 
pathways that binds to gamma-interferon activator sets (GAS) elements and interferon-
stimulated response elements (ISREs) in promoter regions of target genes [383,384]. 
IFN-γ is downregulated via IL-10 [385] whereas IL-2 acts synergistically with 
IFN-γ to reduce tumor size [386].  Although IL-10 is present in normal tissue, it is 
absence from breast tumors and may be explain why IFNγ, IL-2, IL-4 are also not 
detected in tumors [387].  Clinical studies with IFN-γ and hormone therapy as a 
combination therapy produced a favorable response in breast cancer patients [388]. 
1.4.7.1.2. IL-2 
 IL-2 induces proliferation of key immune cells including NK and T cells and its 
therapeutic benefit through gene transfer has been documented in melanoma and renal 
cell carcinoma patients [377].  Antitumorigenic effects are also observed in murine 
breast cancer models after administration of IL-2 gene therapy [389]. 
1.4.7.2. Vaccines targeting breast cancer 
Cancer vaccine immunotherapy uses T cells and exploits their anti-tumor 
cytotoxic T lymphocyte function to specifically target and kill tumor cells [390].  Breast 
cancers exhibit low antigenicity and are non-responsive to immune therapy, however, 
more recent studies have uncovered breast cancer-associated antigens [365].  Tumor-
specific antigens that are integrally required for this therapy fall into 3 categories:  
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tissue-specific differentiation antigens, tumor-specific shared antigens, tumor-specific 
unique antigens [390].  Breast cancer-specific antigens include HER-2/neu [391], 
autoimmunogenic cancer/testis antigen (NY-ESO-1) [392], carcinoembryonic antigen 
(CEA) [393], melanoma-associated antigen 1 (MAGE-1) [394] and Mucin 1 (MUC-1) 
[395].  Cloned tumor antigens are advantageous because the delivery of antigens can be 
controlled and they are safer since the likelihood of inducing an immune response for 
tumor-specific antigens is decreased [376]. 
1.4.7.3. T-cell therapy 
 Clonal expansion of tumor-specific T cells ex vivo is a therapeutic strategy to kill 
tumor cells.  A section of the primary tumor is surgically removed and anti-tumor T 
lymphocytes are generated.  These T-lymphocytes are transferred into patients, migrate 
to tumor sites and ultimately kill tumor cells [390].  Initial trials in breast cancer patients 
showed an increase in survival rate [396]. 
1.4.8. Apoptosis inducers 
Apoptosis is a major death pathway that is evaded by tumor cells through various 
molecules that create barriers to cell death [397].  The Bcl-2 family of proteins, IAPs and 
death receptors function as the major regulatory molecules of this pathway and have all 
been studied as potential therapeutic targets to encourage apoptosis-induced death of 
cancer cells [398]. 
1.4.8.1. Bcl-2 proteins 
Overexpression of Bcl-2 and other family members has been linked with 
resistance to cytotoxic agents due to the ability of these compounds to block cell death 
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[397].  Numerous agents reduce expression of anti-apoptotic members of the Bcl-2 
family and these include antiestrogens, retinoids, Vitamin D and HDAC inhibitors [399-
402].   
Chemicals have also been designed to specifically target Bcl-2 that bind to the 
regulatory sites of Bcl-2 proteins or bind to the BH3 binding site on Bcl-2.  Natural 
products including gossypol, epigallecatechin gallate, theaflavin, chelerythrine and 
antimycin have shown to be BH3-mimicking chemical antagonists [403-406]. 
DNA-based drugs for Bcl-2 proteins are based on the principle that antisense 
nucleotides can selectively bind to mRNA targets and induce ribonuclease-mediated 
mRNA degradation [397].  Oblimersen sodium is a Bcl-2 antisense inhibitor that has 
been successful in Phase III clinical trials for treatment of chronic lymphocytic leukemia 
but not for treatment of refractory multiple myeloma [407]. 
1.4.8.2. IAP proteins 
IAP-family proteins are critical negative regulators of apoptosis that directly bind 
to and inactivate caspases.  Small molecules have been developed that inhibit IAPs by 
displacing caspases and hence promoting apoptosis [397].  Survivin and XIAP antisense 
are both undergoing Phase I clinical trials [408].  Many other inhibitors of XIAP are 
currently being developed both in academia and industry [397]. 
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1.4.8.3. Death receptor pathway 
 TRAIL is a member of the TNF family and is a death receptor that induces 
apoptosis in response to extracellular stimuli.  However, breast cancer cells are 
frequently resistant to TRAIL-induced apoptosis [409].  A new breast cancer therapy 
strategy involves the use of interferon-γ to sensitize tumor cells to TRAIL-induced 
apoptosis [410]. 
 IFN-γ inhibits mammary tumor growth in murine models [411,412] and an 
increase in IFN-γ levels in tumors is positively correlated with a good prognosis [388].  
IFN-γ can enhance sensitivity of tumor cells to apoptosis [410] and the mechanism of 
IFN-γ in producing these effects has also been extensively studied.  Although IFN-γ 
upregulates CD95-induced apoptosis [248], this is not a viable therapeutic approach 
since normal cells also undergo enhanced CD95-mediated apoptosis [413].  IFN-γ also 
increases the expression of TRAIL and decreases expression of TRAIL decoy receptors, 
ultimately increasing apoptosis [414].  In vitro studies showed that caspase pathways and 
Bcl-2 protein levels were modulated in MCF-7 and MDA-MB-231 breast cancer cells 
after treatment with IFN-γ. 
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1.5. DIM as a Model for Development of Mechanism-Based Drugs 
Recent advances in cancer chemotherapy have involved the development of 
drugs that specifically target cancer cells rather than normal cells.  The chemopreventive 
properties of DIM have previously been discovered and studies on the mechanism of 
action of DIM have revealed cancer-specific and cell-context dependent targets of 
growth inhibition that could be exploited for therapeutic purposes. 
1.5.1. DIM 
Cruciferous vegetables (broccoli, brussel sprouts, cabbage, cauliflower, bok 
choy) contain dietary indoles that have a protective effect against a number of cancers 
including breast cancer [123-127,415].  Indole-3-carbinol (I3C) is a phytochemical that 
exhibits antiproliferative and antitumorigenic effects in vitro and in vivo [130,131,133-
135].  DIM is an acid condensation product of I3C (see Figure 1.16) [128,129] and 
extensive research has revealed the chemotherapeutic potential of this compound.  
Multiple molecular mechanisms of cellular action have been suggested to play a role in 
DIM-induced growth inhibition and are described below. 
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Figure 1.16:  Conversion of I3C into condensation products under acidic 
conditions. 
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1.5.1.1. Modulation of cell cycle 
 A number of papers suggest that the growth inhibitory effects of DIM are due to 
modulation of cell cycle proteins and cell cycle arrest.  In MCF-7 breast cancer cells, 
I3C and DIM induce G1 cell cycle arrest, increase p21 gene expression through Sp1 
promoter elements and stimulate cdk6 through Sp1 and Ets6 promoter elements 
[134,416,417].  I3C induces G1 cell cycle arrest in prostate cancer cells [132] whereas in 
HepG2 cells treated with DIM, S-phase retardation was observed [418].   
1.5.1.2. Induction of apoptosis 
 Apoptosis is a regulated program of cell death and has been induced by DIM 
through a variety of mechanisms in cancer cell lines.  DIM induced caspase-8-dependent 
apoptosis in colon cancer cells [419].  Prostate cancer cells treated with DIM exhibited 
signs of apoptosis which could be partially reversed through downregulation of the 
androgen receptor (AR) [420-422].  Induction of endoplasmic reticulum stress and 
subsequent induction of apoptosis was also induced after treatment of pancreatic cells 
with DIM [423].  DIM also sensitizes TRAIL-resistant liver and colon cancer cells to 
TRAIL-mediated apoptosis by downregulation of c-FLIP [424].  In breast cancer cells, 
DIM induced apoptosis [425,426] and this induction involved the inhibition of the 
nuclear translocation of NF-κB in MCF-7 breast cancer cells [427].  In addition, the pro-
apoptotic protein, non-steroidal anti-inflammatory drug-activated gene 1 (NAG-1) was 
upregulated by DIM in colon cancer cells [428]. 
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1.5.1.3. Other cellular effects 
 DIM causes a number of biological effects in addition to apoptosis induction and 
cell cycle arrest.  In MCF-7 breast cancer cells, DIM inhibited mitochondrial H+-ATP 
synthase [429] and activated IFN-γ through upregulation of JNK and p38 [430,431].  
DIM is also an aryl hydrocarbon receptor (AhR) agonist and inhibited breast cancer cell 
growth through negative crosstalk with ER [131].  DIM inhibited angiogenesis in in vivo 
breast cancer xenograft models [432].  DIM increased TGF-α in human endometrial 
cancer cells [433]. 
1.5.2. Ring-DIMs 
Ring-DIMs constitute a new class of anticancer agents and their chemical 
structure is illustrated in Figure 1.17.  The chemotherapeutic effects of DIM and ring-
substituted DIMs on mammary tumor growth in DMBA-induced female Sprague-
Dawley rats and their antigrowth effects in ER-positive MCF-7 and T47D breast cancer 
cells have been investigated.  At a dose of 5/mg/kg/48h (X10), DIM inhibited tumor 
growth, and several ring-substituted DIMs were antitumorigenic at doses ≤1mg/kg/48h 
(X10) [131,434,435].  The in vitro antiestrogenic effects of DIM and ring-substituted 
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Figure 1.17:  Chemical structure of Ring-DIMs.  X=Br, Cl, I, OCH3 
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DIMs were also observed in ER-positive MCF-7 and T47D breast cancer cells.  1,1'-, 
2,2'-, 5,5'-dimethylDIM and 1,1',2,2'-tetramethylDIM were the four most potent methyl-
substituted ring-DIMs and 5,5’-dibromoDIM was the most potent compound in the 
dihalo ring DIM series  [131,434,435].  The DIM compounds bind the aryl hydrocarbon 
receptor (AhR) [131,434,435] and the results suggest that the observed antiestrogenic 
responses may be due, in part, to inhibitory AhR-ERα crosstalk. 
1.5.3. C-DIMs 
Chemical modifications of DIM yield a novel class of synthetic compounds 
termed the 1,1-bis(3-indolyl)-1-(p-substitutedphenyl)methanes as depicted in Figure 1.18.   
Research on the growth inhibitory effects of a series of these compounds with various 
substituents (X) showed that many of the C-substituted DIMs induced nuclear-receptor 
dependent and independent effects including induction of caveolin proteins, induction of 
ER stress, G0/G1 cell cycle arrest and induction of the pro-apoptotic molecule NAG-1 in 
a cell-context dependent manner (Figure 1.19). 
 
 
 
 
Figure 1.18:  Chemical structure of 1,1'-bis(3-indolyl)-1-(p-substitutedphenyl)methanes. 
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1.5.3.1. Nuclear receptors 
Nuclear receptors are important targets for cancer chemotherapy because they 
transcriptionally regulate key genes and are differentially expressed in tissues, which 
allows for the potential of targeting tumor cells overexpressing these receptors.  The 
nuclear receptor superfamily is comprised of steroid receptors, nonsteroidal receptors 
and orphan receptors.  The steroid hormone receptors encompass AR, ER, PR, 
mineralocorticoid receptor (MR) glucocorticoid receptor (GR).  Thyroid hormone 
receptor (TR), vitamin D receptor (VDR), retinoic-acid receptor (RAR), 9-cis-retinoic 
acid receptor (RXR) and ecdysone receptor (EcR) are included in the group of nuclear 
receptors that form transcriptionally active receptor-RXR heterodimers.  In addition, 
several orphan receptors also form heterodimers with RXR and this include the 
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Figure 1.19:  Mechanisms of growth inhibition induced by C-DIMs.  C-DIMs activate both receptor-
dependent and independent mechanisms of growth inhibition that is highly structure and cell context-
dependent.   C-DIMs activate several nuclear receptors including Nur77, PPARγ and other orphan nuclear 
receptors (OR) and also exert inhibitory effects on other nuclear receptors including the estrogen receptor 
and androgen receptor.  Receptor-independent mechanisms of growth inhibition include decreased MMP, 
induction of ER stress and kinase modulation. 
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peroxisome proliferator activated receptor (PPAR), steroidogenic factor 1 (SF-1), nerve 
growth factor-induced receptor (NGFI) and X-linked orphan receptor DAX-1. [436,437] 
Nuclear receptors contain a linker region (D) and three structural domains:  an N-
terminal (A/B) domain, DNA binding (C) domain and ligand binding domain (E) (see 
Figure 1.20). The A/B region contains the constitutive activation function 1 (AF-1) 
domain and is the least conserved domain whereas the DNA binding domain (DBD) is 
the most highly conserved region of nuclear receptors [438].  The DBD is comprised of 
two zinc finger motifs that allow specific recognition of inverted DNA repeats in the 
case of steroid receptor or direct repeats in the the case of RXR-heterodimeric receptors 
Figure 1.20:  Nuclear receptor structure domains.   A typical nuclear receptor contains a variable 
N-terminal region (A/B), conserved DNA binding domain (C), variable hinged region (D), 
conserved ligand binding domain (E) and a variable C-terminal region (F).  Nuclear receptors can be 
divided into 4 categories based on their ligand binding.  [440] 
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[437].  The AF-2 domain is located in the ligand binding domain and is responsible for 
ligand-dependent activation of the receptor [439].  
Steroid hormone receptors typically exist in complexes with chaperone proteins 
either in the nucleus or cytoplasm; upon ligand binding, the receptors dissociate from 
chaperone proteins and bind as a homodimer to hormone response elements on the DNA 
promoter of target genes [440].  RXR-heterodimeric receptors are complexed with 
corepressor proteins typically bound with RXR to cognate DNA binding sites and upon 
ligand binding undergo a conformational change which results in the loss of corepressors 
and recruitment of coactivators [437]. In addition, some nuclear receptors including 
PPARγ can be activated through ligand-independent activation in the N-terminal region 
[441].   
Nuclear receptor ligands have chemical similarities.  They are small, rigid, 
relatively hydrophobic molecules with polar groups capable of forming hydrogen bond 
or electrostatic bonds at the end of the molecule.   The ligand-binding cavity of PPARγ 
is significantly larger than other nuclear receptors and optimized to bind to a wide 
variety of endogenous and exogenous ligands.  [437] 
1.5.3.1.1. PPARγ 
PPARγ is a member of the nuclear receptor superfamily and 15-deoxy-∆12,14-
prostaglandin J2 may be an endogenous ligand for this receptor [442].  The PPAR 
subfamily includes α, β(δ) and γ sub-types which are differentially expressed in various 
tissues and exhibit some overlapping or interconnected activities such as in cholesterol 
transport, metabolism and function [443].  PPARα regulates genes involved in fatty acid 
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utilization during fasting and PPARα agonists are drugs used for treating patients with 
hyperlipidemia.  PPARγ is primarily expressed in adipocytes and plays a role in 
adipocyte differentiation. Thiazolidinediones (TZDs) such as rosiglitazone and 
pioglitazone are PPARγ agonists which are widely prescribed as insulin-sensitizing 
agents for treatment of type II diabetes [443-446]. 
PPARγ is overexpressed in human primary and metastatic breast 
adenocarcinomas [447] and therefore is a therapeutic target for metastatic breast cancer.  
PPARγ agonists exhibit antitumorigenic activity against a wide variety of cancers 
including breast cancer [448-450].  In colon cancer models, there is conflicting evidence 
since the PPARγ agonists troglitazone and pioglitazone promotes or inhibits 
tumorigenesis in colon cancer mouse models, respectively [451,452].  The antineoplastic 
effects of PPARγ ligands have been characterized and include induction of apoptosis, 
cell cycle arrest and terminal differentiation  [447,448,453,454]. 
C-DIMs containing substituents p-CF3, p-tBu, p-C6H5 are PPARγ-active 
compounds in a number of cancer types including breast, colon, ovarian and pancreatic 
cell lines [455-458].  The IC50 values of DIM-C-pPhCF3, DIM-C-pPhtBu and DIM-C-
pPhC6H5 for growth inhibition were 1-5 µM, which was similar to the dose required for 
PPARγ-dependent transactivation [459]. PPARγ-dependent upregulation of p21 was 
reported in both pancreatic and ovarian cancer cell lines treated with C-DIMs [455,458].  
PPARγ-dependent activation of phospho-Akt was also reported in colon cancer cells 
treated with C-DIMs [460]. 
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1.5.3.1.2. Nur77 
Nur77 was originally discovered as a nerve growth factor inducible gene in PC-
12 cells [461] and like PPARγ, Nur77 is overexpressed in cancers including prostate and 
breast cancer [462,463].  Nur77 exhibits both survival and death characteristics.  Nur77 
stimulates cell cycle progression and proliferation in lung cancer cells [464] whereas a 
variety of apoptosis-inducing agents also stimulate Nur77 and lead to the induction of 
apoptosis [463,465,466].  In several cancer cell lines, DIM-C-pPh, DIM-C-pPhCF3 and 
DIM-C-pPhOCH3 activated Nur77 and these compounds also induced cell death in 
pancreatic cancer cells and kidney cancer cells by means of Nur77-dependent TRAIL-
mediated apoptosis and caspase-dependent PARP cleavage [467,468]. 
1.5.3.2. Caveolins 
Caveolins-1, -2 and -3 are membrane proteins that are constituents of 
sphingolipid and cholesterol-rich invaginations in cell membranes termed caveolae [469].  
Caveolins are considered differentiation markers and are most commonly expressed in 
terminally differentiated cells [470,471] whereas tumor cells have reduced expression of 
caveolin proteins [472,473].  PPARγ ligands induced terminal differentiation in breast 
cancer cells [447] and also induce caveolin expression in both colon and breast cancer 
cells [474].  Since C-DIMs activate PPARγ, caveolin expression was assayed in colon 
cancer cells and caveolin-1 and caveolin-2 were upregulated after treatment with C-
DIMs [457].  This upregulation was mediated by PPARγ and represents a receptor-
dependent pathway of terminal differentiation induced by C-DIMs. 
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1.5.3.3. NAG-1 
NAG-1/MIC-1/GDF-15/placental transforming growth factor-β (PTGF-β)/PLAB 
is a member of the TGF-β superfamily and has been shown to induce apoptosis and 
inhibit tumorigenesis in vitro and in vivo [475,476].  Although highly expressed in 
mature epithelial cells lining the intestine, NAG-1 expression is reduced in human colon 
cancer samples [477].  PTGF-β caused cell cycle arrest and induced apoptosis by 
inhibiting cyclin D1 expression in breast cancer cells [478].  Overexpression of NAG-1 
in MDA-MB-468 and MCF-7 breast cancer cells inhibited cell growth [479].  The PI3-
K/Akt/GSK-3β pathway [480], protein kinase C pathway [481], early growth response 
gene-1 (Egr-1) [482,483], activating transcription factor 3 (ATF3) [484] have been 
identified as upstream regulators of NAG-1 in different cell lines. 
 Many different compounds induce NAG-1 including PPARγ agonists and DIM 
[428,482-488], and therefore induction of NAG-1 expression by PPARγ-active C-DIMs 
was also investigated.  C-DIMs induced NAG-1 expression in HCT-116 colon cancer 
cells and this was dependent on the PI3-K-dependent activation of Egr-1 and NAG-1 
induction and NAG-1 induction could be reversed by cotreatment with a PI3-K inhibitor 
[489].  This data represented a receptor-independent pathway for C-DIMs and involved 
activation of PI3-K and Egr-1 that results in induction of NAG-1 expression and 
apoptosis. 
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1.5.3.4. ER stress 
The endoplasmic reticulum is the primary site of protein synthesis and folding 
and requires ATP and calcium to effectively carry out these processes [490].  Under 
stress conditions that perturb calcium or ATP levels, there is an accumulation of 
unfolded proteins and this cellular state is termed ER stress [491].  Unfolded protein 
response (UPR) is a protective mechanism for the cell to combat ER stress and involves 
three transmembrane ER receptors:  pancreatic ER kinase-like (PERK), activating 
transcription factor 6 (ATF6) and inositol-requring enzyme 1 (IRE1) (see Figure 1.21).  
GRP78 functions as a chaperone protein for these receptors to maintain their inactive 
state and once unfolded proteins accumulate, GRP78 dissociates and this activates the 
receptors.  UPR is considered a survival response but under prolonged conditions of 
stress, UPR can trigger apoptosis through activation of CHOP, JNK and Bcl-2 family of 
proteins. [491] 
 Induction of ER stress was seen in several ovarian cancer cell lines treated with 
the C-DIM, DIM-C-pPhtBu [458].  DIM-C-pPhtBu induced GRP78 expression and the 
JNK pathway.  In addition, CHOP was activated in response to treatment of ovarian 
cancer cells with DIM-C-pPhtBu and CHOP bound to response elements in the DR5 
promoter resulting in induction of DR5.  DR5 is associated with the extrinsic pathway of 
apoptosis which was induced by DIM-C-pPhtBu treatment.  This represents a novel 
mechanism of cell death induced by C-DIMs. 
  
 
106 
 
Figure 1.21:  Mediators of the unfolded protein response (UPR).  UPR involves three ER 
transmembrane receptors:  PERK, ATF6 and IRE1 that are present in the inactive state due to GRP78 
functioning as a chaperone protein.  Accumulation of unfolded proteins leads to the dissociation of GRP78 
and activation of the receptors, which induce expression of genes involved with survival, protein 
degradation and apoptosis such as CHOP. [491] 
 
1.5.3.5. Cell cycle 
Cancer cells treated with C-DIMs exhibit changes in cell cycle proteins and cell 
cycle progression.  In both ovarian and pancreatic cancer cells, C-DIMs induced p21 and 
cells were arrested in the G1 phase of the cell cycle [455,458].  In addition to G1 cell 
cycle arrest, C-DIMs induced proteasome-dependent degradation of cyclin D1 in MCF-7 
breast cancer cells and this response was also PPARγ-independent [459]. 
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CHAPTER II 
1,1-BIS(3’-INDOLYL)-1-(P-SUBSTITUTEDPHENYL)METHANES INHIBIT 
PROLIFERATION OF ESTROGEN RECEPTOR-NEGATIVE BREAST 
CANCER CELLS THROUGH ACTIVATION OF MULTIPLE PATHWAYS 
2.1. Synopsis 
 1,1-Bis(3’-indolyl)-1-(p-substitutedphenyl)methanes containing para trifluoro-
methyl (DIM-C-pPhCF3), t-butyl (DIM-C-pPhtBu) and phenyl (DIM-C-pPhC6H5) 
groups activate peroxisome proliferator-activated receptor γ (PPARγ) in estrogen 
receptor-negative MDA-MB-231 and MDA-MB-453 breast cancer cells.  These PPARγ-
active compounds inhibit breast cancer cell proliferation, however, inhibition of G0/G1 to 
S phase progression and cyclin D1 downregulation was observed in MDA-MB-231 but 
not MDA-MB-453 cells.  Nonsteroidal anti-inflammatory drug-activated gene 1 (NAG-
1), a transforming growth factor β-like peptide, was also induced by these compounds 
and response was dependent on cell-context dependent activation of kinase pathways.  
Despite the induction of NAG-1 and downregulation of the antiapoptotic protein 
survivin in both MDA-MB-231 and MDA-MB-453 cells treated with these methylene-
substituted diindolylmethanes (C-DIMs), this was not accompanied by apoptosis.  
Nevertheless the cytotoxicity observed for the C-DIMs in vitro was complemented by 
inhibition of tumor growth in athymic nude mice bearing MDA-MB-231 cells as 
xenografts and treated with DIM-C-pPhC6H5 (40 mg/kg/d).  The inhibition of tumors 
derived from highly aggressive MDA-MB-231 cells suggests a potential role for the C-
DIM compounds in the clinical treatment of ER-negative breast cancer. 
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2.2. Introduction 
 Peroxisome proliferator-activated receptor γ (PPARγ) is a member of the nuclear 
receptor superfamily of transcription factors [444,492,493].  The PPAR subfamily 
includes α, β(δ) and γ sub-types that bind fatty acids and lipids and the receptors play a 
role in lipid metabolism and metabolic diseases that include insulin-resistance, coronary 
artery disease and hyperlipidemia [443-446].  PPARs are differentially expressed in 
various tissues and exhibit some overlapping or interconnected activities such as in 
cholesterol transport, metabolism and function [443].  PPARα regulates genes involved 
in fatty acid utilization during fasting and PPARα agonists are drugs used for treating 
patients with hyperlipidemia.  Thiazolidinediones (TZDs) such as rosiglitazone and 
pioglitazone are PPARγ agonists which are widely prescribed as insulin-sensitizing 
agents for treatment of type II diabetes [443-446]. 
 PPARγ is overexpressed in multiple tumor types and their derived cancer cell 
lines [494,495] and is considered a potential target for development of anticancer drugs.  
Not surprisingly several different structural classes of PPARγ agonists have been 
identified and their anticancer activities have been investigated and these include TZDs, 
15-deoxy-∆12-14-prostaglandin J2 (PGJ2), 2-cyano-3,12-dioxooleana-1,9-dien-28-oic 
acid (CDDO) and related compounds, 1,1-bis(3’-indolyl)-1-(p-substituted-
phenyl)methanes [methylene-substituted diindolylmethanes (C-DIMs)] and several other 
chemical classes [444,456,492,493,496-502].  All PPARγ agonists typically induce fat 
cell differentiation and using RNA interference and PPARγ antagonists several PPARγ-
dependent responses have been characterized in various cancer cell lines.  For example 
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CDDO induces the tumor suppressor gene caveolin 1 in colon cancer cells and this 
response was inhibited by the PPARγ antagonist GW9662, however, many other CDDO-
induced responses were receptor-independent or the role of PPARγ was not investigated 
[503-509]. 
 Research in this laboratory has identified 1,1-bis(3’-indolyl)-1-(p-
trifluoromethylphenyl)methane (DIM-C-pPhCF3), 1,1-bis(3’-indolyl)-1-(p-tbutylphenyl) 
methane (DIM-C-pPhtBu), 1,1-bis(3’-indolyl)-1-(p-biphenyl)methane (DIM-C-
pPhC6H5) as PPARγ agonists in several different cancer cell lines [423,455-
458,460,468,489,510,511].  The PPARγ-active C-DIMs induce PPARγ-dependent 
transactivation in several different cancer cells and their induction of caveolin-1 and p21 
was also PPARγ-dependent but varied with cell context.  C-DIM compounds also induce 
receptor-independent responses including endoplasmic reticulum (ER) stress, activation 
of multiple kinases, induction of non-steroidal anti-inflammatory drug activated gene-1 
(NAG-1) and proteasome-dependent downregulation of cyclin D1.  A previous study 
showed that PPARγ-active C-DIMs inhibited growth of ER-positive MCF-7 breast 
cancer cells, induced apoptosis and downregulated expression of estrogen receptor α and 
cyclin D1 proteins [456].  In this study, we show that DIM-C-pPhCF3, DIM-C-pPhtBu, 
DIM-C-pPhC6H5 induce PPARγ-dependent transactivation in ER-negative MDA-MB-
231 and MDA-MB-453 breast cancer cells and inhibit proliferation with IC50 values ≤ 5 
µM for most compounds in both cell lines.  There were both differences and similarities 
in the effects of C-DIMs in the two cell lines including an increase in the distribution of 
cells in G0/G1 and decreased S phase in MDA-MB-231 but not in MDA-MB-453 cells.  
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PPARγ-active C-DIMs did not affect expression of the cell cycle genes p21, p27 or 
cyclin D1 in MDA-MB-453 cells but induced proteasome-dependent degradation of 
cyclin D1 in MDA-MB-231 cells.  These compounds did not induce caveolin-1 or 
activate ER stress in either cell line but induced NAG-1 and ATF3 in both ER-negative 
cells.  In addition the C-DIM compounds downregulated the antiapoptotic protein 
survivin but did not induce apoptosis in these cells.  In athymic nude mice bearing 
MDA-MB-231 cells as xenografts, treatment with 40 mg/kg/day of DIM-C-pPhC6H5 
significantly inhibited tumor growth and confirmed the anticarcinogenic activity of C-
DIMs both in vivo and in vitro. 
2.3. Materials and Methods 
2.3.1. Cells, chemicals and other materials  
MG132 was obtained from Sigma Chemical Co. (St. Louis, MO).  The human 
breast cancer cell lines MDA-MB-231 and MDA-MB-453 were obtained from American 
Type Culture Collection (ATCC, Manassas, VA). MDA-MB-231 cells were maintained 
in DMEM:F-12 supplemented with 0.22% sodium bicarbonate, 10% fetal bovine serum 
(FBS), and 2 ml/L antibiotic/antimycotic solution (Sigma Chemical Co., St. Louis, MO). 
MDA-MB-453 cells were maintained in RPMI supplemented with 0.15% sodium 
bicarbonate, 0.12% HEPES, 10% fetal bovine serum (FBS), and 2 ml/L 
antibiotic/antimycotic solution (Sigma Chemical Co., St. Louis, MO). Cells were grown 
in 150 cm2 culture plates in an air/CO2 (95:5) atmosphere at 37°C and passaged 
approximately every 5 days.  p21 (C-19), p27 (C-19), cyclin D1 (M-20), cyclin D3 (C-
16), caveolin-1 (N-20), caveolin-2 (N-20), p-Erk (K-23), Erk (E-4), p-Akt (Ser473), Akt 
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(H-136), p-c-Jun (KM-1), c-Jun (D), Grp78 (H-129), ATF-3 (C-19), survivin (FL-142) 
antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA). The NAG-
1 antibody was purchased from Upstate (Lake Placid, NY).  Horseradish peroxidase 
substrate for Western blot analysis was purchased from NEN Life Science Products 
(Boston, MA). 
2.3.2. Cell proliferation assays  
Cells were plated at a density of 3-5 x 104/well in 12-well plates and media was 
replaced the next day with DMEM:F-12 media containing 2.5% charcoal-stripped FBS 
and either vehicle (DMSO) or the indicated ligand and concentration.  Fresh media and 
compounds were added every 48 h.  Cells were counted at the indicated times using a 
Coulter Z1 cell counter.  Each experiment was completed in triplicate and results are 
expressed as means ± SE for each determination. 
2.3.3. Transient transfection assays  
Breast cancer cells were plated in 12-well plates at 1.5 x105 cells/well in 
DMEM:F12 media supplemented with 2.5% charcoal-stripped FBS. PPARγ-Gal4 (0.2 
µg/well), Gal4-LUC (0.5 µg/well) and pCDNA3.1-His-LacZ (0.04 µg/well, Invitrogen, 
Carlsbad, CA) expression plasmid (for normalization of transfection efficiency) were 
transiently cotransfected into MDA-MB-231 and MDA-MB-453 cells using 
Lipofectamine according to the manufacturer’s protocol.  After 5-6 h, cells were treated 
for 24 h with fresh 2.5% stripped bovine medium containing 1, 5, or 10 µM DIM-C-
pPhCF3, DIM-C-pPhtBu, DIM-C-pPhC6H5 dissolved in DMSO, or DMSO alone as a 
solvent control.  After 24 h of treatment, cells were then lysed with 150 µL of 1 X 
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reporter lysis buffer from Promega (Madison, WI) and 30 µL of cell extract were used 
for luciferase and β-gal assays.  Significance was determined by SuperANOVA (p <  
0.05). 
2.3.4. Fluorescence-Activated Cell-Sorting assays (FACS)  
MDA-MB-231 cells and MDA-MB-453 cells were treated with either the vehicle 
(DMSO) or the indicated compounds for 48 h.  Cell were trypsinized, centrifuged and 
resuspended in staining solution containing 50 mg/mL propidium iodide, 4 mM sodium 
citrate, 30 units/mL RNase, and 0.1% Triton X-100.  After incubation at 37OC for 10 
min, sodium chloride was added to give a final concentration of 0.15 M.  Cells were 
analyzed on a FACS Calibur flow cytometer using CellQuest acquisition software.  PI 
fluorescence was collected though a 585/42nm bandpass filter, and list mode data were 
acquired on a minimum of 20,000 single cells defined by a dot plot of PI width versus PI 
area.  Data analysis was performed in ModFit LT using PI width versus PI to exclude 
cell aggregates. 
2.3.5. Western blots 
MDA-MB-231 and MDA-MB-453 cells were seeded in DMEM:F-12 media 
containing 2.5% charcoal-stripped FBS for 24 h and then treated with either the vehicle 
(DMSO) or the indicated compounds.  Whole cell lysates were obtained using high salt 
buffer [50 mM HEPES, 500 mM NaCl, 1.5 mM MgCl2, 1 mM EGTA, 10% glycerol and 
1% Triton X-100 pH 7.5 and 5 µL/mL of Protease Inhibitor Cocktail].  Protein samples 
were incubated at 100OC for 2 minutes, separated on 10% SDS-PAGE at 120 V for 3-4 h 
in 1 X running buffer [25 mM Tris-base, 192 mM glycine, and 0.1% SDS (pH 8.3)] and 
  
 
113 
transferred to polyvinylidene difluoride membrane at 0.2 V for 16 h at 4OC in 1 X 
transfer buffer (48 mM Tris-HCl, 39 mM glycine, and 0.025% SDS).  The PVDF 
membrane was blocked in 5% TBST-Blotto [10 mM Tris-HCl, 150 mM NaCl (pH 8.0), 
and 0.05% Triton X-100 and 5% non-fat dry milk] with gentle shaking for 30 min and 
incubated in fresh 5% TBST-Blotto at 1:200-1:1000 with primary antibody overnight at 
4OC with gentle shaking.  After washing with TBST for 10 min, the PVDF membrane 
was incubated with secondary antibody (1:5000) in 5%TBST-Blotto for 2 h.  The 
membrane was washed with TBST for 10 min and incubated with 10 mL of 
chemiluminescence substrate for 1.0 min and exposed to Kodak X-OMAT AR 
autoradiography film. 
2.3.6. Anti-tumor efficacy studies   
Athymic nude mice (Nu -/-) were injected i.p. with 75 µg of a rat anti-mouse 
asialo GM1 antibody (Wako Chemical Company, Richmond, VA) to reduce natural 
killer cells.  Injections were done on days -4 and -2 prior to the injection of MDA-MB-
231 cells.  At day 0, mice were injected subcutaneously in the left flank with 107 MDA-
MB-231 cells in 100-200 µL serum-free medium.  Three groups of mice (12 mice/group) 
were then treated i.p. with 40 mg/kg DIM-C-pPhC6H5 in 50 µL placebo, 50 µL placebo 
or 50 µL PBS, every day for 35 total injections starting at day 4 post-tumor inoculations.  
Tumor size was measured with calipers, based on the formula L X W 2 where L is the 
length and W is the width of the tumor.  Moribund mice and mice whose tumor burdens 
exceeded 20% of their body weight were euthanized following institutional regulations.   
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2.4. Results 
 Previous studies showed that DIM-C-pPhCF3, DIM-C-pPhtBu and DIM-C-
pPhC6H5 activated PPARγ and inhibited growth of breast, bladder, colon, ovarian and 
pancreatic cancer cells [423,455-458,460,468,489,510,511].  Results in Figures 2.1A and 
2.1B show that these PPARγ-active C-DIMs significantly induced transactivation in ER-
negative MDA-MB-231 and MDA-MB-453 cells transfected with PPARγ-
GAL4/pGAL4.  Rosiglitazone, a thiazolidinedione PPARγ agonist also induced 
transactivation in both cell lines.  GW9662 is a PPARγ antagonist and the induction of 
transactivation by DIM-C-pPhCF3, DIM-C-pPhtBu and DIM-C-pPhC6H5 in MDA-MB-
231 (Figure 2.1C) and MDA-MB-453 cells (Figure 2.1D) transfected with PPARγ-
GAL4/pGAL4 was inhibited after cotreatment with GW9662.  These results demonstrate 
that the PPARγ-active C-DIMs activate PPARγ in ER-negative breast cancer cell lines 
and these results were similar to those previously reported for the same compounds in 
MCF-7 cells [456]. 
 PPARγ-active C-DIMs inhibit growth of pancreatic, colon, bladder and ovarian 
cancer cells and these compounds also inhibited proliferation of ER-positive MCF-7 
cells [423,455-458,460,468,489,510,511].  Results illustrated in Figure 2.2 show that 
DIM-C-pPhCF3, DIM-C-pPhtBu and DIM-C-pPhC6H5 inhibit proliferation of ER-
negative MDA-MB-231 and MDA-MB-453 breast cancer cells and IC50 values were 
generally between 1-5 µM.  The only exception was the decreased potency of DIM-C-
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Figure 2.1: Ligand-induced activation of PPARγ and effects of PPARγ antagonists. Ligand-
dependent activation of PPARγ-GAL4/pGAL4 in MDA-MB-231 [A] and MDA-MB-453 [B] cells. 
Cells were transfected with PPARγ-GAL4/pGAL4, treated with 1, 5, or 10 µM of  DIM-C-pPhCF3, 
DIM-C-pPhtBu, DIM-C-pPhC6H5 and rosiglitazone (positive control), and luciferase activity was 
determined as described in Materials and Methods. Results of all transactivation studies in this figure 
are presented as means ± SE for at least three separate determinations for each treatment group, and 
significant (p < 0.05) induction compared with solvent (DMSO) control is indicated by an asterisk. 
Inhibition of transactivation in MDA-MB-231 [C] and MDA-MB-453 [D] cells by PPARγ antagonist 
GW9662. Cells were transfected with PPARγ-GAL4/pGAL4, treated with 10 µM rosiglitazone or C-
substituted DIMs alone or in combination with 7.5 µM GW9662, and luciferase activities were 
determined as described in [A]. Significant (p < 0.05) inhibition of induced transactivation by GW9662 
is indicated (**).  
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pPhtBu in MDA-MB-453 cells where the IC50 was slightly greater than 5 µM.  PPARγ-
active C-DIMs also affected the % distribution of MDA-MB-231 cells in G0/G1, S and 
G2/M phase of the cell cycle (Figure 2.2C).  Even at concentrations as low as 1 or 5 µM 
the C-DIM compounds consistently increased the % of cells in G0/G1 and decreased 
the % of cells in S phase of the cell cycle.  In contrast, these same concentrations had 
minimal effects on the % distribution of MDA-MB-453 cells in G0/G1, S or G2/M phase 
of the cell cycle (Figure 2.2D) indicating some cell context-dependent differences in the 
effects of C-DIMs on cell cycle progression. 
 PPARγ agonists including C-DIMs affect expression of cell cycle proteins in 
some cell lines and results in Figure 2.3A show that after treating MDA-MB-231 cells 
for 12 h with 10 µM C-DIMs there was decreased expression of cyclin D1 and slightly 
increased levels of p21 or p27 proteins and similar results were observed after treatment 
for 24 h (data not shown).  In contrast, the PPARγ-active C-DIMs did not affect cyclin 
D1, p21 or p27 levels in MDA-MB-453 cells after treatment for 12 h (Figure 2.3B) or 24 
h (data not shown).  The C-DIM-induced downregulation of cyclin D1 in MDA-MB-231 
cells was inhibited in cells cotreated with the proteasome inhibitor MG132 (Figure 2.3C) 
and this PPARγ-independent response was previously observed with these compounds in 
MCF-7 cells (17).  Thus the major effects of the PPARγ-active C-DIMs was induction of 
proteasome-dependent degradation of cyclin D1 (Figure 2.3C) which correlates with the 
inhibition of G0/G1 to S phase progression in MDA-MB-231 cells (Figure 2.2D). 
 PPARγ-active C-DIMs induce several growth inhibitory factors or pathways in 
cancer cell lines including receptor-dependent induction of caveolin-1 and receptor-
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Figure 2.2: Growth inhibition studies and Fluorescence-Activated Cell Sorting (FACS) analysis.  
MDA-MB-231 [A] and MDA-MB-453 [B] breast cancer cells were treated with 1 to 10 µM DIM-C-
pPhCF3, DIM-C-pPhtBu, and DIM-C-pPhC6H5 for 6 days, and cell numbers were determined using a 
Coulter Counter as described in the Materials and Methods. Results are expressed as means ± SE for 
three separate determinations at each time point.  MDA-MB-231 [C] and MDA-MB-453 [D] cells were 
treated for 48 h with 1-5 µM DIM-C-pPhCF3, DIM-C-pPhtBu, and DIM-C-pPhC6H5 and analyzed by 
FACS analysis as described in the Materials and Methods.  Experiments were carried out in 2.5% 
charcoal-stripped serum and DMSO served as the solvent control.  Results are expressed as means ± SE 
for three separate determinations for each treatment group and significance (p<0.05) is indicated by an 
asterisk. 
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 Figure 2.2 (Continued) 
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independent induction of ER stress [423] and NAG-1 [489].  Results illustrated in Figure 
2.3D show that 5-10 µM of the C-DIM compounds did not affect expression of the stress 
protein GRP78 whereas 0.3 µM thapsigargin (positive control) induced GRP78 in MDA-
MB-231 and MDA-MB-453 cells respectively.  Figure 2.3E shows that caveolin 1 
expression is not induced in MDA-MB-453 cells by the C-DIM compounds whereas in 
MDA-MB-231 cell concentration-independent effects on caveolin-1 expression were 
observed.  In contrast, the same compounds induced caveolin 1 in colon cancer cells and 
cotreatment with PPARγ antagonists blocked induction [489]. 
 NAG-1 is a proapoptotic and growth inhibitory protein induced in cancer cell 
lines by diverse agents including C-DIM compounds ([475,481-483,483,489]and results 
in Figures 2.4A and 2.4B show that NAG-1 is induced in MDA-MB-453 and MDA-MB-
231 cells after treatment with 10 µM DIM-C-pPhCF3, DIM-C-pPhtBu and DIM-C-
pPhC6H5.  ATF3, which is ofen co-induced with NAG-1 was also elevated in the ER-
negative breast cancer cells treated with PPARγ-active C-DIMs.  Using DIM-C-
pPhC6H5 as a model, we showed that NAG-1 induction was not inhibited by the PPARγ 
antagonist GW9662 (Figures 2.4A and 2.4B).  Similar results were observed for PPARγ-
active C-DIMs in colon cancer cells where induction of NAG-1 was also PI3-K 
dependent [489].  NAG-1 is induced through multiple pathways including activation of 
kinases in colon cancer cells where PPARγ-active C-DIMs induced NAG-1 through PI3-
K dependent activation of Egr-1 which binds the proximal region of the NAG-1 
promoter [489].  The induction of NAG-1 by DIM-C-pPhC6H5 in the absence or 
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Figure 2.3: Modulation of cell cycle, ER stress and caveolin proteins. MDA-MB-231 [A] or 
MDA-MB-453 [B] cells were treated with 5 or 10 µM DIM-C-pPhCF3, or DIM-C-pPhC6H5 for 12 h 
and whole cell lysates were analyzed by Western blot analysis as described in Materials and Methods. 
MDA-MB-231 [C] cells were pre-treated for 30 minutes with 10 µM proteasome inhibitor MG132 or 
vehicle control and subsequently treated for 12 h with DMSO, 10 µM DIM-C-pPhCF3, or DIM-C-
pPhC6H5 for 12 h and whole cell lysates were analyzed by Western blot analysis as described in 
Materials and Methods.  Experiments were done in triplicate and results shown are typical of Cyclin 
D1, p21, and p27 protein levels for treatment replicates.  MDA-MB-231 and MDA-MB-453 [D,E] 
cells were treated with DIM-C-pPhCF3, DIM-C-pPhtBu and DIM-C-pPhC6H5 or 0.3 µM thapsigargin 
(Tg) (positive control for ER stress) for 24 h [D] or 72 h [E] and whole cell lysates were analyzed by 
Western blot analysis as described in the Materials and Methods.  Experiments were done in triplicate 
and results shown are typical of treatment replicates.  
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Figure 2.4:  Induction of NAG-1 proteins.  MDA-MB-231 [A, left] and MDA-MB-453 [B, left] cells 
were treated with DMSO or 5-10 µM DIM-C-pPhCF3, DIM-C-pPhtBu and DIM-C-pPhC6H5 or 0.3 µM 
thapsigargin (Tg) for 24 h and whole cell lysates were analyzed by Western blot analysis for NAG-1 
and ATF3.  15* represents whole cell lysate sample isolated from SW480 cells and treated with 15 µM 
DIM-C-pPhtBu and based on previous published data, served as a positive control for NAG-1 and 
ATF3 induction. PPARγ-independent activation of NAG-1.  MDA-MB-231 [A, right] or MDA-MB-
453 cells [B, right] were treated for 24 h with DMSO or 10 µM DIM-C-pPhC6H5 and with or without 
co-treatment with 10 µM PPARγ inhibitor GW9662 and whole cell lysates were analyzed by Western 
blot analysis and probed for NAG-1.  Role of kinases in NAG-1 induction [C].  MDA-MB-231 and 
MDA-MB-453 cells were treated with DMSO or 10 µM DIM-C-pPhC6H5 and with or without co-
treatment of the following kinase inhibitors:  20 µM p38 MAPK (SB203580), 20 µM JNK (SP600125), 
5 µM PKC (GF109203X),  20 µM p44/42 MAPK (PD98059) and 20 µM PI3-K (LY294002) for 24 h 
and whole cell lysates were probed for NAG-1.  Activation of kinases in 0-120 min treatment with 10 
µM DIM-C-pPhC6H5 [D,E].  Whole cell lysates isolated from MDA-MB-231 [D] cells were analyzed 
by Western blot analysis and probed for p-Akt and Akt.  MDA-MB-453 [E] cells were analyzed by 
Western blot analysis for p-Akt, Akt, p-Erk, Erk, p-c-Jun, c-Jun.  Experiments were done in triplicate 
and results shown are typical of treatment replicates. 
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Figure 2.4 (Continued) 
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Figure 2.4 (Continued) 
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presence of inhibitors of p38 MAPK (SB203580), JNK (SP600125) PKC (GF109203X), 
p44/42 MAPK (PD98059) and PI3-K (LY294002) is summarized in Figure 2.4C.  In 
MDA-MB-453 cells inhibition of NAG-1 induction by DIM-C-pPhC6H5 was observed 
in cells cotreated with p44/42 MAPK, PI3-K and JNK inhibitors with the latter inhibitor 
being the most effective.  In contrast only LY294002 (PI3-K inhibitor) blocked 
induction of NAG-1 by DIM-C-pPhC6H5 in MDA-MB-231 cells and the JNK inhibitor 
actually enhanced induction of NAG-1 by the C-DIM compound (Figure 2.4C).  Results 
in Figure 2.4D show that DIM-C-pPhC6H5 induces PI3-K-dependent phosphorylation of 
Akt in MDA-MB-231 cells and phosphorylation of MAPK, Akt and c-Jun in MDA-MB-
453 cells (Figure 2.4E) and these induced kinases play a role in the induction of NAG-1 
in the same cell lines.  
 Previous studies showed that DIM, ring-substituted DIMs and C-DIMs induced 
apoptosis in ER-positive MCF-7 cells and the former two compounds did not induce 
apoptosis in MDA-MB-231 cells [425,456].  The effects of the PPARγ-active C-DIM 
compounds on induction of apoptosis were investigated in both MDA-MB-231 and 
MDA-MB-453 cells by determining caspase-dependent PARP cleavage, bax/bcl-2 
expression (Figures 2.5A and 2.5B) and effects on the antiapoptotic protein survivin 
(Figures 2.5C and 2.5D).  There was an increase in bax and decrease in bcl-2 expression 
observed after treatment of MDA-MB-231 and MDA-MB-453 cells with PPARγ-active 
C-DIMs, however, activation of the intrinsic pathway for apoptosis as evidenced by 
caspase-dependent PARP cleavage was not observed.  The antiapoptotic protein, 
survivin, was expressed in MDA-MB-231 and MDA-MB-453 cells and treatment with 
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PPARγ-active C-DIM compounds decreased survivin protein expression (Figures 2.5C 
and 2.5D), however, this response was insufficient for activation of caspase-dependent 
apoptotic pathways. 
 Results in Figure 2.6 show that treatment with DIM-C-pPhC6H5 (40 mg/kg/d) 
decreased tumor growth in athymic nude mice bearing MDA-MB-231 cells as 
xenografts. These results, coupled with the cancer cell growth inhibition studies (Figure 
2.2) clearly show that PPARγ-active C-DIMs effectively inhibit growth of ER-negative 
breast cancer cells and this was comparable to inhibition of colon and bladder tumor 
growth in mouse xenograft models [460,511]. 
2.5. Discussion 
 Several different structural classes of PPARγ agonists have been identified and 
many of these including PGJ2, thiazolidinediones and CDDO inhibit proliferation of 
breast and other cancer cell lines through multiple receptor-dependent and independent 
pathways [454,459,503-509,512-517].  For example in one study 10 µM PGJ2 induced 
rapid morphological changes associated with apoptosis in MDA-MB-231 cells whereas 
100 µM troglitazone induced minimal apoptosis after prolonged (50 h) treatment [454].  
Other studies also show similar differences between induction of apoptosis by PGJ2 and 
troglitazone in MDA-MB-231 cells.  CDDO is a triterpenoid acid and a PPARγ agonist 
that induces both receptor-dependent and independent responses in cell lines and tumors 
derived from multiple tissues including breast cancer cells.  CDDO alone did not induce 
apoptosis in ER-positive T47D or ER-negative MDA-MB-453 cells [516], however, 
CDDO enhanced TRAIL-induced apoptosis in both cell lines.  PPARγ-active C-DIM
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Figure 2.5:  Effects of PPARγ agonists on apoptosis.  MDA-MB-231 [A] and MDA-MB-453 cells 
[B] were treated with DMSO or 5-10 µM DIM-C-pPhCF3, DIM-C-pPhtBu and DIM-C-pPhC6H5 or 10 
µM MG132 for 24 h and whole cell lysates were analyzed by Western blot analysis for PARP112/85,  
bcl-2 and bax.  Time-dependent activation of survivin.  MDA-MB-231 [C] and MDA-MB-453 cells [D] 
were treated for 12-36 h or 24-48 h with DMSO or 10 µM DIM-C-pPhCF3, DIM-C-pPhtBu and DIM-
C-pPhC6H5 .  Whole cell lysates were analyzed by Western blot analysis and probed for survivin.  
Experiments were done in triplicate and results shown are typical of treatment replicates. 
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Figure 2.6:  In vivo antitumorigenic activity of DIM-C-pPhC6H5.  MDA-MB-231 s.c. tumor 
size (mean ± SE) in athymic mice treated i.p. daily starting at day 4 post-tumor inoculation for 35 
total doses with PBS (50 µL), placebo (50 µL) and DIM-C-pPhC6H5 (40 mg/kg in 50 µL placebo).  
The tumor sizes were measured on day 35 and day 39.  On day 32, the tumor sizes were 
446.1±138.3 mm3 (placebo treated), 454.3±97.5 mm3 (PBS treated), 83.3±25.1 mm3 (DIM-C-
pPhC6H5 treated) (t-test, P=0.001 versus PBS treated group); On day 39, the tumor sizes were 
909.9±342.6 mm3 (placebo treated), 1129±371.9 mm3 (PBS treated), 124.7±54.8 mm3 (DIM-C-
pPhC6H5 treated) (t-test, P=0.01 versus PBS treated group). 
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compounds have been identified in this laboratory as a new class of PPARγ agonists and 
several receptor-dependent and independent responses have been characterized.  Results 
of transactivation studies (Figure 2.1) clearly demonstrate that the three PPARγ-active 
C-DIMs induced PPARγ-dependent activity in MDA-MB-231 and MDA-MB-453 cells 
as previously reported in other cancer cell lines [455-458,460,468,489,510,511]. 
 PPARγ agonists typically inhibit cancer cell growth by arresting cells in G0/G1 
and this is often associated with modulation of cyclin D1 (decreased) or induction of the 
cyclin-dependent kinase inhibitor p21 [455-457,512].  PPARγ-active C-DIMs inhibit 
growth of ER-negative MDA-MB-231 and MDA-MB-453 cells (Figure 2.2) but induced 
only a modest increase in cells in G0/G1 and decrease in cells in S-phase in MDA-MB-
231 but not in MDA-MB-453 cells (Figures 2.2C and 2.2D).  These results were 
observed over several time points (12, 24, 48 and 96 h) using 1 or 5 µM concentrations 
of the C-DIM compounds which are sufficient to inhibit cell proliferation (Figure 2.2).  
The growth inhibitory effects of the PPARγ-active C-DIMs on cell cycle proteins were 
also different in the two ER-negative cell lines where 5-10 µM C-DIMs induced cyclin 
D1 downregulation in MDA-MB-231 but not MDA-MB-453 cells (Figures 2.3A-2.3C).  
This was most pronounced after treatment for 12 h and was reversed by the proteasome 
inhibitor MG132 (Figure 2.3C).  The results obtained in MDA-MB-231 cells were 
comparable to the effects of the same C-DIM compounds and PGJ2 in ER-positive 
breast cancer cells where proteasome-dependent degradation of cyclin D1 was also 
reported [456,459].  p21 and p27 proteins were only slightly induced in MDA-MB-231 
cells in a concentration-independent manner and studies with p21 promoter constructs 
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showed that the PPARγ-active C-DIMs did not induce transactivation in cells transfected 
with these constructs (data not shown).  The results suggest that the inhibition of G0/G1 
to S phase progression in MDA-MB-231 cells treated with C-DIMs is primarily due to 
decreased cyclin D1 expression whereas other factors must be involved for inhibition of 
MDA-MB-453 cell proliferation. 
 PPARγ-active C-DIMs induce receptor-dependent caveolin 1 and receptor-
independent ER stress in pancreatic, colon, bladder and ovarian cancer cells 
[423,455,457,458,460,468,475,482,489,511], however, neither caveolin (Figure 2.3E) or 
GRP78 (an ER stress marker) (Figure 2.3D) were induced in MDA-MB-231 or MDA-
MB-453 cells.  In contrast, the TGFβ-like peptide NAG-1 was induced by 10 µM C-
DIMs in both cell lines and was accompanied by a slight induction of ATF3 (Figs. 4A 
and 4B) which is often coinduced with NAG-1 [428,489].  NAG-1 is induced by several 
proapoptotic and growth inhibitory agents including C-DIMs, troglitazone and PGJ2, 
however, the mechanisms of induction are variable [428,460,475,481-483,489].  
Previous studies showed that activation of NAG-1 in colon cancer cells was associated 
with PI3K-dependent activation of early growth response-1 (Egr-1) gene which activates 
NAG-1 through specific proximal promoter sequences [489].  In contrast activation of 
NAG-1 by the phorbol ester TPA was PKC-dependent [481].  In ER-negative MDA-
MB-453 cells, activation of NAG-1 by DIM-C-pPhC6H5 was decreased in cells cotreated 
with the JNK inhibitor SP600125, the MAPK and PI3K inhibitors PD98059 and 
LY294002 respectively (Figure 2.4C).  These results correlated with DIM-C-pPhC6H5-
dependent enhancement of all three kinase pathways in the same cell line (Figure 2.4E).  
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However, in MDA-MB-231 cells, only the PI3K inhibitor LY294002 blocked induction 
of NAG-1 by DIM-C-pPhC6H5 in MDA-MB-231 cells (Figure 2.4C) and only this 
kinase was induced by the C-DIM compound in this cell line (Figure 2.4D).  Thus 
induction of NAG-1 by DIM-C-pPhC6H5 in ER-negative breast cancer cells was due to 
cell context-dependent activation of kinases; and current studies in this laboratory are 
investigating upstream targets that are activated by C-DIMs and mediate selective 
activation of kinase pathways in different cell lines. 
 Although NAG-1 is associated with apoptotic activity, we did not observe 
caspase-dependent PARP cleavage after treatment of MDA-MB-453 and MDA-MB-231 
cells with PPARγ-active C-DIM compounds whereas the proteasome inhibitor MG132 
(positive control) induced PARP cleavage (Figs. 5A and 5B).  Bax/bcl-2 ratios were 
increased in MDA-MB-453 cells treated with 5 or 10 µM PPARγ-active C-DIMs.  
However, increased bax/bcl-2 ratios combined with C-DIM-dependent downregulation 
of the antiapoptotic protein survivin in both cell lines (Figs. 5C and 5D) was not 
accompanied by activation of caspase-mediated apoptosis.  The failure to induce 
apoptosis was not unprecedented since other studies also show that ER-negative breast 
cancer cells are somewhat resistant to PPARγ agonist-induced apoptosis [425,454,516].  
Treatment of MDA-MB-231 cells with high concentrations of troglitazone (100 µM) for 
50 h induced apoptosis in only 30% of the cells [454] and CDDO did not cause caspase-
dependent PARP cleavage in ER-negative MDA-MB-468 cells [459].  High 
concentrations of troglitazone (50 µM) were cytotoxic to ER-negative MDA-MB-435 
cells and decreased survivin expression [518]; and similar results were observed for the 
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C-DIM compounds (Figs. 2.5C and 2.5D). Moreover, like the C-DIM compounds, 
troglitazone also did not induce apoptosis in MDA-MB-435 cells.  However, the lack of 
induction of apoptosis by PPARγ-active C-DIMs did not affect their in vitro cytotoxicity 
or their inhibition of tumor growth in athymic nude mice bearing MDA-MB-231 cells as 
xenografts (Figure 2.6). 
 In summary, PPARγ-active C-DIM compounds induced PPARγ-dependent 
transactivation in MDA-MB-231 and MDA-MB-453 cells and IC50 values for growth 
inhibition were ≤ 5 µM in both cell lines.  However, it was apparent that the effects of 
the PPARγ-active C-DIMs on distribution of cells in G0/G1 and S-phase, expression of 
cyclin D1 and induction of NAG-1 were dependent on cell context whereas NAG-1 was 
induced in both cell lines.  Despite the potent antiproliferative effects of these 
compounds in vitro and in vivo and their downregulation of the antiapoptotic survivin 
protein and induction of the proapoptotic NAG-1 protein in both cell lines, we did not 
observe caspase-dependent PARP cleavage (Figure 2.5) or other indicators of apoptosis 
such as positive Annexin V staining (data not shown).  In ongoing studies, we are 
investigating the potential role of other cell death pathways in breast cancer cells and 
tumors in order to delineate critical markers associated with the potent anticarcinogenic 
activity of C-DIMs. Results of this study are similar to those reported for TZDs and 
CDDO in ER-negative cancer cell lines [516,518] and similarities and differences in the 
effects of these compounds and C-DIMs are also being investigated. 
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CHAPTER III 
INDUCTION OF AUTOPHAGY BY A NEW SERIES OF BREAST CANCER 
CHEMOTHERAPEUTIC AGENTS 
3.1. Synopsis 
Indole-3-carbinol is a phytochemical found in cruciferous vegetables and one of 
its major metabolites, 3,3’-diindolylmethane (DIM), exhibits a broad range of anticancer 
and antitumorigenic activities.  A novel series of methylene--substituted DIMs (C-DIMs), 
namely 1,1-bis(3’-indolyl)-1-(p-substitutedphenyl)methanes containing t-butyl (DIM-C-
pPhtBu) and phenyl (DIM-C-pPhC6H5) groups inhibit proliferation of invasive estrogen 
receptor-negative MDA-MB-231 and MDA-MB-453 human breast cancer cell lines with 
IC50 values between 1-5 µM.  C-DIM-induced cell death could not be reversed by 
zVAD-fmk, a pan-caspase inhibitor in either cell line.  MDA-MB-231 and MDA-MB-
453 cells treated with C-DIMs did not exhibit Annexin V-PI staining patterns consistent 
with apoptosis, suggesting that C-DIMs did not induce Type I (apoptotic) programmed 
cell death.  Cell necrosis, as indicated by propidium iodide (PI) staining and lactate 
dehydrogenase (LDH) release, was also negative after C-DIM treatment of MDA-MB-
453 cells.  Autophagic cell death is an important cell death pathway in breast cancer 
cells after treatment with several chemotherapeutic agents including tamoxifen, EB1089 
and sulforaphane and therefore we investigated the possibility that C-DIMs may also 
induce autophagy in breast cancer cells.  Treatment of MDA-MB-231 and MDA-MB-
453 cells with C-DIMs resulted in an accumulation of light chain associated-protein 3 
(LC3)-II compared to LC3-I protein and this is a characteristic marker of autophagy 
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which is also observed in cells treated with a vitamin D analog and paclitaxel analogs in 
breast cancer cells.  Transient transfection of green fluorescent protein-LC3 also 
revealed that treatment with C-DIMs induced a redistribution of LC3 to autophagosomes 
after C-DIM treatment.  In addition, the autofluorescent drug monodansylcadaverine 
(MDC), a specific autophagolysosome marker, accumulated in vacuoles after C-DIM 
treatment.  Western blot analysis of lysates from cells treated with C-DIMs showed the 
Beclin 1/Bcl-2 protein ratio increased suggesting that C-DIM compounds may represent 
a new mechanism-based agent for treating drug-resistant ER-negative breast tumors 
through induction of autophagic cell death. 
3.2. Introduction 
Autophagy is an evolutionarily conserved mechanism of survival triggered by 
stress-associated damage or nutrient deprivation and is characterized by the formation of 
double-membrane bound cytoplasmic vesicles called autophagosomes [519].  
Autophagosomes subsequently fuse with lysosomes to form autophagolysosomes and 
the vacuolar content is then degraded by lysosomal enzymes.  Under nutrient-deprived 
conditions, autophagy is a form of cell survival and a means to generate ATP and amino 
acids from degraded proteins and organelles.  Autophagy, however, can only be 
considered a short-term mechanism of survival since degradation of most organelles will 
eventually lead to cell death [147].  Type II autophagic cell death is a non-apoptotic 
form of programmed cell death and is morphologically characterized by the 
accumulation of autophagic vacuoles in cells lacking hallmarks of apoptosis such as 
nuclear condensation and cell fragmentation [161].   
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Both autophagy and autophagic cell death are regulated by the autophagy-related 
gene (Atg) family.  Atg6/Beclin 1 is involved in the class III PI3K complex, which is 
essential for autophagosome formation and Beclin 1 overexpression-induced autophagy 
and inhibited tumorigenicity in breast cancer cells [165,520].  The anti-apoptotic protein 
Bcl-2 has an inhibitory action on Beclin 1 and the subsequent formation of 
autophagosomes [521].  Atg8/Light-chain associated-protein 3 (LC3) is also critical for 
autophagosome formation and becomes lipidated during activation of autophagy [522].  
LC3 can be present as either an 18 kDa cytosolic protein, LC3-I, or cleaved to a 16 kDa 
LC3-II derivative that localizes to autophagosomal membranes, the latter form serving 
as a marker protein for autophagic vacuoles [166].  Atg5 and Atg12 are ubiquitinated by 
E1-like enzymes Atg7 and Atg10 and are involved in the recruitment of proteins to 
autophagosomal membranes [523,524].  Although the same autophagy-related genes 
play a role in autophagy and autophagic cell death, both Atg5 and Atg6/Beclin 1 are 
upregulated in autophagic cell death and remain low in autophagy [172].   
Autophagic (Type II) cell death is considered a controversial death pathway.  
Although autophagy may be induced in cells, it may be a mechanism of promoting cell 
survival, not cell death.  Initial evidence supporting the concept of Type II non-apoptotic 
cell death was illustrated when cell death could be induced in several cell lines treated 
with caspase inhibitors [171].  In addition, autophagic cell death is a 
pathophysiologically relevant process since it is associated with retinal degeneration and 
degeneration of neurons in certain pathologies [525,526].  Although apoptosis has long 
been considered the central form of cell death evaded by tumor cells, Type II cell death 
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may also be relevant since reduction of autophagy is observed in tumor cells and is 
associated with tumor promotion since Beclin 1 is a haploinsufficient tumor suppressor 
gene [165,527-530].  Moreover, autophagy may be causally linked to the ability of 
tumor cells to evade immune surveillance since autophagy has been linked to antigen 
processing [531]. 
 Autophagic cell death has been reported to be induced by a number of 
chemotherapeutic agents in various types of cancers [532-537].  Sulforaphane is a 
phytochemical present in cruciferous vegetables and induced autophagic cell death in 
human prostate cancer cells [532].  Autophagic cell death was the predominant form of 
cell death induced by taxol, taxol derivatives and tamoxifen in breast cancer cells 
[533,534].  15-Deoxy-∆12,14-prostaglandin J2 induced autophagic cell death in pancreatic 
cancer cells [535].  Autophagic cell death was also induced in response to radiation 
treatment in breast, colon and prostate cancer cell lines [536].  Temozolide and arsenic 
trioxide induced autophagic cell death in glioma cells [537]. 
Studies in this laboratory have investigated the mechanisms of cell death induced 
by a new series of anticancer agents that are derivatives of phytochemicals found in 
crucifers.  Epidemiology studies have positively linked consumption of cruciferous 
vegetables to decreased risk of certain types of cancer [123-127].  Mechanisms of 
growth inhibition induced by DIM, an oligomerization product of the cruciferous 
phytochemical indole-3-carbinol, have shown anticancer and antitumorigenic effects in 
vitro and in vivo [130-135].  The mechanisms of growth inhibition induced by DIM have 
been well-studied and include G0/G1 cell cycle arrest, induction of ER stress, induction 
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of apoptosis, aryl hydrocarbon receptor (AhR)-dependent antiestrogenicity and 
downregulation of the androgen receptor (AR) [131,134,416,419,420,423,425,426,538].  
C-substituted DIMs (C-DIMs) represent a new class of anticancer agents that activate 
receptor-dependent and receptor-independent pathways in a cell-context dependent 
manner.  In colon, pancreatic, ovarian, prostate, bladder and breast cancer cells, C-DIMs 
activate nuclear receptors PPARγ and Nur77 [455-458,460,468,511].  In ER-negative 
breast cancer cells, the effect of PPARγ-active C-DIMs on the cell cycle, induction of 
the pro-apoptotic protein NAG-1 and activation of kinases is primarily receptor-
independent.  Although C-DIMs modulated Bax and Bcl-2 protein expression, PARP 
was not cleaved, suggesting a caspase-independent form of cell death.  The mechanism 
of cell death induced by C-DIMs in breast cancer cells therefore required further 
examination.  
In the present study, mechanisms of cell death induced by PPARγ-active C-DIMs 
in breast cancer cells were investigated.  Treatment of ER-negative MDA-MB-231 and 
MDA-MB-453 cells with C-DIMs did not activate caspases or increase Annexin V 
staining indicating that apoptotic cell death was not activated. Measurement of LDH 
release and propidium iodide (PI) staining suggested that necrosis was not the 
predominant form of cell death induced in breast cancer cells treated with C-DIMs.  In 
contrast, autophagolysosomes were positively stained with monodansylcadaverine 
(MDC) after treatment with C-DIMs and there was a significant increase in LC3-II/LC3-
I and Beclin 1/Bcl-2 protein ratios.  In addition, after treatment with C-DIMs transfected 
GFP-LC3 localized to autophagosomal membranes of cells.  These data support 
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autophagic cell death as a novel mechanism induced by C-DIMs in ER-negative breast 
cancer cells. 
3.3. Materials and Methods 
3.3.1. Cells, chemicals and other materials  
NADH, zVAD-fmk and propidium iodide (PI) were obtained from Sigma 
Chemical Co. (St. Louis, MO).  Monodansylcadaverine (MDC) was purchased from 
Fluka (Buchs, Switzerland).  The human breast cancer cell lines MDA-MB-231 and 
MDA-MB-453 were obtained from American Type Culture Collection (ATCC, 
Manassas, VA). MDA-MB-231 cells were maintained in DMEM:F-12 supplemented 
with 0.22% sodium bicarbonate, 10% fetal bovine serum (FBS), and 2 ml/L antibiotic 
solution (Sigma Chemical Co., St. Louis, MO). MDA-MB-453 cells were maintained in 
RPMI supplemented with 0.22% sodium bicarbonate, 10% fetal bovine serum (FBS), 
and 2 ml/L antibiotic solution (Sigma Chemical Co., St. Louis, MO). Cells were grown 
in 150 cm2 culture plates in an air/CO2 (95:5) atmosphere at 37°C and passaged every 5 
days.  Beclin 1 (H-300) and Bcl-2 (N-19) antibodies were purchased from Santa Cruz 
Biotechnology (Santa Cruz, CA). The LC3 antibody was purchased from MBL 
International (Wobrum, MA).  Horseradish peroxidase substrate for Western blot 
analysis was purchased from NEN Life Science Products (Boston, MA). 
3.3.2. Cell proliferation assay 
MDA-MB-231 and MDA-MB-453 cells were seeded at a density of 3-5 x 
104/well in 12-well plates and media was replaced the next day with DMEM:F-12 media 
containing 2.5% charcoal-stripped FBS and pre-treated with 20 µM zVAD-fmk or 
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vehicle control for 30 minutes.  Cells were then co-treated with zVAD-fmk or vehicle 
control and DMSO, 10 µM DIM-C-pPhCF3, DIM-C-pPhtBu or DIM-C-pPhC6H5 for 48 
h.  Cells were then counted using a Coulter Z1 cell counter.  Each experiment was 
completed in triplicate and results are expressed as means ± SE for each determination. 
3.3.3. Annexin V staining 
MDA-MB-231 and MDA-MB-453 cells were seeded at a density of 2.5-5 x 
105/well in 6-well plates and media was replaced the next day with DMEM:F-12 media 
containing 2.5% charcoal-stripped FBS and DMSO, 10 µM DIM-C-pPhCF3, DIM-C-
pPhtBu, DIM-C-pPhC6H5 for 48 h.  Cells were also treated for 24 h with 10 µM MG132.  
Cells were then harvested according to the Annexin-V-FITC protocol provided by BD 
Biosciences.  Briefly, floating cells were transferred to an Eppendorf tube and 
centrifuged for 2 minutes at 3000 g.  The adherent cells were trypsinized and transferred 
to the same Eppendorf which was spun and the supernatant was removed.  Cells were 
resuspended in 85 µL of 1X Annexin V binding buffer and 10 µL of PI solution (5 
ug/mL).  Five µL of Annexin V-FITC conjugate was added to each sample and then 
incubated in the dark for 15 minutes before analysis by flow cytometry.  Cells early in 
apoptosis positively stained for Annexin V whereas cells in the later stages of apoptosis 
stained positively for Annexin V and propidium iodide due to late apoptotic cells having 
leaky plasma membranes. 
3.3.4. PI and Hoechst staining 
Vybrant Apoptosis Assay Kit #7 was used from Molecular Probes (Eugene, OR) 
according to the manufacturer’s directions.  Briefly, monolayers of cells were cultured 
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for 48 h in 2-well Coverglass Chamber slides. Slides were washed with culture medium 
without serum or phenol red, and labeled with Hoechst 33343 and propidium iodide at a 
final concentration of 5 µg/mL and 1.0 µg/mL, respectively.  The slides were incubated 
for 30 min on ice and visualized using a BioRad Radiance 2000 Multiphoton microscope.  
At least 3 areas per well were analyzed.  Two wells were analyzed per treatment and per 
time point.   
3.3.5. LDH assay 
MDA-MB-231 and MDA-MB-453 cells were treated for 48 h with DMSO or C-
DIMs as indicated.   An extra 3 wells were treated for 1 h or until all cells had lysed with 
0.3% Triton X in PBS.  For each sample, 200 µL of 1.22 mM pyruvate in 50 mM 
phosphate buffer and 4 µL of 12.4 mg/mL NADH dissolved in 50 mM phosphate buffer 
were each added to a 96-well plate.  20 µL of supernatant from treated cells was then 
added and the plate was incubated at 37 degrees for 30 min.  The LDH concentration 
was measured at 390 nm and the treated groups were compared to Triton X, which was 
considered 100 % LDH release. 
3.3.6. MDC staining 
Monolayers of cells were cultured for 48 h in 2-well Coverglass Chamber slides 
and treated as indicated. Slides were washed with culture medium without serum or 
phenol red.  Cytoplasmic vacuoles were stained with MDC according to the method 
described elsewhere [539].  Briefly, cells were exposed to 50 µM of MDC for 10 
minutes at 37 degrees and visualized using a BioRad Radiance 2000 Multiphoton 
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microscope. At least 3 areas per well were analyzed.  Two wells were analyzed per 
treatment and per time point.    
3.3.7. Western blots 
MDA-MB-231 and MDA-MB-453 cells were seeded in DMEM:F-12 media 
containing 2.5% charcoal-stripped FBS for 24 h and then treated with either the vehicle 
(DMSO) or the indicated compounds.  In experiments where indicated, cells were pre-
treated for 30 min with 10µM of the proteasome inhibitor MG132.  Whole cell lysates 
were obtained using high salt buffer [50 mM HEPES, 500 mM NaCl, 1.5 mM MgCl2, 1 
mM EGTA, 10% glycerol and 1% Triton X-100 pH 7.5 and 5 µL/mL of Protease 
Inhibitor Cocktail].  Protein samples were incubated at 1000C for 2 minutes, separated 
on 10-15% SDS-PAGE at 120 V for 3-4 h in 1 X running buffer [25 mM Tris-base, 192 
mM glycine, and 0.1% SDS (pH 8.3)] and transferred to a polyvinylidene difluoride 
(PVDF) membrane at 0.9 A for 90 minutes at 4OC in 1 X transfer buffer (48 mM Tris-
HCl, 39 mM glycine, and 0.025% SDS).  The PVDF membrane was blocked in 5% 
TBST-Blotto [10 mM Tris-HCl, 150 mM NaCl (pH 8.0), and 0.025% Triton X-100 and 
5% non-fat dry milk] with gentle shaking for 30 min and incubated in fresh 5% TBST-
Blotto with 1:200-1:1000 primary antibody overnight at 40C with gentle shaking.  After 
washing with TBST for 10 min, the PVDF membrane was incubated with secondary 
antibody (1:5000) in 5%TBST-Blotto for 2 h.  The membrane was washed with TBST 
for 10 min and incubated with 10 mL of chemiluminescence substrate for 1.0 min and 
exposed to Kodak X-OMAT AR autoradiography film.  Band intensities were evaluated 
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by scanning laser densitometry (Sharp Electronic Corporation, Mahwah, NJ) using Zero-
D Scanalytics software (Scanalytics Corporation, Billerica, MA). 
3.3.8. GFP-LC3 localization 
Monolayers of cells were cultured for 48 h in 2-well Coverglass Chamber slides 
and treated as indicated. The GFP-LC3 plasmid was kindly provided by Dr. Tamotsu 
Yoshimori (Osaka University, Osaka, Japan).  MDA-MB-231 cells were transfected with 
500-600 ng/well of GFP-LC3 plasmid using Lipofectamine transfection reagent 
(Invitrogen, Carlsbad, CA) according to the manufacturer’s protocol.  MDA-MB-453 
cells were transfected with 600 ng/well of GFP-LC3 plasmid using GeneJuice 
transfection reagent (EMD Biosciences, Madison, WI) according to the manufacturer’s 
protocol.  Cells with GFP-LC3 expression were counterstained with Hoechst DNA dye 
from Molecular Probes (Eugene, OR). Slides were examined by fluorescence 
microscopy using a Zeiss Stallion Dual Detector Imaging System.  A 3 dimensional 
image of cells was captured in z Z-stack.  Optical slices of cells were imaged containing 
GFP fluorescence, the Hoechst-stained DNA and DIC image.  The entire z-stack was 
compiled and subjected to deconvolution.  Cells were examined in more than five fields 
per slide on multiple slides. Data represents the average of all the fields. 
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3.3.9. Statistical analysis 
Statistical differences between different groups were determined by ANOVA and 
Fisher’s test for significance using SuperAnova software.  The data are presented as 
mean ± standard error for at least 3 separate determinations for each treatment. 
3.4. Results 
PPARγ-active C-DIMs activate caspase-dependent apoptosis in colon cancer 
cells [468], however, previous studies reported that C-DIMs did not induce caspase-
dependent PARP cleavage in ER-negative MDA-MB-231 and MDA-MB-453 cells.  To 
verify that the cell death pathway induced by C-DIMs was independent of caspase 
activation, MDA-MB-231 and MDA-MB-453 cells were co-treated with a pan-caspase 
inhibitor, zVAD-fmk.  There was no statistically significant reversal of C-DIM-induced 
cell death after with treatment with zVAD-fmk (Figure 3.1), suggesting that C-DIM 
compounds did not induce caspase-dependent cell death in ER-negative breast cancer 
cells.  
MDA-MB-231 and MDA-MB-453 cells were treated with C-DIMs for 48 h, co-
stained with Annexin V-FITC conjugate which is a marker of apoptosis and propidium 
iodide (PI) and analyzed by flow cytometry (Figure 3.2).  PI is a DNA dye that is 
impermeable to cells with intact membranes and is a marker of late apoptotic or necrotic 
cells that have lost membrane integrity.  Early apoptotic cells stain positive for Annexin 
V whereas cells in the later stages of apoptosis stain positively for both Annexin V and 
PI. The majority of cells treated with solvent control DMSO clustered in the quadrant 
negative for both Annexin V and PI.  After treatment with the apoptosis-inducing 
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Figure 3.1:  Influence of pan-caspase inhibitor zVAD-fmk on growth inhibition induced by C-
DIMs.  MDA-MB-231 [A] and MDA-MB-453 [B] cells were treated for 48 h with 10 µM DIM-C-
pPhCF3, DIM-C-pPhtBu or DIM-C-pPhC6H5 and with or without 20 µM zVAD-fmk. Cells were 
counted as described in Materials & Methods.  Results of all proliferation studies are presented as 
means ± SE for at least three separate determinations for each treatment group.  Significantly (p<0.05) 
decreased growth (compared to DMSO) in cells treated with C-DIMs alone is indicated (*). 
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Figure 3.2:  FACS analysis of cells co-stained with Annexin V and PI.  MDA-MB-231 [A] 
and MDA-MB-453 [B] cells were treated for 48 h or 24 h with 10 µM MG132.  Floating and 
adherent cells were incubated with Annexin V and PI and analyzed by flow cytometry as 
described in Materials & Methods.  Results of all proliferation studies are presented as means ± 
SE for at least three separate determinations for each treatment group.  Significance (p<0.05) 
compared to DMSO is indicated (*). 
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compound MG132, there was a slight increase in MDA-MB-231 cells staining positively 
for Annexin V alone and a statistically significant increase in cells staining positive for 
Annexin V and PI, suggesting that cells treated with MG132 were in the late stages of 
apoptosis.  In contrast, after treatment of MDA-MB-231 with C-DIMs, there was a 
decrease in the number of cells staining positively for Annexin V alone and an increase 
in cells staining positive for Annexin V and PI.  There was also an increase in both 
MDA-MB-231 and MDA-MB-453 cells staining for PI alone after treatment with DIM-
C-pPhCF3.  There was a statistically significant increase in MDA-MB-453 cells staining 
positively for Annexin V alone or both Annexin V and PI, signifying that these cells 
were exhibiting the prototypical characteristics of early and late stages of apoptosis.  In 
contrast, MDA-MB-453 cells treated with C-DIMs exhibited an increase in cells staining 
for Annexin V and PI (Figure 3.2B).  The failure of C-DIMs to induce Annexin V alone 
indicates that the ER-negative breast cancer cells do not undergo the early stages of 
apoptosis.  The increased number of cells staining positive for both Annexin V and PI 
are indicative of C-DIM-induced loss of cell membrane integrity but do not allow us to 
identify which specific cell death pathway is activated. 
Only a few cells were stained with PI after treatment of MDA-MB-231 cells with 
C-DIMs and no PI staining was observed in MDA-MB-453 cells treated with C-DIMs 
(Figures 3.3A and 3.3B).  These results contrast with previous results in MDA-MB-231 
cells treated with 5,5’-dibromoDIM where positive PI staining was observed [425].  
LDH release from cells was significantly elevated after treatment with the lytic agent, 
Triton X in both cell lines however, among the three PPARγ-active C-DIMs only 
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Figure 3.3:  Necrosis detection by PI staining and LDH release.  MDA-MB-231 [A] and MCF-7 
[B] cells were treated for 24 h with DMSO or 10 µM DIM-C-pPhCF3, DIM-C-pPhtBu or DIM-C-
pPhC6H5.  Two fluorescent DNA dyes Hoechst and propidium iodide, were loaded into cells and 
incubated on ice for 30 min and visualized using confocal microscopy as described in the Materials 
and Methods.  The same microscopic field of MDA-MB-231 [A] or MDA-MB-453 [B] cells stained 
with Hoechst and propidium iodide are shown and are representative of other cell areas with the same 
treatment.   At least 3 areas were scanned for each well and two wells were analyzed per treatment 
and per time point.  LDH release after treatment with C-DIMs in MDA-MB-231 [C] and MDA-MB-
453 cells [D].  Cells were treated for 48 h or 1 h with 0.1% Triton X and the supernatants were 
analyzed for LDH as described in the Materials and Methods.  Triton X served as a positive for 100% 
cell lysis and LDH release.  Results are presented as the means ± SE for at least three separate 
determinations for each treatment group.  Statistical significance of treatments compared to DMSO 
(p<0.05) are represented by an asterisk. 
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Figure 3.3 (Continued) 
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DIM-C-pPhCF3 significantly increased levels of LDH release in MDA-MB-453 cells 
and the C-DIMs did not induce LDH release in MDA-MB-231 cells.  Thus only DIM-C-
pPhCF3 significantlly induced necrosis in one of the two cell lines suggesting that 
necrosis was not the predominant death pathway induced by PPARγ-active C-DIMs in 
ER-negative breast cancer cells. 
Several drugs that are cytotoxic to cancer cell lines induce autophagic cell death 
[532-537,540-544] and therefore the effects of C-DIMs on MDC localization, a positive 
marker for autophagolysosomes, was investigated.  The C-DIMs clearly induce MDC in 
vacuoles in MDA-MB-231 cells whereas in cells treated with DMSO a smaller number 
of vacuoles was observed indicating low basal levels of autophagy in these cells (Figure 
3.4A).  Thus, treatment with C-DIMs increased the number and/or size of vacuoles in 
this cell line.  MDC was also localized in vacuoles in MDA-MB-453 cells treated with 
DIM-C-pPhtBu and DIM-C-pPhC6H5 (Figure 3.4B) and after treatment with DIM-C-
pPhtBu, large MDC-stained vacuoles were observed in both cell lines.  These results 
suggest that C-DIMs induced autophagy in MDA-MB-231 and MDA-MB-453 cells. 
LC3 is critical for autophagosome formation and after induction of autophagy 
LC3-I is lipidated to LC3-II which localizes to autophagosomal membranes and the ratio 
of LC3-II to LC3-I protein expression is an indicator of autophagosome formation [166]. 
After treatment of MDA-MB-231 cells with C-DIMs the cleaved form of LC3 was 
increased and this was particularly evident in MDA-MB-231 cells treated with DIM-C-
pPhtBu and DIM-C-pPhC6H5 (Figure 3.5A).  In MDA-MB-453 cells, the cleaved LC3-II 
protein accumulated only after treatment with DIM-C-pPhtBu and DIM-C-pPhC6H5 
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Figure 3.4:  Detection of lysosomal activity with monodansylcadaverine (MDC) staining.  
MDA-MB-231 [A] and MDA-MB-453 cells [B] were treated with DMSO or 10 µM DIM-C-
pPhCF3, DIM-C-pPhtBu or DIM-C-pPhC6H5 for 24 h.  MDC was loaded into cells and 
incubated at 37 degrees for 10 minutes and visualized using confocal microscopy as described in 
the Materials and Methods.   At least 5 areas were scanned for each well and images represented 
are characteristic of treatment replicates. 
  
 
154 
(Figure 3.5C).  Densitometric analyses of LC3-II to LC3-I protein expression in MDA-
MB-231 (Figure 3.5A) and MDA-MB-453 (Figure 3.5C) cells revealed a statistically 
significant increase in the LC3-II/LC3-I ratio and this is consistent with increased 
autophagosome formation.  Confocal microscopy images of a GFP-LC3 construct 
transiently transfected into the two cell lines showed that in untreated or DMSO treated 
cells there was a diffuse GFP staining pattern whereas after treatment with C-DIMs, 
GFP-LC3 was primarily localized in vacuoles (Figures 3.5B and 3.5D).  In MDA-MB-
231 cells there was an increase in the number of vacuoles positively stained for GFP-
LC3 after treatment with DIM-C-pPhtBu and DIM-C-pPhC6H5 compared to DMSO 
(Figure 3.5B).  The effect of DIM-C-pPhCF3 was less pronounced than with the other 
two compounds in MDA-MB-231 cells and this was consistent with the higher necrotic 
activity of this compound (Figure 3.2).  In MDA-MB-453 cells, the size of the vacuoles 
was substantially increased after treatment with DIM-C-pPhtBu whereas only the 
number of vacuoles increased in cells after treatment with DIM-C-pPhC6H5 (Figure 
3.5D).  These data suggest that C-DIM compounds activated the autophagic cell death 
pathways in MDA-MB-231 and MDA-MB-453 cells. 
Although the same autophagy-related genes (Atg5, Atg6, Atg7) play a role in 
autophagy and autophagic cell death, both Atg5 and Atg6/Beclin 1 are upregulated in 
autophagic cell death and remain low in autophagy [172].  The anti-apoptotic protein 
Bcl-2 has an inhibitory action on Beclin 1 and the subsequent induction of autophagy 
[521] and therefore the effects of C-DIMs on expression of these proteins were further 
investigated.  Treatment of MDA-MB-231 cells with C-DIMs increased Beclin 1 and 
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Figure 3.5:  LC3 cleavage and translocation after treatment with C-DIMs.  MDA-MB-231 [A] 
and MDA-MB-453 cells [B] were treated for 24 h with DMSO or 10 DIM-C-pPhCF3, DIM-C-
pPhtBu or DIM-C-pPhC6H5 and whole cell lysates were analyzed as described in Materials & 
Methods.  Experiments were carried out in triplicate and results shown are typical of LC3 protein 
levels for treatment replicates.  Densitometric analyses of LC3-II (cleaved form) and LC3-I protein 
expression in MDA-MB-231 [A] and MDA-MB-453 [B] cells was carried as described in the 
Materials and Methods and results are expressed as means ± SE for 3 replicate determinations for 
each treatment group. *Significantly different from DMSO (p<0.05). Translocation of transiently 
transfected GFP-LC3 plasmid.  GFP-LC3 was transiently transfected into MDA-MB-231 [C] and 
MDA-MB-453 [D] and cells were treated with DMSO or 10 µM C-DIMs as outlined in the 
Materials and Methods.  Confocal microscopy images of live cells were captured after treatment 
with C-DIMs for 24 h and differential interference contrast (DIC) and DIC/GFP overlay images of 
the same microscopic field are illustrated.  At least 3 areas were scanned per well and the images 
depicted are representative of treatment replicates. 
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Figure 3.6:  Modulation of autophagy-related gene Beclin 1 and Bcl-2 protein expression.  MDA-
MB-231 [A] and MDA-MB-453 [B] cells were treated for 24 h with DMSO or C-DIMs and whole cell 
lysates were isolated and analyzed by Western blot analysis according to procedures outlined in the 
Materials and Methods.  Densitometric analyses of Beclin 1 and Bcl-2 protein expression in MDA-MB-
231 [C] and MDA-MB-453 [D] cells was carried as described in the Materials and Methods and results 
are expressed as means ± SE for 3 replicate determinations for each treatment group. *Significantly 
different from DMSO (p<0.05). 
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decreased Bcl-2 protein levels (Figure 3.6A) and densitometric analyses of these 
proteins showed that C-DIMs increased Beclin 1/Bcl-2 ratios compared to that observed 
for DMSO (Figure 3.6C).  Beclin 1 protein levels increased only after treatment with 
DIM-C-pPhtBu and DIM-C-pPhC6H5 and Bcl-2 protein was decreased in MDA-MB-453 
cells treated with all 3 C-DIM compounds (Figure 3.6B).  However, a statistically 
significant increase in Beclin 1/Bcl-2 protein ratios was only observed in cells treated 
with DIM-C-pPhtBu and DIM-C-pPhC6H5 (Figure 3.6D).  These results suggest that 
PPARγ-active C-DIMs induce cell death (Figure 3.1) in ER-negative breast cancer cells 
through activation of the autophagic death pathway and this demonstrates the versatility 
of this novel class of anticancer drugs which activate receptor-independent apoptotic and 
autophagic cell death in different cancer cell lines. 
3.5. Discussion 
C-DIMs inhibit ER-negative MDA-MB-231 and MDA-MB-453 breast cancer 
cell growth and tumor growth in athymic nude mice bearing MDA-MB-231 cells as 
xenografts.  C-DIMs represent a novel series of compounds that exert their growth 
inhibitory and antitumorigenic effects in a cell context-dependent manner.  C-DIMs 
transactivate PPARγ in a number of cancer cell types including ovarian, bladder, colon, 
pancreatic and ER-negative and ER-positive breast cancer cells [455-458,460,511].  
PPARγ agonists inhibit cancer growth by molecular mechanisms that include G1 cell 
cycle arrest, induction of apoptosis and terminal differentiation [447,448,453,454].  
PPARγ-active C-DIMs and other PPARγ agonists also activate PPARγ-independent 
growth inhibitory pathways including induction of NAG-1, ER stress and apoptosis 
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[458,489,503,545-548].  C-DIMs induce NAG-1 which is proapoptotic in some cancer 
cell lines, however, in MDA-MB-231 and MDA-MB-453 cells these compounds 
induced NAG-1 but not apoptosis.  In addition, induction of other receptor-dependent 
and independent proapoptotic and differentiation pathways such as ER stress and 
caveolin 1 was not observed in ER-negative breast cancer cells.  The precise mechanism 
of cell death induced by C-DIMs in ER-negative breast cancer cells treated with C-DIMs 
still remains elusive.   
EB1089 is a vitamin D analog that induced caspase-independent cell death in 
ER-positive MCF-7 and ER-negative MDA-MB-231 and MDA-MB-453 breast cancer 
cells and similar results were observed for C-DIMs which also induced caspase-
independent cell death since growth inhibition could not be reversed after co-treatment 
with the pan-caspase inhibitor zVAD-fmk (Figure 3.1).  We also confirmed that C-DIMs 
did not induce Annexin V staining indicative of early apoptotic cells in ER-negative 
breast cancer cells, whereas the proapoptotic agent MG132 did induce cells staining with 
Annexin V alone (Figure 3.2).  These results coupled with previous studies showing that 
C-DIMs also did not induce caspase-dependent PARP cleavage in these cell lines 
confirm that these compounds do not induce cell death through activation of apoptotic 
pathways. Other chemotherapeutic agents also induce non-apoptotic cell death in breast 
cancer cells.  For example, the cytotoxic drug paclitaxel and related analogs induced cell 
death in breast cancer cells, however, only a small percentage of cells were undergoing 
apoptosis [534].  Thus, the current studies suggest that an alternative form of cell death 
is induced by C-DIMs in ER-negative breast cancer cells and this contrasts with the 
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induction of caspase-dependent apoptosis in ER-positive MCF-7 cells treated with C-
DIMs [456]. 
 Necrosis is an alternative form of cell death and although initially considered an 
uncontrolled form of cell demise, there is increasing evidence supporting the concept of 
programmed necrosis [549].  For instance, DNA damaging agents induced programmed 
cell death in Bax-/-Bak-/- cells but only in those cells actively proliferating and these 
observations suggested an intrinsic cellular control point that decides cellular fate [550].  
This form of cell death is particularly appealing for chemotherapeutic agents since many 
tumor cells have dysfunctional apoptotic pathways and therefore apoptosis-inducing 
agents are not always effective for treating cancer [549].  In MDA-MB-231 cells, 
minimal staining of PI and a statistically significant release of LDH was observed only 
after treatment with DIM-C-pPhCF3; however, no signs of necrosis were seen after 
treatment of these cells with DIM-C-pPhtBu or DIM-C-pPhC6H5 (Figures 3.3A and 3C).  
The lack of LDH release and PI staining in MDA-MB-453 cells treated with C-DIMs 
(Figures 3.3B and 3.3D) suggested that necrosis was not induced by all 3 compounds.  
These results also indicate significant differences between C-DIMs and the structurally-
related ring-substituted DIMs where 5,5’-dibromoDIM induced necrotic cell death in 
ER-negative breast cancer cells whereas DIM-C-pPhtBu and DIM-C-pPhC6H5 did not 
activate this cell death pathway in the same cell line [425]. 
Autophagic cell death is an alternative form of programmed cell death where 
cells lack the hallmarks of apoptosis but there is an accumulation of autophagic vacuoles 
in the cytoplasm [161]. Structurally diverse chemotherapeutic agents have been reported 
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to induce autophagic cell death in various cancer cell lines [532-537]. For example, the 
PPARγ agonist PGJ2 induced autophagic cell death in prostate cancer cells [535] and the 
cruciferous phytochemical sulforaphane induced autophagic cell death in prostate cancer 
cells [532].  Therefore we also examined the effects of C-DIMs on activation of 
autophagy in MDA-MB-231 and MDA-MB-453 breast cancer cells.  There are several 
biochemical methods for detecting autophagic activity including acidic dyes that label 
vacuoles which exhibit lysosomal activity [539].   Autophagic cell death in prostate 
cancer cells treated with sulforaphane exhibited lysosomotropic staining of cytoplasmic 
vacuoles with acridine orange [532].  Other chemotherapeutic candidate drugs induce 
signs of autophagy in breast cancer cells [533,534,543,551].  Prenylated flavones 
inhibited cell growth and induced autophagy in both ER-positive MCF-7 and ER-
negative MDA-MB-231 breast cancer cells and this response was typified by the 
formation of cytoplasmic vacuoles that stained with the autophagic marker MDC [551].  
The vitamin D analog EB1089 also inhibited cell growth in MCF-7 breast cancer cells 
and increased uptake of MDC into cytoplasmic vacuoles [543].  These observations were 
similar to effects of C-DIMs on ER-negative breast cancer cells which also exhibited 
increased uptake of MDC into vacuoles (Figure 3.4) suggesting that these compounds 
induce autophagy.  Therapeutic agents such as EB1089 and prenylated flavones typically 
induce punctate lysosomotropic staining whereas treatment with DIM-C-pPhtBu in 
particular induced formation of very large MDC-stained vacuoles (Figure 3.4).  These 
differences in staining may be due in part to differences in the size of autophagosomes in 
the size of autophagosomes in various cancer cell lines [552]. 
  
 
162 
LC3, a critical protein involved in the early stage of autophagosome formation, 
becomes lipidated upon induction of autophagy [522].  Induction of LC3-II protein 
expression, an increase in the ratio of LC3-II/LC3-I expression and translocation of LC3 
to autophagosomal membranes are diagnostic molecular markers indicative of autophagy 
[166]. For example, breast cancer cells treated with camptothecin and paclitaxel analogs 
both increased the ratio of LC3-II/LC3-I protein expression [534,553].  Treatment of 
MDA-MB-231 and MDA-MB-453 cells with C-DIMs also induced a statistically 
significant increase in the LC3-II/LC3-I protein expression ratio (Figures 3.5A and 3.5B), 
which is consistent with the induction of autophagy by these compounds.  With the 
exception of DIM-C-p-PhCF3 in MDA-MB-453 cells, treatment with C-DIMs also 
induced translocation of GFP-LC3 from the cytoplasm to autophagosomal membranes 
(Figures 3.5C and 3.5D).  Chemotherapeutic agents EB1089 or radiation that induce 
autophagic cell death typically induce GFP-LC3 staining patterns in breast cancer cells 
similar to those observed in this study with C-DIMs [536,543]. 
An important difference between autophagy as a survival mechanism versus 
autophagic cell death involves the Atg5 and Atg6/Beclin 1 genes, which are upregulated 
in autophagic cell death and remain low in autophagy [172].  The anti-apoptotic protein 
Bcl-2 is also critically involved as a negative regulator of the induction of autophagy by 
Beclin 1 [521].  Ceramide [554], camptothecin [555] and EB1089 [543] induce 
autophagic cell death in breast cancer cells and all of these agents increase Beclin 1 
protein expression.  These observations are similar to the significant increase of Beclin 1 
protein levels and Beclin 1/Bcl-2 ratios in MDA-MB-231 and MDA-MB-453 cells after 
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treatment with C-DIMs (Figure 3.6) and suggest that these ER-negative breast cancer 
cells are undergoing autophagic cell death in response to C-DIMs.   
In summary, results of this study demonstrate the C-DIM compounds clearly 
decrease ER-negative breast cancer cell survival and like some other cancer 
chemotherapeutic drugs induce autophagic cell death.  These results are in contrast to the 
mechanisms of action of C-DIMs in colon, pancreatic, ovarian, prostate and bladder 
cancer cell lines where these same compounds induce both PPARγ-dependent and 
independent growth inhibitory and proapoptotic responses [456-458,460,468,489,511].  
The mechanisms associated with the cell context-dependent differences in the anticancer 
activities of C-DIMs and their mechanisms of induction of autophagic cell death in ER-
negative breast cancer cells are currently being further investigated.  The unusual 
activity of C-DIMs is also being exploited for the clinical treatment of ER-
negative/highly invasive breast tumors that normally only respond to highly cytotoxic 
drugs which induce serious toxic side effects. 
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CHAPTER IV 
INHIBITION OF BREAST CANCER CELL GROWTH AND INDUCTION OF 
CELL DEATH BY 1,1-BIS(3'-INDOLYL)METHANE (DIM) AND 5,5'-
DIBROMODIM* 
4.1. Synopsis 
 1,1-Bis(3'-indolyl)methane (DIM) and the 5,5'-dibromo ring substituted DIM 
(5,5'-diBrDIM) inhibited growth of MCF-7 and MDA-MB-231 breast cancer cells, and 
IC50 values were 10 - 20 and 1 - 5 µM, respectively, in both cell lines.  DIM and 5,5'-
diBrDIM did not induce p21 or p27 protein levels or alter expression of Sp1 or Sp3 
proteins in either cell line.  In contrast, 10 µM 5,5'-diBrDIM downregulated cyclin D1 
protein in MCF-7 and MDA-MB-231 cells 12 and 24 hr after treatment.  DIM (20 µM) 
also decreased cyclin D1 in MCF-7 (24 hr) and MDA-MB-231 (12 hr), and the 
DIM/5,5'-diBrDIM-induced degradation of cyclin D1 was blocked by the proteasome 
inhibitor MG132.  Both DIM and 5,5'-diBrDIM induced apoptosis in MCF-7 cells and 
this was accompanied by decreased Bcl-2, release of mitochondrial cytochrome c, and 
decreased mitochondrial membrane potential as determined by the red/green 
fluorescence of JC-1.  DIM and 5,5'-diBrDIM induced extensive necrosis in MDA-MB-
231 cells; however, this was accompanied by decreased mitochondrial membrane 
potential primarily in cells treated with 5,5'-diBrDIM but not DIM.  Thus, DIM and 5,5'-
*Reprinted with permission from Cancer Letters.   Vanderlaag K, Samudio I, 
Burghardt R, Barhoumi S, Safe S.  Inhibition of breast cancer cell growth and 
induction of cell death by 1,1-bis(3'-indolyl)methane (DIM) and 5,5'-dibromoDIM, 
2006, 236(2): 198-212. 
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diBrDIM induce cell death in MCF-7 and MDA-MB-231 cells by overlapping and 
different pathways, and the ring-substituted DIM represents a novel class of uncharged 
mitochondrial poisons that inhibit breast cancer cell and tumor growth. 
4.2. Introduction 
Epidemiology studies indicate that increased consumption of cruciferous 
vegetables is associated with decreased rates of multiple cancers [126] [123-125,127].  
Phytochemicals identified in these vegetables exhibit anticarcinogenic activity in 
laboratory animal and cell culture studies, and one of these compounds is indole-3-
carbinol (I3C) which occurs as a glycoside conjugate, glucobrassican [reviewed in 
[417,556,557]].  I3C conjugates are hydrolyzed in the acid environment of the gut and 
form several condensation and rearrangement products including 1,1-bis(3'-
indolyl)methane (DIM) [128,129].  Several studies show that cruciferous vegetables (or 
their extracts), I3C and DIM exhibit antitumorigenic activity in in vivo rodent models 
and inhibit growth of cancer cells lines in vitro [130-135,416,426,558-565].  For 
example, I3C inhibited growth and/or formation of 7,12-dimethylbenz[a]anthracene 
(DMBA)-induced and spontaneous age-dependent mammary tumors and decreased the 
incidence of spontaneous endometrial tumors in rodent models [130,133,561,562].  
Studies in this laboratory have investigated the chemotherapeutic effects of DIM and 
ring-substituted DIMs on mammary tumor growth in DMBA-induced female Sprague-
Dawley rats.  At doses of 5 mg/kg/every second day, DIM inhibited tumor growth, and 
several ring-substituted DIMs, including the 5,5'-dibromo analog (5,5'-diBrDIM), were 
antitumorigenic at doses ≤ 1 mg/kg/every second day [131,434,435]. 
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 The in vivo antiestrogenic effects of DIM and ring-substituted DIMs were also 
observed in estrogen receptor (ER)-positive MCF-7 and T47D breast cancer cells.  The 
DIM compounds bind the aryl hydrocarbon receptor (AhR) in the µM range 
[131,434,435], and the results suggest that the observed antiestrogenic responses may be 
due, in part, to inhibitory AhR-ERα crosstalk.  However, there is also evidence that DIM 
inhibits growth of ER-negative breast cancer cells and other ER-independent cancer cell 
lines.  These responses are accompanied by cell context-dependent induction of 
apoptosis, p21 expression, and/or inhibition of G0/G1 → S phase progression 
[132,134,416,417,426,563,565].  Many of these studies used a relatively high 
concentration (50 µM) of DIM, and the data suggest that DIM acts primarily through 
AhR-independent pathways.  The major objectives of this study were (a) to investigate 
growth inhibition and apoptosis induced by DIM and 5,5'-diBrDIM in Ah-responsive 
(MCF-7) and non-responsive (MDA-MB-231) breast cancer cell lines, (b) to determine 
the effect of lower doses (< 20 µM) of these compounds on critical cell cycle genes and 
apoptosis, and (c) to determine potential differences in the effects of DIM and 5,5'-
diBrDIM in MCF-7 and MDA-MB-231 cells.  The results of this study show that 1 - 20 
µM DIM and 5,5'-diBrDIM significantly inhibited growth of both MCF-7 and MDA-
MB-231 cells; this was accompanied by minimal effects on expression of p21 or p27 
proteins but both compounds induced proteasome-dependent degradation of cyclin D1.  
DIM and 5,5'-diBrDIM also induced the release of cytochrome c and decreased Bcl-2 
protein in MCF-7 and MDA-MB-231 cells; however, induction of PARP cleavage by 
these compounds was observed only in MCF-7 cells.  The major difference between 
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DIM and 5,5'-diBrDIM in both cell lines was the rapid and persistent decrease in 
mitochondrial membrane potential (MMP) by 5,5'-diBrDIM, suggesting that the ring-
substituted DIMs may be a new class of mitochondrial poisons for treatment of breast 
cancer. 
4.3. Materials and Methods 
4.3.1. Cells, chemicals and other materials  
 MG132 and JC-1 (5,5',6,6'-tetrachloro-1,1',3,3'-tetraethylbenzimidazolyl-
carbocyanine iodide) and β-actin antibody (A1978) were obtained from Sigma Chemical 
Co. (St. Louis, MO).  The human breast cancer cell lines MDA-MB-231 and MCF-7 
were obtained from American Type Culture Collection (ATCC, Manassas, VA). MDA-
MB-231 cells were maintained in DME:F-12 supplemented with 0.22% sodium 
bicarbonate, 10% fetal bovine serum (FBS), and 2 ml/L antibiotic solution (Sigma 
Chemical Co., St. Louis, MO). MCF-7 cells were maintained in DME:F-12 
supplemented with 0.22% sodium bicarbonate, 5% fetal bovine serum (FBS), and 2 ml/L 
antibiotic solution (Sigma Chemical Co., St. Louis, MO).  Cells were grown in 150 cm2 
culture plates in an air/CO2 (95:5) atmosphere at 37°C and passaged every 5 days.  The 
following antibodies were purchased from Santa Cruz Biotechnology (Santa Cruz, CA):  
p21 (C-19), p27 (C-19), cyclin D1 (M-20), Sp1 (PEP-2), Sp3 (D-20), Ah receptor (N-19), 
Bcl-2 (C-2), PARP (F-2), and cytochrome c (A-8).  Horseradish peroxidase substrate for 
Western blot analysis was purchased from NEN Life Science Products (Boston, MA). 
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4.3.2. Cell proliferation assays 
 Cells were plated at a density of 5 x 104/well in 12-well plates, and culture media 
was replaced the next day with DME:F-12 media containing 2.5% charcoal-stripped 
FBS and either vehicle (DMSO) or the indicated ligand and concentration.  Fresh media 
and compounds were added every 48 hr.  Cells were counted at the indicated times using 
a Coulter Z1 cell counter.  Each experiment was completed in triplicate and results are 
expressed as means ± SE for each determination. 
4.3.3. Western blots 
 MDA-MB-231 and MCF-7 cells were seeded in DME:F-12 media containing 
2.5% charcoal-stripped FBS for 24 hr and then treated with either the vehicle (DMSO) 
or the indicated compounds.  In experiments where indicated, cells were pre-treated for 
30 min with 10 µM of the proteasome inhibitor MG132.  Whole cell lysates were 
obtained using high salt buffer [50 mM HEPES, 500 mM NaCl, 1.5 mM MgCl2, 1 mM 
EGTA, 10% glycerol and 1% Triton X-100 pH 7.5 and 5 µL/mL of Protease Inhibitor 
Cocktail].  Protein samples were incubated at 100°C for 2 minutes, separated on 10% 
SDS-PAGE at 120 V for 3-4 hr in 1 X running buffer [25 mM Tris-base, 192 mM 
glycine, and 0.1% SDS (pH 8.3)] and transferred to a polyvinylidene difluoride (PVDF) 
membrane at 0.1 V for 16 hr at 4°C in 1 X transfer buffer (48 mM Tris-HCl, 39 mM 
glycine, and 0.025% SDS).  The PVDF membrane was blocked in 5% TBST-Blotto [10 
mM Tris-HCl, 150 mM NaCl (pH 8.0), and 0.05% Triton X-100 and 5% non-fat dry 
milk] with gentle shaking for 30 min and incubated in fresh 5% TBST-Blotto with 
1:1000 primary antibody for 5-6 hr with gentle shaking.  After washing with TBST for 
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10 min, the PVDF membrane was incubated with secondary antibody (1:5000) in 
5%TBST-Blotto for 2 hr.  The membrane was washed with TBST for 10 min and 
incubated with 10 mL of chemiluminescence substrate for 1.0 min and exposed to 
Kodak X-OMAT AR autoradiography film.  Band intensities were evaluated by 
scanning laser densitometry (Sharp Electronic Corporation, Mahwah, NJ) using Zero-D 
Scanalytics software (Scanalytics Corporation, Billerica, MA).  Quantitation of band 
intensities in DMSO and treatment groups was normalized to the loading control protein, 
β-actin.  The fold-induction was determined by comparing band intensities in the treated 
vs. DMSO control groups. 
4.3.4. Mitochondrial membrane potential   
 Monolayers of cells were cultured for 48 hr in 2-well Coverglass Chamber slides.  
Cells were treated with DMSO (vehicle control), 10 µM 5,5-diBrDIM, or 20 µM DIM 
for different time intervals (6, 12 or 24 hr).  Slides were then washed with culture 
medium without serum or phenol red, and labeled with JC-1 [566-568] at a final 
concentration of 5 µg/mL for 10 min at 37°C.   Following washing, cells were analyzed 
using a Meridian Ultima confocal microscope (Meridian Instruments, Okemos,MI).  
Excitation of JC-1 was done using a 488 nm wavelength and emission was collected 
using a dichroic 560nm SP in combination with 2 filters 530 nm/30 BP and 585 nm/42 
BP.  At least 8 areas per well were scanned.  Two wells were analyzed per treatment and 
time point. Two experiments were conducted on different days.   
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4.3.5. Apoptosis assay  
 Vybrant Apoptosis Assay Kit #7 was used from Molecular Probes (Eugene, OR) 
according to the manufacturer’s directions.  Briefly, monolayers of cells were cultured 
for 48 hr in 2-well Coverglass Chamber slides.  Slides were washed with culture medium 
without serum or phenol red, and labeled with Hoechst 33343, YO-PRO-1 and 
propidium iodide at a final concentration of 5 µg/mL, 100 nM and 1.0 µg/mL, 
respectively.  The slides were incubated for 30 min on ice and visualized using a 
Meridian InSIGHT Point Confocal Microscope.  At least 3 areas per well were analyzed.  
Two wells were analyzed per treatment and per time point.  Short-term 50% EtOH 
treatment was initially utilized to ensure all 3 dyes could be visualized under conditions 
of necrosis.  Hoechst 33343 is a vital blue fluorescing DNA stain that is membrane 
permeable and brightly stains the condensed chromatin of apoptotic cells, whereas nuclei 
of live cells exhibits lower fluorescence.  The red propidium iodide is another DNA 
staining dye that only stains nuclei of cells with compromised plasma membrane and 
thus does not stain normal or apoptotic cells.  The green fluorescent YO-PRO-1 dye can 
enter apoptotic cells in contrast to the propidium iodide and therefore apoptotic cells 
show green fluorescence only while dead cells show primarily red propidium iodide 
fluorescence and some green fluorescence. 
4.3.6. Statistical analysis 
 Treatment-induced effects on the mitochondrial membrane potential as well as 
relative Western blot band intensities were statistically analyzed by ANOVA and 
Fisher's test for significance using SuperAnova software.  The densitometric mean band 
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intensities of treatment groups are presented as the mean fold-induction normalized to 
the vehicle control (DMSO) ± SE for at least 3 separate determinations for each 
treatment.  The MMP data are presented as the normalized ration (to vehicle control) of 
Jaggr/JC-1 ± SE for a minimum of 8 separate determinations for each treatment. 
4.4. Results 
MCF-7 and MDA-MB-231 breast cancer cells express the Ah [569]; although, 
MDA-MB-231 cells are Ah-nonresponsive and this may be due, in part, to 
overexpression of heat shock protein 90 which blocks ligand-dependent activation of the 
Ah [570].  One of the objectives of this study is to determine the role of the Ah receptor 
in mediating the growth inhibitory effects of DIM and 5,5'-diBrDIM in Ah-responsive 
MCF-7 and Ah-nonresponsive MDA-MB-231 cells.  Preliminary cell proliferation 
studies in MCF-7 and MDA-MB-231 cells using bromo-, methyl- and chloro-
substituents at 4,5,6,7 positions indicated that 5,5'-diBrDIM was the most active ring-
substituted DIM, and this study investigated the growth inhibition and apoptosis induced 
by DIM and 5,5'-diBrDIM.  The IC50 values for growth inhibition by 5,5'-diBrDIM were 
< 5 µM in both cell lines, whereas the corresponding IC50's for DIM were 10 - 20 µM 
(Figure 4.1).  These in vitro differences between DIM and 5,5'-diBrDIM in breast cancer 
cell growth inhibition were comparable to their corresponding anticarcinogenic effects in 
DMBA-induced rat mammary tumor growth [19, 27, 28].  Based on the growth 
inhibitory effects of these compounds in both Ah responsive (MCF-7)
  
 
172 
5,5'-diBrDIM
0
0.5
1
1.5
2
2.5
0 2 4 6
Time (Days)
C
e
ll
 n
u
m
b
e
r 
(
x
1
0
5
) DMSO
5µM
10µM
20µM
5,5'-diBrDIM
0
0.5
1
1.5
2
2.5
3
3.5
4
0 2 4 6
Time (Days)
C
e
ll
 n
u
m
b
e
r 
(
x
1
0
5
) DMSO
5µM
10µM
20µM
DIM
0
0.5
1
1.5
2
2.5
3
3.5
0 2 4 6
Time (Days)
C
e
ll
 n
u
m
b
e
r 
(
x
1
0
5
) DMSO
5µM
10µM
20µM
DIM
0
0.5
1
1.5
2
2.5
0 2 4 6
Time (Days)
C
e
ll
 n
u
m
b
e
r 
(
x
1
0
5
) DMSO
5µM
10µM
20µM
MCF-7 MDA-MB-231
C
e
ll
 n
u
m
b
e
r 
(
x
1
0
5
)
C
e
ll
 n
u
m
b
e
r 
(
x
1
0
5
)
C
e
ll
 n
u
m
b
e
r 
(
x
1
0
5
)
C
e
ll
 n
u
m
b
e
r 
(
x
1
0
5
)
A B
Figure 4.1: Inhibition of breast cancer cell growth by DIM and 5,5'-diBrDIM.  MCF-7 [A] and 
MDA-MB-231 [B] cells.  Cells were cultured for six days and treated every second day with DMSO 
(solvent control) or different concentrations of DIM or 5,5'-diBrDIM and the number of cells was 
determined as described in the Materials and Methods.  Results are expressed as means ± SE for at least 
3 separate determinations for each treatment group, significant (p < 0.05) growth inhibition was 
observed for ≥ 5 (MCF-7 cells) or ≥ 10 µM (MDA-MB-231 cells) for DIM or < 5 µM 5,5'-diBrDIM in 
both cell lines. 
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and non-responsive (MDA-MB-231) cells, it is evident that the antimitogenic activities 
of DIM and 5,5'-diBrDIM do not require a functional AhR. 
 Several studies report that I3C and DIM inhibit G0/G1 → S phase progression 
through modulation of key cell cycle regulatory proteins [134,416,417,563].  Results 
illustrated in Figures 4.2 and 4.3 summarize the effects of 1 - 10 µM 5,5'-diBrDIM and 5 
- 20 µM DIM on p21, p27 and cyclin D1 levels in MDA-MB-231 and MCF-7 cells, 
respectively.  Both MDA-MB-231 and MCF-7 cells express the Ah receptor, and levels 
were similar in DMSO (Figure 4.2B) and various treatment groups.  The Ah receptor 
band staining was more intense using extracts from MDA-MB-231 cells.  In MDA-MB-
231 cells (Figure 4.2A), both compounds did not induce concentration-dependent 
changes on either p21 or p27 levels after treatment for 12 or 24 hr, whereas cyclin D1 
protein levels were decreased by 5,5'-diBrDIM and DIM after treatment for 24 hr.  A 
similar approach was used for MCF-7 cells (Figure 4.3); 10 µM 5,5'-diBrDIM decreased 
cyclin D1 levels (12 and 24 hr), and similar results were observed for 20 µM DIM after 
treatment for 24 hr.  p27 levels were unaffected by 5,5'-diBrDIM or DIM, and p21 
protein was increased by DIM (10 and 20 µM) and decreased by 5,5'-diBrDIM (5 and 10 
µM) only at the 12 and 24 hr time points, respectively.  In addition, other cell cycle 
proteins (cdk2, cdk4, cdk6) are unaffected by the treatments (data not shown). 
 Hong and coworkers [134] previously reported that 50 µM DIM induced p21 
mRNA and protein levels for up to 72 hr in MCF-7 and MDA-MB-231 cells, and this 
was associated with enhanced Sp1 and Sp3 interactions with GC-rich motifs in the p21 
promoter.  Treatment of MCF-7 and MDA-MB-231 cells with 1 - 10 µM 5,5'-diBrDIM
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Figure 4.2:  Effects of DIM and 5,5'-diBrDIM on cell cycle genes in MDA-MB-231 cells.  [A]  
Western blot analysis.  The effects of DMSO (D) (solvent control), DIM and 5,5'-diBrDIM on cyclin 
D1, p27 and p21 protein levels were determined by Western blot analysis of whole cell lysates from the 
different treatment groups as described in the Materials and Methods.  Quantitation of cyclin D1 [B] 
and p27/p21 [C] protein levels.  Based on results obtained for three separate experiments for each 
treatment, the levels of cyclin D1, p21 and p27 relative to DMSO (D) treatment were quantitated and 
results are expressed as means ± SE.  Significant (p < 0.05) inhibition of cyclin D1 protein levels is 
indicated by an asterisk.  The loading control was β-actin. 
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Figure 4.3: Effects of DIM and 5,5'-diBrDIM on cyclin D1, p21 and p27 protein expression in 
MCF-7 cells.  [A]  Western blot analysis.  MCF-7 cells were treated with DMSO (D) or different 
concentrations of DIM or 5,5'-diBrDIM for 12 or 24 hr, and whole cell lysates were analyzed by 
Western blot analysis as described in the Materials and Methods.  Quantitation of cyclin D1 [B] and 
p27/p21 [C] protein levels.  Levels of cyclin D1, p21 and p27 proteins in treatment groups were 
determined in 3 separate experiments as described in [A] and mean values ± SE relative to DMSO 
(D) are presented.  Significant (p < 0.05) changes in levels relative to DMSO are indicated by an 
asterisk.  The loading control was β-actin. 
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or 5 - 20 µM DIM (Figure 4.4) caused minimal changes in Sp1 or Sp3 levels in either 
cell line.  Cellular responses to 50 µM DIM and higher concentrations of 5,5'-diBrDIM 
(≥ 20 µM) were not feasible in this study due to high cytotoxicity observed in the breast 
cancer cell lines within 24 hr after treatment (data not shown).  Nevertheless, these data 
show that the growth-inhibitory activity of DIM or 5,5-diBrDIM at the doses and 
conditions used in this study was not related to modulation of Sp1/Sp3 ratios. 
 Carter and coworkers [571] have reported in a microarray experiment that DIM 
downregulates cyclin D1 gene expression in human keratinocytes and, in MCF-7 cells, a 
structurally-related series of methylene-substituted DIM compounds induce proteasome-
dependent degradation of cyclin D1 [459].  Therefore, the effects of DIM and 5,5'-
diBrDIM on activation of proteasome-dependent degradation of cyclin D1 was 
investigated in MCF-7 and MDA-MB-231 cells.  The proteasome inhibitor MG132 
significantly inhibited downregulation of cyclin D1 protein in MCF-7 cells treated with 
10 µM 5,5'-diBrDIM (12 and 24 hr) or 20 µM DIM (24 hr) (Figure 4.5A).  Cyclin D1 
downregulation was also reversed by MG-132 in MDA-MB-231 cells treated with 10 
µM 5,5'-diBrDIM (12 and 24 hr) or 20 µM DIM (12 hr).  These results suggest that DIM 
and 5,5'-diBrDIM (ring-substituted DIM) induce proteasome-dependent downregulation 
of cyclin D1 in MCF-7 and MDA-MB-231 cells as previously reported for methylene-
substituted DIMs in the former cell line [459]. 
 Previous studies with I3C and/or DIM indicate that these compounds activate 
multiple pathways in breast and other cancer cell lines, and these include induction of 
apoptosis, modulation of Bcl-2/Bax levels, and alteration of MMP by I3C and/or DIM in  
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Figure 4.4: Sp1 and Sp3 protein levels in MCF-7 and MDA-MB-231 cells treated with DIM or 
5,5'-diBrDIM.  [A]  MCF-7 cells and [B] MDA-MB-231 cells.  The treatment protocols were 
identical to those described in Figures 2 and 3, and Sp1/Sp3 protein levels were determined by 
Western blot analysis and quantitated [relative to DMSO (D) treatment].  Results illustrated in the 
Figure are derived from the same whole cell lysates used for Western blot analytical data illustrated 
in Figures 2 and 3.  Results of triplicate analysis (means ± SD) for Sp1 and Sp3 levels in both cell 
lines showed that Sp1 (5 µM DIM) and Sp3 (5 µM DIM) levels were increased (< 50%) in MCF-7 
but not MDA-MB-231 cells (data not shown).  The loading control was β-actin. 
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Figure 4.5: Effects of MG-132 on DIM-/5,5'-diBrDIM-induced downregulation of cyclin D1 
protein in MCF-7 [A] and MDA-MB-231 [B] cells.  Cells were treated with DMSO (D), 10 µM 
5,5'-diBrDIM, 20 µM DIM, 10 µM MG-132, or their combinations (as indicated) for 12 or 24 hr, and 
whole cell lysates were examined by Western blot analysis as described in the Materials and 
Methods.  Each treatment group was replicated (3X), and results are expressed as means ± SE relative 
to DMSO (control).  Significantly (p < 0.05) decreased cyclin D1 (*) or inhibition of this decrease by 
MG-132 (**) are indicated.  The loading control was β-actin. 
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MCF-7 and tumorigenic MCF10Ca1a cells [132,426,563,565,572].  We therefore further 
investigated the effects of 5,5'-diBrDIM and DIM on parameters associated with 
mitochondrial damage and cell death pathways.  MDA-MB-231 cells were treated for 48 
and 96 hr with 5 or 10 µM 5,5'-diBrDIM, 5, 10 or 20 µM DIM, and cell lysates were 
analyzed for PARP cleavage, Bcl-2 and cytochrome c protein levels (Figure 4.6A).  
PARP cleavage was not observed in any of the treatment groups; however, after 96 hr 
both DIM and 5,5'-diBrDIM caused a decrease in Bcl-2 and an increase in cytochrome c 
levels.  After treatment of MDA-MBA-231 cells with 10 µM 5,5'-diBrDIM for 96 hr, 
there was extensive cell death and minimal protein was available for analysis (Figure 
4.6A).  As a control for this experiment, both cycloheximide (CHX) and the proteasome 
inhibitor MG-132 induced PARP cleavage in MDA-MB-231 cells (Figure 4.6B).  A 
similar protocol was used for MCF-7 cells treated with DIM and 5,5'-diBrDIM for 48 
and 72 hr (Figure 4.6C).  5,5'-diBrDIM (10 µM) induced PARP cleavage and increased 
cytochrome c levels after 48 hr and these responses as well as decreased Bcl-2 protein 
were observed after 72 hr.  Comparable effects (but less pronounced) were also observed 
for DIM.  The same mitochondrial responses were also investigated in MCF-7 and 
MDA-MB-231 cells treated for only 24 hr with higher concentrations of DIM (40 µM) 
and 5,5'-diBrDIM (20 µM) which were cytotoxic after > 30 hr treatment (Figure 4.6D).  
The results demonstrated that PARP cleavage, decreased Bcl-2 and increased 
cytochrome c protein levels could be observed within 24 hr in MCF-7 cells, whereas 
only Bcl-2 was affected in MDA-MB-231 cells at this time point.  Despite the temporal 
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differences in the various indicators of cell death pathways in MCF-7 and MDA-MB-
231 cells, nuclear staining of these cells  
treated with DIM or 5,5'-diBrDIM showed specific treatment-related effects (Figure 4.7).  
MDA-MB-231 and MCF-7 cells were treated for 24 hr with 5 - 10 µM 5,5'-diBrDIM and 
20 µM DIM, and normal, necrotic and apoptotic cells were distinguished by confocal 
microscopy using a fluorescent triple-dye assay.  In MCF-7 cells (Figure 4.7A), 
treatment with 5,5'-diBrDIM (5 µM) and DIM (20 µM) for 24 hr increased the number 
of apoptotic cells, which were represented by an increase in the number of cells 
exhibiting both blue (Hoechst dye) and green (YO-PRO-1) fluorescence.  Minimal 
necrosis (propidium iodide staining) was observed.  Cells treated with 10 µM 5,5'-
diBrDIM were primarily detached from this dish and could not be further evaluated.  In 
contrast, the predominant cell death pathway in MDA-MB-231 cells treated with 5 - 10 
µM 5,5'-diBrDIM was necrosis (Figure 4.7B) as evidenced by the intense propidium 
iodide nuclear staining.  DIM (20 µM) induced blue and green staining with Hoechst and 
YO-PRO-1 dyes but no propidium iodide staining which indicated induction of 
apoptosis in MDA-MB-231 cells.  Ethanol was used as a reference toxicant which 
induced blue, green and red staining with all three dyes. 
 We also examined decreased MMP in MCF-7 and MDA-MB-231 cells after 
treatment with DIM or 5,5'-diBrDIM using JC-1 which forms aggregates on the inner 
mitochondrial membrane of cells with higher MMP [566-568].  5,5'-DiBrDIM induced a 
time-dependent decrease in MMP in MCF-7 cells; however, DIM induced an initial 
increase (6 and 12 hr) and only a slight decrease in MMP after 24 hr (Figures 4.8A and
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Figure 4.6: Effects of DIM and 5,5'-diBrDIM on MDA-MB-231 and MCF-7 cell mitochondrial 
proteins.  [A]  Mitochondrial proteins in MDA-MB-231 cells after treatment for 48 hr or 96 hr.  Cells 
were treated with different concentrations of DIM or 5,5'-diBrDIM for 48 or 96 hr, and whole cell 
lysates or cytosolic fractions (for cytochrome c analysis) were isolated and examined by Western blot 
analysis as described in the Materials and Methods.  Ten µM 5,5'-diBrDIM was cytotoxic to MDA-
MB-231 cells after treatment for 96 hr, and decreased band intensities were due to the low yield of 
cells.  [B]  Treatment with cycloheximide (CHX) and MG-132.  As a positive control for PARP 
cleavage, MDA-MB-231 cells were treated with 10 µM cycloheximide or MG-132, respectively, for 
20 hr, and whole cell lysates were examined by Western blot analysis as described in the Materials 
and Methods.  [C]  Mitochondrial proteins in MCF-7 cells after treatment for 48 or 72 hr.  Whole cell 
lysates or cytosolic fractions (for cytochrome c release) were isolated from the different treatment 
groups were examined by Western blot analysis as described in [A].  [D]  Treatment of cells for 24 
hr.  MCF-7 and MDA-MB-231 cell mitochondrial proteins were determined after treatment with up 
to 40 and 20 µM DIM and 5,5'-diBrDIM, respectively, for 24 hr.  Whole cell lysates or cytosolic 
fractions (for cytochrome c analysis) were examined by Western blot analysis as described in the 
Materials and Methods. 
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Figure 4.6  (Continued) 
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Figure 4.7: Characterization of 5,5'-diBrDIM and DIM-induced cell death in MCF-7 [A] and 
MDA-MB-231 [B] cells.  MCF-7 and MDA-MB-231 cells were treated for 24 hr with DMSO, 5  
or  10 µM 5,5’-diBrDIM, or 20 µM DIM.  Three fluorescent DNA dyes Hoechst, YO-PRO-1 and 
propidium iodide, were loaded into cells and incubated on ice for 30 min and visualized using 
confocal microscopy as described in the Materials and Methods.  Necrotic cells are identified by 
propidium iodide staining, whereas apoptotic cells exhibit green YO-PRO-1 and bright blue 
Hoechst fluorescence.  The same microscopic field of MCF-7 [A] or MDA-MB-231 [B] cells 
stained with Hoechst, YO-PRO-1 and propidium iodide are shown and are representative of other 
cell areas with the same treatment.   At least 3 areas were scanned for each well and two wells were 
analyzed per treatment and per time point.  Five µM 5,5'-diBrDIM- and 20 µM DIM-treated MCF-
7 cells exhibited minimal necrosis.  The majority of cells treated with 10 µM 5,5'-diBrDIM 
detached from the dish and it was not possible to identify the cell death pathway using this assay.  
In MDA-MB-231 cells, 50% EtOH treatment was initially utilized as a positive control for necrotic 
cells and visualization of all three fluorescent dyes.  MDA-MB-231 cells treated with 5 and 10 µM 
5,5'-diBrDIM exhibited numerous propidium iodide stained cells, whereas cells treated with 20 µM 
DIM primarily showed YO-PRO-1 staining. 
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4.8B).  5,5'-DiBrDIM induced a highly significant decrease in the MMP in MDA-MB-
231 cells 6, 12 and 24 hr after treatment, whereas DIM had only minimal effects on the 
MMP in MDA-MB-231 cells (Figures 4.8C and 4.8D).  These results suggest that, 
although both DIM and 5,5'-diBrDIM induce downregulation of cyclin D1 protein, 
growth inhibition and necrosis in MDA-MB-231 cells, their effects on MMP are not the 
same, suggesting some differences in their mechanisms of action in which direct 
mitochondrial targeting is the predominant pathway for the ring-substituted 5,5'-
diBrDIM. 
4.5. Discussion 
I3C and DIM exhibit anticarcinogenic activities in cancer cells and in in vivo 
models, and contribute to the chemoprotective effects associated with consumption of 
cruciferous vegetables [123-127,130-135,416,426,434,435,558-565].  DIM exhibits 
multiple activities and interacts directly with the trout ER, human androgen receptor and 
Ah [134,434,435].  Ligands that activate the Ah inhibit growth of breast, prostate, 
endometrial and pancreatic cancer cells [131,573-576], and both DIM and 5,5'-diBrDIM 
inhibited DMBA-induced rat mammary tumor growth at doses < 5 or < 1 mg/kg every 
second day, respectively [131,435].  Hong and coworkers [134] reported that DIM 
inhibited growth of Ah-responsive and non-responsive MCF-7 and MDA-MB-231 breast 
cancer cells and similar growth inhibitory responses were also observed for DIM and 
ring-substituted DIMs (Figure 4.1).  MCF-7 cells were responsive to growth inhibition 
by these compounds and this may be due, in part, to activation of the AhR.  However, 
the results observed in MDA-MB-231 cells treated with DIM and ring-substituted DIMs  
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Figure 4.8: Time-dependent mitochondrial membrane depolarization after treatment of 
MCF-7 [A, B] or MDA-MB-231 [C, D] cells with 5,5’-diBrDIM and DIM.  MCF-7 and MDA-
MB-231 cells were treated for 6, 12 or 24 hr with DMSO, 10 µM 5,5’-diBrDIM and 20 µM DIM, 
and cells were loaded with the potential-sensitive JC-1 dye and visualized as described in the 
Materials and Methods.  The ratio of Jaggr/JC-1 for each treatment was normalized to DMSO and 
these results are shown for MCF-7 [A] and MDA-MB-231[C] cells as the mean ± SE for at least 8 
replicate determinations for each treatment group. Representative fluorescent images are also 
depicted in [B] and [D] for MCF-7 and MDA-MB-231 cells, respectively. Significance (p<0.05) is 
denoted by an asterisk (*). 
  
 
187 
(Figure 4.1) indicate that growth inhibition and cytotoxicity observed after treatment 
with DIM or ring-substituted DIMs is AhR-independent.    
It was reported that concentrations of DIM ≥ 50 µM induced p21 mRNA and 
protein levels in MCF-7 and MDA-MB-231 cells, and this was associated with enhanced 
binding of Sp1 and Sp3 to GC-rich elements in the p21 gene promoter [134].  In this 
study, 20 µM DIM was cytotoxic in MDA-MB-231 and cytostatic in MCF-7 cells 
(Figure 4.1) and 10 µM concentrations of the ring-substituted DIMs were cytotoxic in 
both cell lines (Figure 4.1).  Higher concentrations of DIM (40 µM) or 5,5'-diBrDIM (20 
µM) could only be used in short term (24 hr) studies since these concentrations resulted 
in 100% cell death and detachment from the cell culture wells within 48 hr after 
treatment.  DIM had minimal effects on p21 or p27 levels in MDA-MB-231 and MCF-7 
cells (Figures 4.2 and 4.3), and a < 3-fold increase in p21 protein was observed only in 
MCF-7 cells treated with 10 or 20 µM DIM for 12 hr.  We did not observe any changes 
in Sp1 or Sp3 levels in MCF-7 or MDA-MB-231 cells treated with 1 - 10 µM 5,5'-
diBrDIM or 5 - 20 µM DIM (Figure 4.3) which were also growth inhibitory (Figure 4.1).  
These results suggest that the cytotoxic and cytostatic effects of DIM (< 20 µM) or 5,5'-
diBrDIM (< 10 µM) in MCF-7 and MDA-MB-231 cells are independent of changes in 
Sp1, Sp3 and p21 expression as previously reported [134]; however, this does not 
exclude the reported effects of higher concentrations (e.g. 50 µM) of DIM on Sp1, Sp3 
and p21 levels.  The major effects of DIM and 5,5'-diBrDIM on cell cycle proteins 
associated with G1 → S phase progression was decreased cyclin D1 protein expression 
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in both cell lines (Figures 4.2 and 4.3).  Downregulation of cyclin D1 protein by DIM 
and 5,5'-diBrDIM in MCF-7 and MDA-MB-231 cells was blocked by the proteasome 
inhibitor MG-132 (Figure 4.5) as previously reported for methylene substituted DIMs in 
the former cell line [459].  These results indicate that both ring- and methylene-
substituted DIM compounds which are di- or triarylmethane analogs, respectively, may 
exhibit common pathways for inducing proteasome-dependent degradation of cyclin D1, 
and we are currently investigating the mechanisms of this process. 
 Previous studies show that I3C and DIM also affect mitochondrial function 
[132,426,563,565,572] and treatment of MDA-MB-231 or MCF-7 cells with 50 µM 
DIM decreased Bcl-2 and increased Bax protein levels and the percentage of apoptotic 
cells [426].  In this study, we also observed decreased Bcl-2 protein and this was 
accompanied by increased levels of cytochrome c released into the cytosol in both cell 
lines treated with DIM or 5,5'-diBrDIM (Figure 4.6).  In contrast, PARP cleavage was 
induced only in MCF-7 and not in MDA-MB-231 cells (Figure 4.6) and we previously 
also observed induction of PARP cleavage by methylene-substituted DIMs in MCF-7 
cells [35].  Lipophilic cations [577-579]  and other lipophilic chemicals such as 15-
deoxy-∆12,14-prostaglandin J2 [535] target the mitochondria in some cell lines and induce 
mitochondrial membrane depolarization and increased mitochondrial membrane 
permeability.  Cell death pathways induced by DIM and 5,5'-dibrDIM were investigated 
in MCF-7 and MDA-MB-231 cells using Hoechst 33343 dye, the green fluorescent YO-
PRO-1 dye that can enter apoptotic cells, and propidium iodide which stains necrotic cell 
nuclei.  DIM and 5,5'-diBrDIM induced YO-PRO-1 staining but no propidium iodide 
  
 
189 
staining in MCF-7 cells (Figure 4.7A) which is indicative of apoptosis.  The results are 
consistent with the induction of PARP cleavage by the same compounds in MCF-7 cells 
(Figure 4.6).  In contrast, only DIM induced apoptosis in MDA-MB-231 cells (Figure 
4.7B) and treatment with 5,5'-dibrDIM resulted in propidium iodide-stained cells and 
necrosis.  These results demonstrate that DIM and 5,5'-diBrDIM induce overlapping and 
different cell death pathways that are cell context-dependent. 
 Rahman and coworkers [563] also showed that I3C induced the loss of MMP in 
MCF-7 cells, and this may be due, part, to DIM which is formed in cell culture from 
spontaneous dimerization of I3C [580].  Results in Figure 4.8 illustrate the effects of 
DIM and 5,5'-diBrDIM on the fluorescence of JC-1, a dye that accumulates and 
oligomerizes in the inner mitochondrial membrane and exhibits a distinct red 
fluorescence.  This response is associated with permeabilization of various 
mitochondrial pores/channels and release of pro-apoptotic/necrotic factors [577-579].  
Using confocal microscopy and a potential-sensitive dye, it was evident that 5,5-
diBrDIM decreased the ratio of red/green fluorescence indicative of decreased MMP, 
whereas the effects of DIM were minimal (Figure 4.8).  DIM and 5,5-'diBrDIM induced 
apoptosis in MCF-7 cells; however, only the latter compound decreased MMP 
throughout the 24 hr treatment.  5,5'-diBrDIM primarily induced necrosis of MDA-MB-
231 cells, and MMP was decreased after treatment with 5,5'-diBrDIM but not DIM, 
suggesting that introduction of the ring substituents significantly enhanced the 
mitochondriotoxic effects of this compound.   
  
 
190 
 In summary, results of this study indicate that DIM and 5,5'-diBrDIM inhibit 
growth of MCF-7 and MDA-MB-231 breast cancer cells through multiple pathways 
including activation of proteasome-dependent degradation of cyclin D1, induction of cell 
necrosis, apoptosis and decreased MMP, and these effects were essentially Ah receptor-
independent.  For most responses, 5,5'-diBrDIM was significantly more potent than DIM, 
and 5,5'-diBrDIM significantly decreased MMP in both MDA-MB-231 and MCF-7 cells, 
whereas DIM had minimal effects on MMP.  Preliminary results also indicate that other 
ring-substituted DIMs decrease MMP in breast cancer cells (data not shown).  Current 
studies are focused on development of 5,5'-diBrDIM and related compounds as a new 
class of mitochondrial poisons and on determining their specific mechanisms of 
mitochondrial toxicity in different cancer cell lines.  
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CHAPTER V 
SUMMARY 
Cancer is the second-leading cause of death in the United States and 1 in 2 men 
and 1in 2 women are expected to develop cancer in their lifetime.  Breast cancer 
accounts for one third of all new cancer cases in women in the US and over 41,000 are 
expected in 2006.  Due to the high incidence of breast cancer, there is a great need to 
develop more effective treatments for this disease. 
Cancer can be defined as abnormal cells that grow uncontrollably and have the 
ability to invade normal tissues and many cytotoxic chemotherapeutic agents kill cancer 
cells by targeting rapidly dividing cells.  This therapeutic approach causes many adverse 
side effects to normal cells that are also rapidly proliferating.  Current chemotherapeutic 
drug design strategies have focused on identifying targets specific to cancer cells, which 
include the 6 hallmarks of cancer:  self-sufficiency in growth signals, insensitivity to 
anti-growth signals, evading apoptosis, limitless replicative potential, sustained 
angiogenesis and tissue invasion and metastasis. 
Breast cancer can be classified into 2 different categories:  early stage ER-
positive breast cancer and later stage ER-negative breast cancer.  ER-positive breast 
cancer is defined by tumor cells that express ER and respond to the mitogenic effects of 
estrogen.  This type of breast cancer can be treated effectively by drugs such as selective 
estrogen receptor modulators (SERMs) or aromatase inhibitors that exploit the estrogen-
induced growth signaling pathway.  SERMs inhibit E2 binding to ER and aromatase 
inhibitors interefere with the conversion of testosterone to estrogen.  Although both are 
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effective, prolonged use of SERMs is associated with an increased risk of endometrial 
cancer and aromatase inhibitors can increase bone loss. 
Epidemiology studies have linked increased consumption of cruciferous 
vegetables to decreased incidence of several cancers including breast cancer.  DIM is the 
dimerization production of the cruciferous phytochemical indole-3-carbinol (I3C) and 
has both I3C and DIM exhibit growth inhibitory and antitumorigenic effects in vitro and 
in vivo cancer models.  My research has investigated the mechanisms of growth 
inhibition in breast cancer cells for two series of substituted DIMs:  methylene-
substituted DIMs and ring-substituted DIMs.  Both series of compound exhibit great 
potential for treating breast cancer and these C-DIM analogs are active against ER-
positive and ER-negative breast cancer cells/tumors in both in vitro and in vivo models.  
1,1-Bis(3’-indolyl)-1-(p-substitutedphenyl)methanes containing para 
trifluoromethyl (DIM-C-pPhCF3), t-butyl (DIM-C-pPhtBu) and phenyl (DIM-C-
pPhC6H5) groups activate peroxisome proliferator-activated receptor γ (PPARγ) in ER-
negative MDA-MB-231 and MDA-MB-453 breast cancer cells.  These PPARγ-active 
compounds inhibit breast cancer cell proliferation, however, inhibition of G0/G1 to S 
phase progression and cyclin D1 downregulation was observed in MDA-MB-231 but not 
MDA-MB-453 cells.  Nonsteroidal anti-inflammatory drug-activated gene 1 (NAG-1), a 
transforming growth factor β-like peptide, was also induced by these compounds and 
response was dependent on cell-context dependent activation of kinase pathways.  
Despite the induction of NAG-1 and downregulation of the antiapoptotic protein 
survivin in both MDA-MB-231 and MDA-MB-453 cells treated with these methylene-
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substituted diindolylmethanes (C-DIMs), this was not accompanied by apoptosis.  
Nevertheless the cytotoxicity observed for the C-DIMs in vitro was complemented by 
inhibition of tumor growth in athymic nude mice bearing MDA-MB-231 cells as 
xenografts and treated with DIM-C-pPhC6H5 (40 mg/kg/d).   
Although C-DIMs inhibited breast cancer cell growth, the mechanism of 
inhibition required further investigation into apoptotic, necrotic and autophagic cell 
death.  C-DIM-induced cell death could not be reversed by zVAD-fmk, a pan-caspase 
inhibitor in either cell line.  Treatment of MDA-MB-231 and MDA-MB-453 cells with 
C-DIMs did not elevate annexin V-propidium iodide (PI) staining patterns consistent 
with apoptosis, suggesting that C-DIMs did not induce Type I (apoptotic) programmed 
cell death.  Cell necrosis (Type III cell death), as indicated by propidium iodide (PI) 
staining and lactate dehydrogenase (LDH) release, was also negative after treatment of 
MDA-MB-453 cells with C-DIMs.  Autophagic (Type II) cell death is an important cell 
death pathway in breast cancer cells after treatment with several chemotherapeutic 
agents including tamoxifen, EB1089 and sulforaphane, and therefore we investigated the 
possibility that C-DIMs may also induce autophagy in breast cancer cells.  Treatment of 
MDA-MB-231 and MDA-MB-453 cells with C-DIMs resulted in an accumulation of 
light chain associated-protein 3 (LC3)-II compared to LC3-I protein and this is a 
characteristic marker of autophagy which is also observed in breast cancer cells treated 
with a vitamin D analog and paclitaxel analogs.  Transient transfection of MDA-MB-231 
and MDA-MB-453 cells with green fluorescent protein-LC3 also revealed that treatment 
with C-DIMs induced a redistribution of LC3 to autophagosomes after C-DIM treatment.  
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In addition, the autofluorescent drug monodansylcadaverine (MDC), a specific 
autophagolysosome marker, accumulated in vacuoles after C-DIM treatment.  Western 
blot analysis of lysates from cells treated with C-DIMs showed the Beclin 1/Bcl-2 
protein ratio increased, suggesting that C-DIM compounds may represent a new 
mechanism-based agent for treating drug-resistant ER-negative breast tumors through 
induction of autophagic cell death. 
 The growth inhibitory effects of ring-substituted DIMs were investigated in both 
ER-positive MCF-7 and ER-negative MDA-MB-231 breast cancer cells.  DIM and the 
5,5'-dibromo ring substituted DIM (5,5'-diBrDIM) inhibited growth of MCF-7 and 
MDA-MB-231 breast cancer cells, and IC50 values were 10 - 20 and 1 - 5 µM, 
respectively, in both cell lines.  DIM and 5,5'-diBrDIM did not induce p21 or p27 
protein levels or alter Sp1 or Sp3 protein expression in either cell line.  In contrast, 10 
µM 5,5'-diBrDIM downregulated cyclin D1 protein in MCF-7 and MDA-MB-231 cells 
12 and 24 h after treatment.  DIM (20 µM) also decreased cyclin D1 in MCF-7 (24 hr) 
and MDA-MB-231 (12 hr), and the DIM/5,5'-diBrDIM-induced degradation of cyclin 
D1 was blocked by the proteasome inhibitor MG132.  Both DIM and 5,5'-diBrDIM 
induced apoptosis in MCF-7 cells and this was accompanied by decreased Bcl-2, release 
of mitochondrial cytochrome c, and decreased mitochondrial membrane potential as 
determined by the red/green fluorescence of JC-1.  DIM and 5,5'-diBrDIM induced 
extensive necrosis in MDA-MB-231 cells; however, this was accompanied by decreased 
mitochondrial membrane potential primarily in cells treated with 5,5'-diBrDIM but not 
DIM.  Thus, DIM and 5,5'-diBrDIM induce cell death in MCF-7 and MDA-MB-231 
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cells by overlapping and different pathways, and the ring-substituted DIM represents a 
novel class of uncharged mitochondrial poisons that inhibit breast cancer cell and tumor 
growth. 
 In summary, ring-substituted DIMs are highly effective drugs for treatment of 
breast cancer and are more potent than DIM both in vitro and in vivo models.  5,5’-
diBrDIM inhibited growth in both ER-negative and ER-positive breast cancer and acted 
as a mitochondrial poison.  The PPARγ-active C-DIMs inhibit growth in ER-negative 
breast cancer cells and are antitumorigenic in mouse xenografts and therefore represent a 
new class of anticancer agents that exhibit immense therapeutic potential for treating 
invasive ER-negative breast cancer.  These compounds exert their growth inhibitory 
effects through a variety of pathways including cell cycle arrest, induction of TGF-β-like 
peptides and autophagic cell death.  In addition, the C-DIMs investigated in this study 
exhibit distinctive preferences in terms of cellular targets:  DIM-C-pPhCF3 is the most 
potent PPARγ agonist and inducer of p21; DIM-C-pPhtBu is the best mitochondrial 
poison; and DIM-C-pPhC6H5 induces the TGF-β-like peptide NAG-1 to the greatest 
extent.  In summary, the substituted DIMs target multiple mechanisms in a cell-context 
dependent manner and this property contributes to the great therapeutic potential for 
application of these compounds in the treatment of invasive breast cancer. 
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